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The study of genetics is an integral part to understanding the biology behind our complex traits 
and can be approached in a variety of ways. Technological advancements in the field of 
genomics have enabled unprecedented large-scale studies which have identified numerous 
statistical associations between many diseases and our genes. Recently, studies involving gene 
expression have become an increasingly popular approach to understanding the biological 
pathways underlying statistical associations. In this dissertation, I address specific challenges 
related to the study of gene expression, including meta-imputation of expression across 
multiple datasets with only summary-level imputation models available, correcting for technical 
biases towards reference alleles in array-based expression assays, and identifying tissue-specific 
and population-specific regulatory variants and trait-associated loci in the context of systems 
genetics with whole genome sequencing, transcriptomics profiles, morphometric traits, and 
clinical endpoints. 
In Chapter 2, I develop a method which leverages multiple datasets to accurately impute tissue-
specific gene expression levels. Our method, Smartly Weighted Averaging across Multiple 
Tissues (SWAM) does not train directly from data, but rather performs a meta-imputation by 
combines extant imputation models by assigning weights based on their predictive 
performance and similarity to the tissue of interest. I demonstrate that when using the same 
set of resources, SWAM improves imputation accuracy compared to existing approaches that 
impute tissue-specific expression by training directly from raw data. The major benefit of using 
the SWAM meta-imputation framework is the flexibility to combine multiple pre-trained 
imputation models trained from privacy-protected raw datasets. Indeed, prediction accuracy is 




In Chapter 3, I examine the benefits of using deep whole genome sequencing to empower and 
refine existing microarray-based eQTL studies. I revisited a well-known hybridization bias that 
arises in microarray studies caused by genetic polymorphisms within target probe sequences. In 
this chapter, I interrogated the impact of genetic variants from whole genome sequencing to 
accurately identify and characterize this bias at both the probe and probeset level. I evaluated 
several approaches to account for hybridization bias, including methods to remove variant-
overlapping probes, and a novel method to adjust hybridization bias for each probe. I 
demonstrate that accounting for variant-overlapping probes when quantifying expression levels 
reduces reference bias and false positives in cis-eQTL analyses. I also demonstrate that 
adjusting for hybridization bias with deeply sequenced genomes is ideal to avoid reference bias, 
although leveraging publicly available variant catalogues such as the 1000 Genomes data 
provides comparable benefits. 
In Chapter 4, I performed a systems genetic study of Pima Native Americans enrolled in a 
diabetic nephropathy study. I integrate whole genome sequences, transcriptomic profiles, and 
morphometric traits derived from two micro-dissected renal compartments – glomerular and 
tubulointerstitial – and clinical phenotypes to identify significant associations between these 
molecular and complex traits. I identified thousands of eQTLs, including kidney-specific and 
population-specific eQTLs. I also identified many transcriptional associations with 
morphometric and clinical phenotypes enriched for kidney-specific biological pathways. 
Moreover, through dimension reduction techniques, I identified genome-wide significant 
genetic associations with a morphometric trait (podocyte volume), and with a composite trait 
representing albumin-creatin ration and glomerular surface volume, which was obtained from 
dimensionality reduction techniques. Studying this unique and richly-phenotyped cohort 
resulted many population- and tissue-specific regulatory variants, genes, and pathways 








Chapter 1 Introduction 
 
1.1 Systems genetics: an overview 
Genetics is a subject of biology in which we seek to understand genes, which are basic physical 
units of inheritance and play a major role in the manifestation of traits in living organisms. One 
major focus in this field is to understand how differences in our genome (DNA variation) affect 
complex traits. The study of genetics has many important health and medical implications, such 
as determining genetic pre-disposition to various diseases, and characterizing response to drug 
treatment. Systems genetics is a study approach which seeks to holistically understand the 
causal biological pathways that connect our DNA to endpoint traits. By examining many 
molecular phenotypes such as gene expression, epigenomic marks, protein levels, and 
metabolite abundance, we gain a deeper understanding of the complicated biology underlying 
many diseases [1]. Although the study of genetics has long pre-dated our knowledge of the 
existence of DNA [2], recent rapid developments in technology have facilitated unprecedented 
research in this topic, providing a high resolution view of many molecular traits. For example, 
with advances in DNA sequencing technology, we have been able to conduct large-scale genetic 
studies for many diseases, detecting numerous genetic variants that could potentially influence 
the disease [3,4]. Advances in technology for gene expression assays have allowed us to study 
one of the very important intermediate phenotypes in systems genetics [5]. From these 
developments, thousands of trait-associated genetic loci are being mapped to regulation of 
gene expression, which in turn directly affect protein building and cell function [6,7]. 
In this thesis, I delve into some of the topics and challenges that arise in the study of systems 
genetics, particularly focusing statistical and computational aspects of gene expression studies. 
In this chapter, I provide a background on the history of related fields, technical developments 
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and challenges that have arisen in gene expression. We then provide an overview of some of 
the work we have contributed and how they address some the challenges faced in systems 
genetics studies. 
1.2 Genome-Wide Association Studies (GWAS) 
Genome-Wide Association Studies (GWAS) examine the statistical association between many 
genetic loci and traits. This approach became very popular starting in the early 2000s due to 
massive improvements in SNP array genotyping and whole-genome sequencing (WGS) 
technologies. In the past 15+ years, SNP-arrays have been widely used to study the effects of 
common genetic variants at a large scale. For example, multiple genetic susceptibility variants 
were identified in a study of type 2 diabetes for over 2,000 Finnish individuals, where SNP-
arrays were used to genotype over 300,000 markers [8]. In 2015, a meta-analysis study was 
performed on over 300,000 individuals, and identified 97 genetic loci associated with obesity 
[9]. One limitation of SNP-arrays is that it only prior known genomic locations can be 
genotyped, and rare and population-specific variants can be missed [10].  
Another approach to obtain genotypes is whole-genome sequencing, which seeks to 
characterize the genome of an individual down to a single base-pair resolution. This approach 
allows for detection of rare and population-specific variants. The history of WGS dates back to 
the 1990s, where many viruses [11] and bacteria were fully sequenced for the first time, along 
with a few animals. The Human Genomes project, completed in 2003, was the world’s largest 
collaborative biological project, with the goal of mapping every gene within the human 
genome. This project however, used Sanger sequencing, which is extremely labor-intensive and 
low throughput, which would not be viable to study high number of individuals [12]. The advent 
of short-read sequencing technologies has enabled re-sequencing human genomes in an 
affordable, massively parallel manner, allowing for population-scale genetic studies. For 
example, the 1000 Genomes project sought to provide a detailed catalogue of human variation 
across 2,504 human genomes in 26 populations [13,14].  Recently, the Genome Aggregation 
Database (gnomAD) has aggregated 125,748 exomes and 15,708 genomes from various human 
sequencing studies and have identified over 750 million variants, including >400,000 loss-of-
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function variants [15]. In addition to providing a high-resolution view in GWAS studies, WGS has 
also allowed for imputation of genotypes of individuals who were array genotyped. There are 
now freely available genotype imputation servers which can impute genotypes based on 
various populations from different reference panels [16]. 
Currently, the NHGRI-EBI GWAS catalog has publicly available information on >227,000 
significant associations across >4,800 (as of Dec 15, 2020) [3,4]. Despite the numerous 
association signals detected by GWAS, there are still many challenges and the biology behind 
these associations are still not clearly understood. For example, heritability (which can be 
calculated without genotypes) for many traits and complex diseases have not been fully 
accounted for from GWAS alone [17]. A very well-known example is human height, which has 
an estimated 80% heritability (proportion of variation explainable by genetic variation), yet only 
25%-50% of this heritability has been explained by genetic variants [18,19]. One plausible 
explanation is that many rare variants with high effect size have yet to be discovered from 
GWAS. Other hypotheses posit that there could be thousands or even millions of variants that 
all contribute a very small amount of heritability to each trait [20]. Another possible 
explanation could be attributed to trait heterogeneity, and that trait definitions could be 
subjective or inconsistent within the same study. In such scenarios, studying intermediate 
phenotypes such as objective biomarkers or gene expression could potentially provide better 
insight compared to using endpoint traits. There are other open-ended questions for GWAS 
that have also been discussed, including the notion that GWAS signals are often not easily 
interpretable in a biological setting. Some of the reasons for this include linkage-disequilibrium 
(LD) structures between associated variants, which confounds identification of causal variants. 
Other reasons include the lack of our understanding on the function of each individual genetic 
variants beyond the protein-coding regions of the genome, and the complex causal pathways 
that connect genetic variation to end-point phenotypes [21]. Despite the tremendous successes 
from GWAS, it is evident that the biological process that links our genotypes to traits is 
extremely complex. To fully understand the genetic architecture underlying complex traits, it is 
important to study the intermediate phenotypes that link these two endpoints together, such 
as gene expression. 
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1.3 Gene expression: an intermediate phenotype to understand GWAS signals 
The functional mechanisms behind trait-associations are very diverse and many avenues of 
research can be taken to understand their underlying biology. For example, some genetic 
variants have been shown to directly knockout a gene or disrupt protein function, such as 
nonsense mutations from the PCSK9 lowering plasma levels of LDL cholesterol [22]. There has 
also been mounting evidence that many GWAS risk variants are located outside of coding 
regions and either co-localize with, or directly regulate gene expression levels [23–26]. To 
understand the functional aspect of these variants, there are many different intermediate 
phenotypes that that can be studied, including gene expression (characterized by eQTLs), DNA 
methylation (meQTLs) [27,28], chromatic accessibility marks (caQTLs) [29,30], and protein 
levels (pQTLs)[31]. Among these, studies involving gene expression levels have been very 
popular and have played a central role in understanding biological pathways behind many traits 
[25,32,33].  
The genetic study of gene expression – originally coined as genetical genomics [34], and is a 
part systems genetics – has been important in unraveling the complex interaction between our 
genes, our environment, and many diseases [35]. While our genotypes provide the blueprint for 
protein coding which in turn affects our traits, these genes must be “expressed” before the 
phenotype becomes apparent [36,37]. Transcription is the process of copying DNA and 
converting it into RNA, is a fundamental unit for translation of DNA into proteins and enzymes, 
which eventually affects phenotypes and clinical endpoints [38]. While our DNA is the same in 
every cell, gene expression can be different based on cell function. Therefore, studying gene 
expression can provide insight into the differences between our tissues and cell types, allowing 
us to compare tissue-specific profiles, which may be more relevant to the trait of interest 
compared to studying genotypes alone.  
1.4 Expression Quantitative Trait Loci Studies (eQTLs): background 
Expression quantitative trait loci (eQTL) mapping is an approach which seeks to understand the 
regulatory function of genetic variants, and to determine regions of the genome that affect 
transcription. This is typically done by treating gene expression levels as a quantitative trait, and 
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calculating the statistical association between expression and genotypes [39,40]. A genetic 
variant can regulate expression levels both proximally (cis-) or distally (trans-). So far, most of 
the focus in eQTL studies have been for cis-acting variants due to the limited statistical power 
to detect trans-eQTLs with limited sample sizes [41,42]. Furthermore, cis-eQTLs have been 
shown to have higher effect sizes, and a substantial proportion of trans-eQTLs is found to be 
mediated by cis-eQTLs [43,44], For the work conducted in this thesis, we primarily focus on cis-
acting eQTLs due to higher power for detection, and the availability of cis-eQTL repositories.  
Over the years, many eQTL studies have been conducted and many of these studies have 
managed to provide interpretable insight into GWAS signals. The first genome-wide mapping of 
expression levels was performed in 2002 in a genetic linkage study for two strains of yeast [45]. 
Since then, eQTL studies have been carried out for various cell types in many organisms, 
including mice and humans [46,47].  In 2007, a study mapping genetic loci with expression 
levels of genes in EBV-transformed lymphoblastoid cell lines have been able to explain GWAS 
association signals in childhood asthma [48]. Another study found that variants associated with 
Crohn’s disease were likely to be regulatory variants for the PTGER4 gene [49]. 
Initially, many eQTL studies performed on humans were based on blood-derived cell types, due 
to the ease of collection [39]. However, it has been shown that studying the most relevant 
tissue to the trait in question would provide greater insight into clinical traits. For example, 
Emilsson et al. demonstrated that expression levels of genes for the adipose tissue were 
correlated with over 50% of obesity related traits, whereas only 10% of blood-derived gene 
expression levels were correlated with these same traits [23]. With the decreasing cost and 
increasing availability of obtaining expression data, eQTL databases have been generated for 
many different tissue types. For example, the GEUVADIS consortium has generated an eQTL 
repository on lymphoblastoid cell lines for 462 individuals from the 1000 Genomes project [47]. 
The Depression Genes and Networks (DGN) cohort has 922 participants with RNA sequencing 
for whole blood, and have discovered over 10,000 eGenes regulated by genetic variation [50]. 
The GTEx consortium is an on-going project which initially assayed 44 tissues spanning the 
blood, digestive, respiratory, reproductive, brain and many other tissue types. The list of tissues 
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has since expanded with more samples being included into the study, with 49 tissues currently 
having enough sample size to conduct eQTL analysis [51,52].  
 
1.5 Transcriptome-Wide Association Studies (TWAS) 
With the increasing availability of external eQTL and measured gene expression reference 
panels, transcriptome-wide association studies (TWAS) have become popular in recent years. 
The objective of TWAS is to leverage eQTL (or measured gene expression) information to 
elucidate the regulatory aspect for many GWAS risk variants [53]. Instead of using genotypes as 
explanatory variables, TWAS examines the association between trait and gene expression. This 
is typically done by imputing expression levels from individual-level genotypes and performing 
association analysis between imputed expression and traits. Because the imputed expression is 
a function of genotypes, TWAS essentially assigns scores to genetic loci based on their impact 
on gene regulation. As a result, the association signals found in TWAS are mostly driven by 
regulatory variants, providing biological insight for many of these GWAS signals [54]. In terms of 
power, TWAS has a much lower multiple testing burden as genes number in the tens of 
thousands, as opposed to the millions of SNPs often tested in GWAS. However, power can be 
lost for signals that are driven by non-regulatory associations.  
We do note that while TWAS can be conducted using measured expression, predicted 
expression is often preferred for several reasons. The first is that genotype data are typically 
easier and much more feasible to collect compared to tissue-specific expression data. It is 
overall much more cost effective and to obtain genotype data and use external eQTL databases 
to impute the expression. Secondly, predicted expression in theory should capture only the 
genetic regulated component of expression, and should be impervious to potential confounders 
such as environmental effects [55,56]. Finally, significant associations using predicted 
expression can be linked to specific genetic markers which can be cross-referenced with GWAS 
signals. This is particularly useful for determining potential causal candidate SNPs in cases of 
high linkage-disequilibrium between significant GWAS variants. 
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Since using imputed expression is the preferred method for conducting TWAS, accurate and 
powerful eQTL discovery is essential for these studies. A recently developed and widely used 
tool to impute expression is PrediXcan, which first uses an elastic net to detect cis-eQTLs from 
tissue-specific expression and genotypes. Next, a prediction database is generated and 
PrediXcan can automatically create a file with imputed expression levels using individual-level 
genotypes as an input [55]. Therefore, this tool can leverage many of the previously generated 
gene expression resources such as GTEx, DGN and GEUVADIS. For example, the authors used 
PrediXcan to create prediction databases for 44 GTEx tissues (now 49 from GTEx version 8) as 
well as the whole-blood tissue type from the DGN (depression gene network) cohort, for all 
tissue-specific “well-predicted” genes (cross-validated R-squared > 0.01). Using these prediction 
databases to impute expression levels, the authors performed TWAS on seven diseases from 
the Wellcome Trust Case Control Consortium (WTCCC) study [58], and identified 29 genes 
associated with type 1 diabetes, with numerous other genes being associated with autoimmune 
diseases. In 2016, SLINGER, an extension to PrediXcan was developed where the cis- 
requirement for eQTL discovery was removed. The authors demonstrated that prediction 
accuracy was improved, increasing the number of estimable genes by more than 2,000 for the 
DGN whole blood expression data. Furthermore, TWAS conducted on the 7 same WTCCC traits 
displayed significantly elevated r2 with many associations being highly reflective of actual 
variation in expression levels [58]. 
As the current pool of transcriptomic resources continues to expand and become higher 
quality, TWAS with predicted expression will become increasingly useful as a means to uncover 
the regulatory aspect of genetic association. 
 
1.6 The evolution of gene expression technologies 
1.6.1 Array-based expression profiling 
Traditionally, gene expression levels have been measured using microarrays. This technology 
was developed in the early 1990s where Fodor et al demonstrated that short DNA or RNA 
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molecules (oligonucleotides) could be synthesized onto a glass slide through photolithography 
[59]. This allowed for miniaturization of the chip, which Schena et al in 1994 demonstrated 
would accommodate high-capacity parallelization of multiple genes [60]. Modern day 
microarrays typically use short probe sequences known as features, which are designed to 
hybridize with specific known gene regions. The quantification of hybridization of probes 
compares the relative color intensity of a perfect match probe against a mismatch probe 
(serving as a baseline), which can then be converted into expression levels using various 
statistical approaches. This high-throughput method provides a snapshot of the overall gene 
expression profile of an isolated tissue sample that the researcher is studying.  
Since the focus of gene expression experiments are to capture meaningful biological variation 
between individuals, we ideally want to have a high signal-to-noise ratio. Unfortunately, the 
microarray technology is highly susceptible to systematic biases which may affect expression 
estimates. For example, lab conditions and protocols may contribute to systematic differences 
(known as batch effects) between microarray experiments [61]. Furthermore, microarrays may 
have high sensitivity of the experimental setup to variations in hybridization temperature [62]. 
In addition, the purity and degradation rate of genetic material [62], and the amplification 
process [63], may also impact the estimates of gene expression. There have been studies on the 
lab effects on the quality of gene expression data. For example, Beekman et al. demonstrated 
that to minimize variation, the experiments should be ideally performed in the same lab. 
However, they also showed that the interlaboratory findings were also generally consistent 
when the correct statistical methods were applied [64]. Dobbin et al. found high between-
laboratory concordance for individuals when the same protocols were followed for each lab 
[65]. In addition to standardization of lab protocols to minimize experimental variation, various 
statistical methods have been used to normalize microarray data. For example, Bolstad et al 
showed that a quantile-normalization approach for probe intensity values produced the low 
variance and bias between different arrays, while also being computationally fast [66]. Over the 
years, other gold standard approaches have been developed such as the Robust Multi-array 
Averaging (RMA) method which using a median polish approach to convert probe-level data 
into probeset (or gene) level expression [67]. In 2007, Johnson et al implemented both 
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parametric and non-parametric Bayesian frameworks to combine probeset-level data across 
multiple microarray platforms [68].  
In addition to systematic batch effects, microarrays are also susceptible to cross-hybridization, 
where unintended sequences hybridize to a probe, artificially inflating the probe intensity levels 
[69]. This also creates a non-independence between probes, as well as high background levels 
which limit the ability to detect a high range of difference between genes [70,71]. Indeed, the 
background noise and cross-hybridization makes it difficult for microarrays to differentiate 
between low-abundance versus non-expressed transcripts [72]. Another well-known limitation 
of microarrays is a reduced hybridization for certain probes when individuals have sequence 
variation within the probe boundaries. This commonly can lead to negatively biased estimates 
in expression levels, which also could create false positives in association analyses. 
1.6.2 RNA Sequencing 
A more recent approach to measure gene expression has been to use genome sequencing 
technology to identify the quantity of RNA in a biological sample. By directly sequencing 
transcripts, we bypass the requirement of using interrogating probes. This helps overcome 
many of the limitations of microarrays, avoiding the need for a priori knowledge of RNA target 
sequences, and reducing susceptibility to hybridization issues. Initially, expression sequencing 
was done using Sanger sequencing to quantify levels of complementary DNA (cDNA). While 
Sanger sequencing is still viable on a smaller scale, this approach is low-throughput and has 
given way to newer methods [73,74]. Tag-based methods such as SAGE (serial analysis of gene 
expression) and CAGE (cap analysis of gene expression) were developed as a high-throughput 
methods which also provided precise quantification of expression levels [75,76]. These methods 
however are unable to discover novel genes and many short tags are unable to be uniquely 
mapped to the genome. Furthermore, these approaches were unable to distinguish between 
splice isoforms [77,78]. 
The development of next generation sequencing (NGS) technologies has greatly enabled the 
study of transcriptomics. RNA sequencing (RNA-seq) is a high throughput method which refers 
to the deep sequencing and quantification of (cDNA). These sequence fragments can be 
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assembled either using a reference genome or done using de novo sequencing.  RNA-seq has 
been able to overcome many of the limitations from the older gene-expression technologies 
(both microarrary and older sequencing approaches) and revolutionizes the study of 
transcriptomics [77]. For example, RNA sequencing has been able to detect novel transcripts 
and isoforms, and reveal splice variants [72,79,80], giving it a distinct advantage over the 
Sanger, SAGE and CAGE sequencing approaches. 
Compared to microarrays which require a priori knowledge of the sequences, RNA-seq directly 
identifies the transcript sequences [78]. RNA sequencing also provides a higher sensitivity to 
low and high levels of expression, which microarrays often cannot. Since RNA sequencing does 
not have an upper limit for quantification of sequences, we observe a high dynamic range of 
expression levels. For example, a 9000-fold range was detected for genes within the yeast 
genome [81], and a range of five orders of magnitude was detected for 40 million reads within 
the mouse genome [82]. Because of its high resolution, RNA-seq can also reveal the precise (1 
base pair) location of transcript boundaries, give information on how exons are connected and 
reveal sequence variations [77,80].  
RNA-seq traditionally has been performed using bulk tissue, which averages the expression 
levels over many cell types. Recently there has been evidence that gene expression can be 
heterogeneous between cells within the same tissue, which lead to substantial functional 
consequences [83–85]. The first study to profile gene expression using NGS at the cellular level 
was performed in 2009, using only a single mouse blastomere to detect over 5000 more 
expressed genes than compared to microarrays [86]. Since then, there have been a plethora of 
studies that profile expression at the single cell resolution, providing insight that would not be 
detectable at the bulk-cell level. For example, Shaffer et al. characterized the variability in 
melanoma cells at the single-cell level which predicted resistance to drug treatment [87]. Over 
the years, single cell RNA-seq (scRNA-seq) has been used for many applications, including 
tracing cell lineage and classifying cell types, as well as genomic profiling of rare cell types [88]. 
However, current challenges include cost of sequencing, and high levels of noise compared to 
bulk RNA-seq, resulting in computational and statistical challenges. As computational methods 
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improve and sequencing costs continue to decrease, scRNA-seq will provide even greater 
insight into cell biology and genetics [89]. 
1.7 Challenges 
1.7.1 Accurate imputation of gene expression leveraging multiple datasets 
The primary purpose of gene expression imputation is to harness naturally occurring genetic 
variation to understand the relationships between gene expression and complex traits through 
TWAS [55,56]. However, expression studies tend to have much smaller sample sizes compared 
to GWAS datasets, due to many challenges of obtaining RNA samples. For example, extracting 
RNA from various tissue types requires a biopsy of the tissue sample, which is far more difficult 
to perform on living individuals compared to obtaining their saliva or blood. In addition, RNA-
seq experiments do not have the same level of automation compared to DNA sequencing or 
genotype-arrays, as lab protocols can differ in terms of extracting and storing many different 
tissue types. As a result, expression profiles can be heterogeneous across different batches or 
labs, which presents challenges in combining multiple datasets or performing meta-analysis. 
Indeed, RNA experiments are currently performed on a much smaller scale compared to those 
studying DNA. For example, GTEx has examined expression levels for 948 individuals with a 
tissue-maximum of 803 individuals (skeletal muscle tissue), while the UK Biobank phenome-
wide study of depression contained >400,000 subjects [90,91]. Given these sample size 
differences [92], eQTL detection and hence gene expression prediction accuracy can be limited 
by the availability of high quality tissue data. 
Given the current state of available gene expression data, there can be several ways to improve 
the power of TWAS based on imputed expression. One idea is to improve prediction accuracy 
by leveraging information from multiple tissues. This takes advantage of the idea that gene 
expression profiles can often be shared across different tissue types. This could make the 
downstream analysis (such as TWAS) much more powerful. Since the original PrediXcan paper 
[55], there have numerous publications extending the method to include multiple datasets or 
tissue types. For example, instead of training one tissue at a time, UTMOST jointly trains every 
tissue simultaneously, producing gene expression estimates for each tissue. While PrediXcan 
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performs a penalized regression across all genetic variants, UTMOST penalizes across both 
genetic variants and tissues. By doing so, this method captures the cross-tissue similarity for all 
genes, and improves imputation accuracy compared to using the single-tissue method [93]. 
Other methods use multiple single-tissue predictions to perform TWAS directly without further 
imputing multi-tissue gene expression. For example, MultiXcan (an extension of PrediXcan) 
improves power for TWAS by performing multivariate regression between predicted expression 
(derived from PrediXcan) and trait (using principal components to avoid multicollinearity 
between tissues). The extension of this approach, S-MultiXcan performs TWAS using summary-
level GWAS results, in a similar manner to MetaXcan, but across all tissues simultaneously [94].  
While these methods have enriched the original PrediXcan by ultimately providing higher 
power for TWAS, they are not without limitations. For example, UTMOST re-trains prediction 
models and requires full raw data of genotypes and gene expression measurements for every 
tissue and individual. While the prediction models derived from UTMOST are freely available for 
download, researchers are unable create tailored prediction models based selected tissue types 
unless they have full access to the data. In addition, there must be some overlap between 
samples for each tissue, and therefore disjoint resources cannot be integrated. MultiXcan 
integrates multiple imputed expression profiles to enhance power of discovery but does not 
provide aggregate or multi-tissue gene expression predictions. While the primary objective of 
imputing expression is to perform TWAS, there are also merits to generating imputations 
outside of this context. For example, imputed gene expression levels can be used as 
instrumental variables for Mendelian Randomization purposes.  
In Chapter 2, we propose a novel method which integrates information from multiple datasets 
and tissues using a meta-analysis style approach. This method does not require the full set of 
raw data, but only measured expression and genotypes for a single tissue of interest. As such, 
information from multiple disjoint reference panels can be integrated. We demonstrate using 
GTEx tissues that our method improves prediction accuracy over PrediXcan and UTMOST, using 
the GEUVADIS consortium measured expression as external validation. We also demonstrate 
that combining other reference panels (such as GTEx + DGN whole blood) can further improve 
imputation accuracy, highlighting the importance of using multiple external datasets. Finally, 
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we demonstrate that our approach increases signal detection in TWAS compared to other 
approaches that impute gene expression (PrediXcan and UTMOST).  
1.7.2 Revisiting array-based eQTL studies in whole genome sequencing era  
Moving forward, it is clear that RNA-seq and scRNA-seq are the next generation technologies 
for gene expression studies. Although microarrays are an aging technology, they are still a 
viable option and still used for modern day expression studies [95,96]. For example, the NCBI 
GEO archive as of January 29, 2020 has roughly twice as many microarray datasets (roughly 
24,000) compared to RNA-Seq (roughly 12,000) [97–99]. There are also studies in which 
transcriptomic profiles were already collected on microarrays and the RNA samples are no 
longer available for assaying with newer technologies. 
Despite the relevance of microarrays even in this current era, there are many shortcomings for 
this technology. One very well-known limitation is the negative bias in probe hybridization 
when the genetic sequences of the individuals being studied differ from the microarray probe 
sequences [100,101]. Array-based technologies use target probe sequences based on the 
reference genome sequences, not necessarily accounting for genetic variations. For individuals 
carrying non-reference alleles in the probe sequences, the RNA strands are less likely to bind to 
the oligonucleotides, which in turn results artifactual cis-eQTLs that does not reflect true 
associations between genetic variants and expression levels. A common characteristics of these 
artifactual cis-eQTLs is that non-reference alleles are almost always associated with negative 
effect sizes because the non-reference alleles reduces the hybridization affinity [102]. 
There have been some solutions proposed to remove or mitigate this bias. For example, 
Quigley uses common variants from the 1000 Genomes reference panel to identify probes that 
overlap with a genetic variant, and removes said probes from the expression calculation [103]. 
One potential shortcoming to this approach is that if the 1000 Genomes markers do not match 
the study population, problematic probes may be missed while other probes may be 
unnecessarily removed. While this may work well for European samples, populations 
underrepresented by the 1000 Genomes reference panel may have inaccurate expression 
estimates. Dannemann et al. developed a statistical approach to determine probes with 
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reduced binding affinity by comparing the hybridization levels for probes of interest to probes 
from a control group [104]. However, this requires assays of a control group that are not 
affected by negative binding affinity.  
The advent of next generation whole genome sequencing (WGS) technologies enables us to 
comprehensively catalogue all genetic variants. This affords us a new opportunity to 
comprehensively account for the negative hybridization effect across all genetic variations. As 
reported by Quigley, the negative hybridization bias in eQTL results appeared to be only 
partially resolved when using common variants only [103]. With the availability of WGS data for 
many study cohorts with transcriptomic profiles available through array-based technology, it is 
now possible to understand the full extent of the hybridization bias and to identify best practice 
to account for the bias in downstream analysis. 
Chapter 3 of this dissertation comprehensively assesses the hybridization bias by leveraging 
WGS to identify the exact list of variant-overlapping probes. Here, the magnitude and effect of 
negative hybridization is characterized at both the probe and probeset (gene) level. We then 
evaluate existing approaches to identify the best practice for probe-level correction and 
compare these approaches in downstream eQTL analysis. Finally, we explore possible 
alternative bias-correction methods that leverage whole genome sequence data. We 
demonstrate that not all variant-overlapping probes have a negative hybridization bias, and 
that removing them might unnecessarily alter expression estimates by adding noise. This in turn 
could potentially mask true positives in eQTL studies. We derive and implement a probe-level 
imputation method, which instead of removing probes, we adjust their expression based on the 
values from other probes within the probeset. This approach appears to resolve the negative-
hybridization bias while also preserving the overall correlation between genes. 
1.7.3 Analysis of eQTLs on understudied tissues and populations capitalizing on discovery of 
novel eQTLs 
With advances in high throughput technology, many resources are being generated for 
transcriptomic profiles of various tissues within the human body. For example, the GTEx 
consortium has now collected samples of 54 tissues across 948 donors. Some easily accessible 
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tissues, such as blood or cell lines, have been extensively studied with very large sample sizes. 
In another study, the eQTLgen consortium has meta-analyzed blood eQTLs of 31,684 samples 
across 37 studies across 11M common SNPs, identifying ~17,000 cis-eQTL genes [105]. 
However, while some tissues have been well-studied, not all have been examined equally. For 
example, kidney transcriptomics is still generally underrepresented and is still an emerging area 
of research [106]. The kidney is a vital human organ which is responsible for many tasks, 
including the control of body fluid volume, electrolyte balance, and removal of toxins through 
filtering processes. In addition, there are many kidney-related diseases that can arise that 
disrupt function, such as chronic kidney disease (CKD), nephrotic syndrome (NS), end stage 
renal disease (ESRD), and diabetic nephropathy (DN) [107]. In studying gene expression for the 
kidney, there are many challenges that include organ heterogeneity, low sample size, lack of 
healthy tissue samples, disease heterogeneity, as well as the underrepresentation of many 
populations. These challenges are highlighted below and are key points that Chapter 4 will 
address. 
Although there have been some kidney transcriptomes profiled, these studies have had 
limitations, such as low sample size, or expression being assayed using bulk tissue only. For 
example, in the GTEx consortium, the Kidney – Cortex tissue (bulk tissue) has only 73 RNA 
sequenced samples, while the Kidney – Medulla has only 4 RNA sequenced samples. (This is in 
part because most of the healthy kidneys of GTEx participants are donated and unavailable for 
expression studies. The remaining samples available for RNA-seq tend to be lower quality 
samples.) This is low compared to many other tissues in this cohort, (skeletal muscle, whole 
blood, subcutaneous adipose, thyroid, lung all have over 500 individuals) and the total number 
of kidney eGenes as well as ratio of detection (eGenes divided by total number of expressed 
genes) are near the bottom for all tissues. Another study published in 2017 identified 1,886 
candidate eGenes in 96 individuals with chronic kidney disease (CKD). However, the RNA 
sequencing was performed on bulk tissue [108], which would not differentiate between the 
heterogeneous compartments of the kidney. Clinical studies of kidney function are often 
interested in the filtration ability of the glomerulus (GFR) [109]. As such, there has been 
evidence that microdissection of the kidney into glomerular and tubulointerstitial 
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compartments would allow for increased specificity of kidney transcriptomic studies compared 
to studying the cortex [110,111]. Recently, the nephrotic syndrome study network (NEPTUNE) 
cohort performed such study, describing glomerular- and tubular- specific transcriptomic 
profiles for 187 individuals with nephrotic syndrome (NS) [106]. While this study provided a 
detailed compartment-specific eQTL landscape of individuals with NS, it is a rare disease 
characterized by damaged kidneys, and often progresses serious diseases such as CKD and end-
stage renal disease [112]. While this is an invaluable transcriptomic resource, there is also merit 
in studying relatively healthier kidneys, as it could provide more insight into common disease-
related traits. 
In addition to tissue heterogeneity, many renal diseases are also heterogeneous. If association 
studies are performed using heterogeneous traits, latent substructures among individuals could 
generate spurious results or mask signals in the analyses. To characterize various kidney 
diseases, clinical measurements such as glomerular filtration rate (GFR) or albumin-creatinine 
ratio (ACR) can be used. However, there are other fine-resolution phenotypes, such as 
morphometric measurements that can be obtained from renal biopsies that snapshot the 
physical state of the kidney at a given moment. Using these phenotypes could potentially be 
very important pieces of information to connect the dots between genetic variants and 
complex renal traits. 
Finally, there is also importance to studying population-specific expression data. Since most 
GWAS and transcriptomic studies are heavily biased towards individuals of European descent, 
this can lead to reduced accuracy in predicted gene expression for non-European individuals 
[113]. Performing genetic studies of diverse populations allow for trans-ethnic fine mapping, 
which can pinpoint potential causal variants that may be masked due to LD structures of a 
single population otherwise [114]. In addition, studying isolated populations have revealed 
novel population-specific variants that may be too rare for detection in other populations. For 
example, studying the isolated Sardinian population has detected novel GWAS loci for 
hemoglobin levels, and lipid and blood inflammatory markers [115,116]. Studies on the Finnish 
population for 64 quantitative traits have also identified 19 unique or enriched (20-fold more 
common compared to non-Finnish Europeans) genetic loci [117]. 
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In Chapter 4, we provide a transcriptomic landscape of the kidney on a cohort which addresses 
many of the challenges in tissue-specific systems genetic studies. In this work, we integrate 
multiple datasets to provide a genomic and transcriptomic profile for microdissected 
glomerular and tubulointerstitial tissues from 97 Pima Native American individuals from a 
diabetic nephropathy. This cohort gives the opportunity to study many high-resolution 
phenotypes from a population-specific group of individuals, with relatively healthy tissue 
samples. From this dataset, we use gene expression data assayed from both microarray and 
RNA-seq platforms, kidney morphometric traits, and whole genome sequencing to conduct 
various analyses. Although the sample size is relatively low, the abundance of high-quality data 
provides many insights into the regulatory aspects of the kidney for this population. Here, we 
discover both tissue-specific and population-specific regulatory variants which highlights the 


















Chapter 2 Meta-imputation of Transcriptome from Genotypes 
Across Multiple Datasets Using Summary Statistics 
 
2.1 Abstract 
Transcriptome wide association studies (TWAS) can be used as a powerful method to identify 
and interpret the underlying biological mechanisms behind GWAS by mapping gene expression 
levels with phenotypes [53,54]. In TWAS, gene expression is often imputed from individual-level 
genotypes of regulatory variants identified from external resources, such as Genotype-Tissue 
Expression (GTEx) Project [55,56]. In this setting, a straightforward approach to impute 
expression levels of a specific tissue is to use the model trained from the same tissue type. 
When multiple tissues are available for the same subjects, it has been demonstrated that 
training imputation models from multiple tissues types improves the accuracy because of 
shared eQTLs between the tissues and increase in effective sample size. However, existing 
methods require access of genotype and expression data across all tissues for joint training 
[93]. Moreover, they cannot leverage the abundance of various expression datasets across 
various tissues for non-overlapping individuals. 
Here, we explore the optimal way to combine imputed levels across training models from 
multiple tissues and datasets in a flexible manner using summary-level data. Our proposed 
method (SWAM) combines arbitrary number of transcriptome imputation models to linearly 
optimize the prediction accuracy given a target tissue. By integrating models across tissues 
and/or individuals, SWAM can improve the accuracy of transcriptome imputation or to improve 
power to TWAS without having to access each individual-level dataset. To evaluate the accuracy 
of SWAM, we combined nearly 48 tissue-specific gene expression imputation models from the 
GTEx Project as well as imputation model trained from a large eQTL study of Depression 
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Susceptibility Genes and Networks (DGN) Project [50] to tested imputation accuracy in 
GEUVADIS lymphoblast cell lines (LCL) samples [47]. We also extend our meta-prediction 
method to meta-TWAS to leverage multiple tissues in TWAS analysis with summary-level 
statistics. Our results capitalize on the importance of integrating multiple tissues to unravel 
regulatory impacts of genetic variants on complex traits. 
 
2.2 Introduction 
Genome wide association studies (GWAS) have been able to identify numerous associations 
between genetic variants and complex traits. However, interpreting the biological mechanisms 
underlying the association signals remains a challenge [118]. Recently, studies involving gene 
expression have become increasingly popular as a means to provide biologically meaningful 
insight into statistical associations [55,56]. Transcriptome-wide association studies (TWAS) is a 
widely used method to translate GWAS association signals into more interpretable units by 
examining the association between phenotypes and gene expression levels imputed from 
genotypes. Associations identified from TWAS can be interpreted as potentially causal 
relationships between the traits and the genes through gene regulation [54,119,120]. While 
TWAS may not detect associations driven by functional mechanisms irrelevant to gene 
regulation, it increases the specificity and interpretability in identifying GWAS signals driven by 
gene regulation. Imputed gene expression can be utilized in various contexts of association 
analysis beyond TWAS, such as Mendelian randomization [121,122] or estimation of trait 
heritability attributable to cis-eQTLs [123]. Since genotype data from DNA is far easier and 
cheaper to obtain than expression data from tissues, TWAS based on imputed expression offers 
excellent augmentation to study the genetic component of gene regulation in addition to RNA-
seq-based studies. 
The first-generation methods to impute gene expression levels from genotypes train the model 
from a single-tissue dataset comprising of many individuals with both genotypes and expression 
profiles [55,56]. For example, a widely-used method PrediXcan [55] uses Elastic net 
regularization to identify cis-eQTLs (expression quantitative loci) to train the model to impute 
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gene expressions from genotypes. Other methods, such as TWAS [56], employ different 
regularization but typically produces a linear model to impute gene expressions as a weighted 
sum of cis-eQTL genotypes. Imputation models are trained using these methods from various 
population-scale transcriptomic datasets, such as the Genotype-Tissue Expression (GTEx) 
project [52,123], Depression Genes and Network (DGN) study [50], and The Cancer Genome 
Atlas (TCGA) [124], and these models are made available in public repository such as predictDB 
(http://predictdb.org/) or FUSION (http://gusevlab.org/projects/fusion/) so that expression 
imputation or TWAS can be performed from any genotyped individuals.  
Although these first-generation methods for transcriptome imputation have been quite useful, 
they have limited accuracy mostly due to limited sample size in the training datasets where 
both genome-wide genotypes and transcriptome-wide expression levels are available. While 
millions of individuals have been genotyped or sequenced to date [4,125–127], the sample-size 
of current population-scale transcriptome data are typically limited only to hundreds or 
thousands [128] (with the largest study cohort having around 30k participants [129]), primarily 
due to the difficulty in collecting high quality tissues (other than whole blood) from living 
donors. Moreover, transcriptomic datasets are prone to potential batch effects between 
studies [68,130–132], making it difficult to integrate across multiple datasets to build a large 
and harmonized resource to be trained from. Furthermore, there are hundreds or thousands of 
different types of tissues or cells, requiring orders of magnitude larger effort to 
comprehensively profiles transcriptomes in population-scale across tissues, as in GTEx Project.  
Recently, methods to address the shortcomings of the first-generation methods have been 
developed. When transcriptomic profiles are available across many tissues, such as in GTEx 
Project, transcriptome imputation can improve by leveraging the shared genetic components 
across tissues. Even though each tissue represents a unique transcriptomic profile, a large 
fraction of eQTLs are shared across tissues [133], and the availability of multiple expression 
measurements across tissues can help more precisely identify the shared eQTLs, which in turn 
can improve the imputation accuracy. For example, UTMOST trains a transcriptome imputation 
model a simultaneously across all tissues using a combination of L1 and L2 penalization across 
markers and tissues, respectively [93]. Another multi-tissue approach, MultiXcan, does not 
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impute transcriptomes, but performs a multi-tissue TWAS across all tissues by including each 
tissue-specific imputed expression as a predictor variable to improve power to identify 
association between a trait and a gene, in which the underlying mechanism potentially involves 
multiple tissues or cell types [94]. 
Even though UTMOST substantially improves the accuracy of transcriptome imputation, it 
assumes that expression measurements across multiple tissues are available for overlapping set 
of genotypes individuals for training imputation models. While this assumption can be met 
when training from the GTEx dataset (assuming granted access to the individual-level data), it 
may not be realistic in other circumstances where expression measurements are available for 
non-overlapping individuals (such as in TCGA), or it is infeasible to obtain individual-level 
genotypes and expression data due to limited access privilege. As population-scale 
transcriptomic resources are rapidly increasing, it should be possible in principle to integrate 
these resources to better impute transcriptomes. While there have been additional methods 
which have been developed to increase the accuracy of gene expression or TWAS [94,134–136], 
none of them – to the best of our knowledge – are able to perform “meta-imputation”, which 
systematically integrates multiple imputation models without the need to access to individual-
level data. 
Here we propose Smartly Weighted Averaging across Multiple tissues (SWAM), a multi-tissue 
transcriptome imputation method based on a flexible meta-analysis across multiple imputation 
models. Unlike UTMOST, SWAM does not require access to all genotypes and expression 
datasets for training its imputation model. Instead, it takes individual transcriptome imputation 
models trained from individual tissues while optimizing the expected imputation accuracy for a 
target tissue. Moreover, it can seamlessly integrate imputation models trained from multiple 
datasets comprising of different individuals and tissues. As a result, SWAM can integrate across 
hundreds of imputation models across GTEx, DGN, and TCGA projects without requiring all 
individual-level data to substantially improve the imputation accuracy over existing methods, as 
we demonstrate with GEUVADIS data. Moreover, we demonstrate that SWAM improves the 




2.3.1 Smartly Weighted Averaging across Multiple Tissues (SWAM) 
We propose Smartly Weighted Averaging across Multiple tissues (SWAM), a method that 
provides a flexible framework to impute tissue-specific expression by integrating single-tissue 
imputation models across many tissues and datasets (Figure 2.1). The key principle behind 
SWAM is to improve the accuracy of transcriptomic imputation by determining the optimal 
linear combination of multiple imputation models in terms of expected imputation accuracy. To 
do this, SWAM requires a reference tissue (tissue of interest) to be defined as a basis to 
determine the relative contributions from multiple imputation models. Using the individual-
level genotypes and expression of only the reference tissue, SWAM integrates imputation 
models trained from different tissues and datasets (e.g. GTEx, DGN, and TCGA) without 
requiring individual-level data except for the reference tissue.    
The first step of SWAM is to apply each transcriptomic imputation model to the reference 
genotypes, which results in individual-level, tissue-specific imputed expression. The second step 
of SWAM compares each imputed expression with the measured expression of the reference 
tissue to calculate optimal weights by linearly combining multiple prediction models to 
maximize expected mean squared error (MSE) (see Methods for the details). The output of 
second step is an integrated transcriptomic imputation model compatible with the PrediXcan 
and MetaXcan software tools. Using this SWAM model, we can impute the transcriptome of any 
samples of interest with genotype information available (via PrediXcan), or to use the model 
and covariance matrix directly to perform TWAS (via MetaXcan) when GWAS summary statistics 
are available (Supplementary Figure 2.1).  
2.3.2 Simulation study demonstrates the robustness of SWAM across various scenarios 
We performed simulation studies to evaluate SWAM’s ability to robustly impute expression by 
leveraging tissue-specific and cross-tissue components across a wide spectrum of parameter 
settings. To do this, we independently simulated multi-tissue expression levels along with 
genotype data for both our training and validation sets (see section 2.5, Materials and Methods 
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for details). We compared SWAM with two heuristic approaches – naïve average, which equally 
weights individual tissue and best tissue, which only uses the tissue with the highest expected 
imputation accuracy – as well as with single-tissue imputation.  
As expected, we observed naïve average to be particularly powerful when the causal variants 
are shared across all relevant tissues (Figure 2.2A), identifying 94% of genes as significantly 
imputable at FDR < 0.05. When all causal variants were tissue-specific, the naïve average only 
identified 25% of genes to be imputable. On the other hand, best-tissue was more powerful 
(38%) than naïve-average when the all causal variants were tissue-specific, but worse when all 
causal variants are shared. When only single-tissue was used for imputation, the performance 
stayed similar regardless of the tissue-specificity. Encouragingly, SWAM outperformed all three 
methods across all ranges of tissue-specific and cross-tissue heritability settings. We believe this 
is because SWAM learns tissue-specific weights without pre-conceptions of tissue relatedness, 
and thus determines the weights for relevant tissues while ignoring unrelated ones. 
A similar trend is observed when we vary the number of relevant tissues that shares cross-
tissue heritability (Figure 2.2B). In the case where there are no relevant tissues other than the 
target tissue, naïve average is least powerful while SWAM performs as well as the single tissue 
approach. This suggests that in this scenario, SWAM is correctly giving non-zero weights to only 
the target tissue, making it similar to the single-tissue method. In the other scenario where 
every tissue is relevant, SWAM provides a similar power to the naïve average approach, 
suggesting that SWAM is robustly assigning weights to each relevant tissue. Similarly, when 
there are more tissues available in overall (assuming 50% are relevant tissue sharing cross-
tissue heritability), the power of SWAM and naïve average keep increasing while single-tissue 
and best-tissue remain similar (Figure 2.2C).      
Our simulation study also evaluated the impact of sample size of the reference tissue. We 
hypothesized that single-tissue would perform poorly when the sample size of the reference 
tissue was small, which was indeed observed in our results (Figure 2.2D). When the reference 
tissue has sample sizes of 50, 100, 200, we observed that single tissue method identified 36%, 
66%, and 92% of imputable genes. Because additional tissues are helpful especially when the 
24 
 
reference tissue has smaller sample size, the best tissue approach performed better at lower 
sample size (59% at n=50), but worse at higher sample size (88% at n=200). Similarly, naïve 
average also performed better at lower sample size (63% at n=50), but worse at higher sample 
size (78% at n=200). However, SWAM consistently outperformed single tissue across all cases 
(59%, 86%, 97% at n=50, 100, 200).  This implies that borrowing information from a relevant 
tissue (to the reference) is useful in these situations and SWAM robustly estimates the weights 
from each tissue accounting for the uncertainty from different sample sizes. 
2.3.3 SWAM outperforms other transcriptome imputation methods in evaluations with real 
data by considering the bias-variance tradeoff 
We applied SWAM to create multi-tissue imputation models from GTEx v6, using 
lymphoblastoid cell lines (LCL; the official tissue name in GTEx was “Cells – EBV-transformed 
lymphocytes”) as the reference tissue, to evaluate its imputation accuracy of LCL 
transcriptomes of 344 European samples from the GEUVADIS consortium [47]. We compared 
the accuracy of SWAM with various methods, including single tissue imputation models 
(generated by PrediXcan), naïve average, best tissue, and another multi-tissue method 
UTMOST.   
Among the single-tissue imputation models, we observed that the imputation from LCL 
identified 1,552 genes as significantly imputable at FDR < 0.05. Interestingly, we observed that 
another tissue, fibroblast cell lines (FCL; the official tissue name in GTEx was “Cells – Cultured 
fibroblasts”), identified even more genes (1,690 genes) as significantly imputable for GEUVADIS 
LCL expression levels. One of the outstanding differences between LCL (n=114) and FCL (n=272) 
models were the sample size used for training. We suspect that this is due to (1) the difference 
in sample size (i.e., FCL imputation has less variance) and (2) the similarity of transcriptomic 
profiles between LCL and FCL (i.e., FCL model tends not to introduce large bias). However, 
tissues with larger sample size did not always result in more accurate imputation. When we 
examined the results from Skeletal muscle model (n=361), which had the largest sample size in 
GTEx v6, we identified only 1,197 genes as significantly imputable. This is likely because the 
large differences of transcriptomic profiles between LCL and Skeletal muscle (i.e., Skeletal 
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muscle model tends to introduce large bias). These examples demonstrate that both sample 
size and tissue relevancy are important for maximizing the imputation accuracy. In statistical 
terms, our primary interest was to reduce the mean-squared error (MSE), which is the sum of 
Bias2 and Variance. We suspect that FCL model performed better than LCL models due to much 
smaller variance (because of larger sample size), and better than Skeletal muscle models due to 
much smaller bias (Supplementary Figure 2.2). We hypothesized that by combining imputations 
from multiple models, we can minimize MSE by substantially reducing variance without 
introducing excessive bias, which was our main motivation for developing SWAM. 
When evaluating the multi-tissue methods, our two heuristic approaches, best-tissue and naïve 
average identified 2,493 and 2,666 significantly imputable genes, respectively, which was >47% 
and >57% higher than any single tissue models. UTMOST (using LCL as the reference) also 
substantially increased the number of imputable genes (2,238 genes, >32% increase over any 
single tissue), but surprisingly, it had fewer than the imputable genes compared to the two 
heuristic approaches. Finally, when we applied SWAM specifying GTEx LCL as the reference 
tissue, the number of imputable genes further increased to 3,040, which is >79% larger than 
any other single tissue models (Supplementary Table 2.1, Figure 2.3A). Interestingly, SWAM 
improved the imputation accuracy over UTMOST even though it requires individual-level data 
only for one tissue (i.e., LCL) in GTEx while UTMOST requires simultaneous access to individual-
level data across all tissues. These results demonstrate that SWAM offers an accurate and 
flexible meta-imputation framework by optimally combining multiple imputation models across 
tissues. 
2.3.4 SWAM enables meta-imputation of expression levels across multiple heterogeneous 
datasets 
One of the important advantages of SWAM compared to other multi-tissue imputation 
methods is the ability to integrate imputation models across heterogeneous datasets where 
samples may not necessarily overlap. To evaluate the benefit of SWAM’s ability for multi-
dataset “meta-imputation”, we integrated imputation models trained from GTEx v7 and v8, as 
well as 922 whole blood transcriptomes from Depression Gene Network (DGN). The rationale to 
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include GTEx v7 and v8 models is that the datasets are slightly different from v6 (for example, 
v7 has more samples in all tissues except for LCL, FCL, and whole blood) and integrating 
multiple training models from slightly different versions of datasets may improve the accuracy. 
The reason to include DGN whole blood is that the sample size is much larger than any 
individual tissue GTEx, so it may help further reduce the variance and MSE of the imputation 
model.  
When applying SWAM to GTEx v6, v7, or v8 datasets individually, the number of significantly 
imputed genes at FDR < .05 were 3,040, 3,060, and 3,203, respectively (Figure 2.3B). However, 
when all datasets were combined, the number of imputable genes increased to 3,342. These 
results suggest that imputation across multiple datasets can help even when the datasets are 
highly overlapping. When we additionally integrated SWAM with the DGN whole blood model, 
which detected 2,390 imputable genes by itself, the number of imputable genes by the 
integrated SWAM model further increased to 3,413. Note that we needed individual-level data 
only for the reference tissue/data (GTEx v6 LCL in our experiment), so an arbitrary combination 
of imputation models, which consist of only summary-level data, can be seamlessly added to 
the meta-imputation framework of SWAM.  
Overall, using all 49 GTEx v8 tissues in combination with the DGN whole blood model provided 
the highest number of predictable genes, with a 112.9% improvement over the corresponding 
GTEx v8 PrediXcan-LCL model (single tissue), and a 13.5% improvement over the GTEx v6 
version of SWAM-LCL (multi-tissue) (Figure 2.3B). Regardless of the version of GTEx used, 
including the DGN whole blood model gives a substantial improvement in number of 
predictable genes compared to not including it in the model. Another interesting observation is 
that while PrediXcan-LCL (v6) appears to perform better than PrediXcan-LCL (v7), SWAM-LCL 
derived from v7 performs better than v6 SWAM-LCL. This may suggest that while GTEx v7 
PrediXcan-LCL may not have had a significant improvement in eQTL detection compared to its 
predecessor, other tissues may have improved in more substantial ways. This is because the 
sample size for LCL in v7 decreased by 18 samples, whereas other non-blood tissues had 
substantial sample size gains of up to 89 individuals. Here, SWAM leverages the increase in 
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quality from other tissues, which allows for better overall prediction regardless of the quality of 
the target tissue itself. 
2.3.5 SWAM robustly captures both tissue-specific and cross-tissue regulatory components 
The key component behind the robust performance of SWAM is that it learns how to distribute 
weights across multiple imputation models for each gene individually. If a gene shares eQTLs 
across many tissues, the SWAM’s weights will be distributed evenly across tissues and the 
model will behave similarly to the naïve average heuristic. For example, ERAP2 is a well-known 
gene with shared eQTLs profiles across most tissues. In the GTEx (v6), ERAP2 can be reliably 
imputed with any of the 44 single-tissue imputation models from PrediXcan with r2 > 0.77 or 
more eQTLs. As a result, the weights from SWAM is almost evenly distributed across the 
tissues, ranging from 0.018 to 0.027 (Supplementary Figure 2.2A), and the accuracy of SWAM 
(r2 = 0.795) is very similar to the accuracy of naïve average (r2 = 0.796).  
On the other hand, when the imputation model from the reference tissue is not particularly 
good due to smaller sample size or other technical issues, SWAM can substantially improve 
accuracy by leveraging eQTL sharing from other tissues. For example, the single-tissue 
imputation accuracy of GSTM1 is relatively low in LCL tissue (r2 = 0.368) compared to the 
accuracy of the 38 other tissues in which a PrediXcan imputation model is available (average r2 
= 0.61). Using SWAM, the predictive R-squared increases to r2 = 0.741 by assigning positive 
weights to 31 tissues (Supplementary Figure 2.2B).  
Finally, for genes that are highly tissue-specific, the SWAM’s weights will be distributed similarly 
to the best tissue heuristic. For example, CTSK is expressed in most tissues, but has eQTLs in 
only 16 tissues, (Supplementary Figure 2.2C). SWAM assigns weights to 7 of these tissues, and 
substantially improves the predictive accuracy from r2 = 0.111 to r2 = 0.447.  
2.3.6 Comparison of imputation models in the context of TWAS 
We conducted TWAS analysis using SWAM, UTMOST, and PrediXcan models via MetaXcan 
[137]. In addition, we also used S-MultiXcan [94] to simultaneously test all of the PrediXcan 
models using their PCA regression approach. We used a Bonferroni correction to establish p-
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value threshold for each analysis separately, based on the number of genes imputed. Overall, 
we found that among the methods that directly estimate expression levels (SWAM, UTMOST, 
PrediXcan), SWAM outperformed the other methods in terms of number of associations 
detected (see Supplementary Tables 2.4, 2.5, 2.6). For example, PrediXcan models on average 
detected 23.7, 23.2 and 4.0 transcriptome-trait associations for HDL, LDL and T2D respectively. 
For SWAM, we observed an average of 79.7, 77.8 and 8.4 associations per tissue, whereas 
UTMOST yielded an average of 69.3, 61.6 and 8.8 associations per tissue, for the three traits 
respectively. 
We plotted transcriptome-wide signals for the LDL trait using the GTEx v6 liver model for 
PrediXcan, UTMOST and SWAM (Figure 2.4). One interesting signal gained from the SWAM 
analysis is the APOC1 gene, which is primarily expressed in the liver and has been implicated in 
playing a role in HDL and LDL/VLDL (very low-density lipid) metabolism [138].  
One potential shortcoming for both multi-tissue approaches (SWAM and UTMOST) appear to 
be that the number of unique signals (across all tissues) is fewer than those generated by 
PrediXcan’s single tissue models. For example, SWAM produces 210 unique associations for the 
HDL trait, while we see 187 unique associations from UTMOST and 248 unique associations 
from PrediXcan. Similarly, MultiXcan detects 284 significant associations when scanning across 
all tissues (based off the PrediXcan models). It appears that while the multi-tissue methods can 
leverage information from other tissues to predict expression accurately, marginal association 
signals in TWAS are potentially lost using these approaches. However, we found that a high 
number of these unique signals from the PrediXcan TWAS appeared only in one or two tissues 
(92.5% for HDL, 98.2% for LDL and 100% for T2D).  
With all these various considerations, SWAM appears to improve TWAS power for a given 
tissue, although ultimately may yield fewer signals compared to comprehensive tissue scans 
using PrediXcan or MultiXcan. While SWAM outperforms other methods in terms of prediction 
accuracy, there may not be a clear-cut winner in terms of performance in TWAS. The best 
approach to use will likely depend on the needs of the researcher, and each approach may 
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provide different yet complementary insights into understanding the biological mechanisms 
from these association studies. 
 
2.4 Discussion 
The transcriptome serves as an intermediate phenotype linking genetic variants to complex 
traits. Association studies between traits and gene expression, when used in conjunction with 
GWAS, provide additional insight into the biological mechanisms of complex traits. Prediction of 
gene expression in the context of transcriptome wide association studies is a promising 
approach to understanding the connection between our genes and many traits. Yet, there are 
still many challenges that arise when performing association studies with predicted expression. 
Current tissue-specific prediction models are trained using data obtained from their respective 
tissues, which can vary greatly in data quality and sample size. As such, there is a great deal of 
variability among tissues in the prediction accuracy of tissue-specific gene expression levels. For 
example, PrediXcan was able to significantly predict only 2086 vagina-specific genes, while it 
discovered 8171 genes specific to the tibial nerve tissue. Furthermore, the prediction accuracy 
of significant genes within a tissue are also highly variable, with some genes such as ERAP2 
having very high (>80% of variation explained by eQTLs) predictability and other genes (~1% of 
variation explained by eQTLs) with low predictability.  
In this paper we developed SWAM, a method that determines the level of eQTL sharing 
between tissues and uses the shared information from other tissues to improve the prediction 
accuracy for the target tissue. By simultaneously examining the relatedness of multiple tissues, 
SWAM in essence increases the effective sample size of prediction models. Using GEUVADIS LCL 
data, we compared SWAM to single-tissue approaches. We found that our multi-tissue 
approach, in addition to increasing the number of significantly predictable genes for each 
tissue, also improved the overall prediction accuracy for genes that were already significantly 
predictable using PrediXcan. We improved the power of TWAS by running a SWAM-adapted 
version of MetaXcan for various traits, finding an increased number of significant 
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transcriptome-trait associations, even when correcting for the larger number of genes 
predicted.  
Although SWAM provides a substantial improvement for the number of significantly predictable 
genes for many tissues and generally increases power for TWAS, there are some shortcomings 
and caveats to consider with the approach. It is important to note that unlike PrediXcan, SWAM 
does not actually perform model training or eQTL discovery. Instead, it evaluates the efficacy of 
various single-tissue prediction models (in this case, the GTEx tissues) and assigns weights to 
the models based on their relatedness to the target tissue. Therefore, for SWAM to work, there 
must already be a database of prediction models that it can use to derive the multi-tissue 
weighting. Because we are utilizing existing prediction models, we acknowledge that there will 
be cases where the SWAM prediction accuracy could be similar or worse to the single-tissue 
prediction, especially if the gene has shared eQTLs across many tissues or if the single-tissue 
prediction model was already performing well. The improvement observed in our validations 
and TWAS are an overall trend, and as with any analysis, interpretation of any specific results 
should be approached with caution. Furthermore, the improvement for any given gene has an 
upper limit which is dependent on the pool of single tissue models available. There may be 
tissues that have very few relevant other tissues to draw information from. For any given gene 
within the target tissue, SWAM automatically assigns weights of non-relevant tissues to zero 
based on a threshold. However, for the purposes of our study, the threshold was tuned to be 
more lenient, allowing for more tissues to be included in the prediction of each gene’s 
expression levels. A more lenient threshold will yield more genes, but a lower sensitivity to the 
target tissue. A stricter threshold will provide predictions that are more specific to the target 
tissue but will provide predictions for fewer genes and may reduce prediction accuracy in some 
genes. Optimal tuning of this threshold may depend on the target tissue, and the goals of the 
analysis. Further work could help determine the ideal way to tune these thresholds, perhaps 
using a different threshold depending on the gene and tissue in question.  
Next, our empirical validation of prediction accuracy was tested on European individuals (344 
samples from GEUVADIS) and thus SWAM’s performance with other populations has not yet 
been determined. A future direction of research could be to examine whether a single model 
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derived from mixed populations would represent each of the populations accurately, or if a 
different model should be trained on each population separately. Currently, evidence suggests 
that training from the correct ancestry group is the ideal approach for population-specific 
prediction [139], which emphasizes the importance of reference panel resources derived from a 
wide array of ancestries. Alternative approaches could be to leverage trans-ancestry 
correlation, which has been shown to increase predictive R2 in the context of polygenic risk 
scores [140]. 
Finally, while SWAM improved the number of association signals for any given tissue in TWAS 
compared to UTMOST and single tissue PrediXcan, aggregation of signals (MultiXcan/combining 
PrediXcan signals) suggest that other approaches may yield more unique signals. It is unclear 
which approach is preferable in this scenario, and the answer may depend on unraveling the 
causality of association signals. Recently, there have been a number of publications which have 
addressed this issue, such as PTWAS which uses instrumental variables (IVs) to investigate the 
causal relationship between expression levels and complex traits [134], or phenomeXcan, which 
integrates GWAS and gene expression and regulation data to identify likely causal pathways 
[141]. Future directions could include using IVs or functional annotation to interpret TWAS 
signals. 
To conclude, we propose a novel method for gene expression prediction, which extends already 
established single-tissue prediction models into a multi-tissue setting. By combining 
information from multiple models, we were able to increase overall tissue-specific prediction 
accuracy for many genes and increase power for transcriptome-wide association studies. 
 
2.5 Materials and Methods 
2.5.1 SWAM Notation and Framework 
Our framework for SWAM is designed to find the optimal linear combination of imputed 
expression levels from multiple tissues and datasets. For simplicity, we will denote each (tissue, 
dataset) combination as a source. We assume there are 𝐾 imputation models from individual 
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sources, with each model indexed as 𝑗 ∈ (1, . . , 𝐾). We also denote 𝑟 ∈ {1, … , 𝐾} to represent 
the index of the reference source. The inputs for SWAM are: (1) 𝑓 (∙) – the single-source 
imputation models and (2) 𝒀𝒓 and 𝑿𝒓 – the individual-level gene expression measurements and 
genotypes for the reference source. For each gene 𝑔, let 𝒔 = 𝑓 (𝑿|𝑔) be imputed expression 
from a single source. Then we can represent any linearly combined multi-tissue imputed 
expression 𝒎  as 
𝒎 = 𝑤 𝒔  
where 𝑤  is the weight contributed by 𝑗-th source. SWAM learns 𝑤  by leveraging individual-
level data from the reference source as we describe later.  
2.5.2 Multi-tissue methods using naïve average or best-tissue 
There are two heuristic approaches to impute expressions from multiple sources - naïve 
average and best tissue. Naïve average defines weights uniformly as 𝑤 = … = 𝑤 = 1 𝐾 . For 
best tissue, the weights are defined as a dichotomous variable: 
𝑤 =
1     if 𝑗 = argmax(𝑐𝑜𝑟 𝒔 , 𝒚 )
0       otherwise                               
 
where 𝒚  represents the individual-level expression measurements of the reference source.  
2.5.3 Smartly Weighted Average across Multiple Tissues (SWAM) 
Here we describe how SWAM calculates optimal 𝑤 , whose derivation is shown in the 
Supplementary Text. It is important to note that SWAM works ideally when the tissue type 
intended to be imputed matches to the tissue types of the reference source. We define 𝒚  as 
the 𝑛 × 1 vector of individual-level expression measurements for the reference source, and as 
before, 𝑿𝒓 to be the corresponding 𝑛 × 𝑚 matrix of individual-level genotypes.  The first step is 
to impute expression using each of the 𝐾 models using the reference genotypes. Thus, we 
obtain 𝐾 sets of imputed expressions, 𝒔 = 𝑓 (𝑋 |𝑔), with each being a single-source 
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prediction for the samples in the reference data. The weights for SWAM are given by 
 
𝒘𝒈 = 𝑤 , 𝑤 , … , 𝑤 =
𝑐𝑜𝑟(𝒔 , 𝒔 ) ⋯ 𝑐𝑜𝑟(𝒔 , 𝒔 )
⋮ ⋱ ⋮
𝑐𝑜𝑟(𝒔 , 𝒔 ) ⋯ 𝑐𝑜𝑟(𝒔 , 𝒔 )
+ 𝜆𝐼
𝑐𝑜𝑟(𝒔 , 𝒚 )
⋮
𝑐𝑜𝑟(𝒔 , 𝒚 )
 
 
Here, the correlation matrix account for the similarity between the imputation models, and the 
vector containing the entries 𝑐𝑜𝑟 𝒔 , 𝒚  account for the empirical similarity of imputed 
expressions from each model to the measured expressions in the reference source. When 𝑗 =
𝑡, because 𝑐𝑜𝑟 𝒔 , 𝒚  will be prone to overfitting, we replace this value to a 5-fold cross-
validated correlation instead, which is available from PrediXcan output. Finally, 𝜆𝐼 acts to 
regularize the weights, providing numerical stability for the inversion of the covariance matrix. 
The calibration of  𝜆 is further discussed in the Supplementary Text. 
2.5.4 Simulations 
Our simulation study sought to examine SWAM’s ability to detect the correct shared 
components between related tissues across a wide spectrum of parameter settings. We 
compared SWAM with naïve average, best tissue and single tissue approaches. For each 
simulation, we independently generate individual-level genotypes and expression multiple 
tissues. For the reference set, we simulated 𝑋 , an 𝑛 × 𝑚 genotype where 𝑛  is the number of 
individuals and 𝑚 the number of SNPs. In our simple simulation, we assume that each SNP is 
independent, with non-reference allele frequency (AF) distributed with Beta(1,3). The 
genotypes were simulated using a binomial distribution based off the AF. To simulate multi-
tissue expressions, for each tissue 𝑗 ∈ (1, . . , 𝐾) we specific effect sizes 𝜷𝒋, to simulate 
expressions 𝒚𝒋 = 𝑋 𝜷𝒋 + 𝜀 . For reference tissue (i.e. 𝑗 = 𝑟), we assume two causal SNPs with 
nonzero elements in 𝜷𝒋, where one SNP is expected to explain tissue-specific heritability (ℎ ) 
for the reference tissue and the other SNP explains the cross-tissue heritability (ℎ ), summing 
up to total heritability (ℎ = ℎ + ℎ ). Other tissues (i.e. 𝑗 ≠ 𝑟) were divided into “related 
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tissues” and “independent tissues”. For related issues, 𝜷𝒋  had only one non-zero values 
corresponding to cross-tissue heritability (ℎ ). For independent tissues, all 𝜷𝒋 had zero values. 
Finally, we generated another set of validation genotypes matrix 𝑋  with size 𝑛 × 𝑚, and the 
validation expressions (𝒚𝒗 = 𝑋 𝜷𝒓 + 𝜀 ) of reference tissue using the same settings to use for 
evaluation. 
We then trained tissue-specific imputation models 𝑓 (. ), 𝑗 ∈ (1, … , 𝐾) by applying an elastic-net 
model (using glmnet R package [142]) for each pair of 𝑋  and 𝒚𝒋. The tuning parameters for 
elastic net were determined via a five-fold cross-validation technique. Using 𝒚𝒓, 𝑋  and 𝑓 (. ), 
we obtained naïve average, best tissue and SWAM models as detailed in the framework and 
weights section. To calculate the proportion of imputable genes, we performed linear 
regression between 𝒚𝒗 and the imputed expression from genotypes 𝑋  using the different 
methods to obtain a p-value.  
Each simulation was repeated for 1,000 times in each setting. We varied parameters to 
evaluate their impact on the performance of each method. We varied  ℎ ∈ {0, 0.1, ⋯ ,1} 
(default 0.1), ℎ /ℎ ∈ {0, 0.1, ⋯ ,1} (default 0.5), 𝐾 ∈ {2, 4, 6, 8, 10, 20, 30, 40, 50} (default 10), 
fraction of independent tissues ranging {0, 0.1, ⋯ ,0.8} (default 0.5), 𝑛 ∈ {50,100, ⋯ ,500} 
(default 200), and the p-value threshold ranging {10 , 10 , ⋯ , 0.01, 0.05, 0.1} (default 0.05). 
Throughout all simulations, 𝑚 = 35, 𝑛 = 200 were used. 
2.5.5 Input Datasets: Genotypes, Expressions, and Imputation Models 
In our experiments with real datasets, we leveraged multiple published datasets where 
genotypes, expressions, and imputation models are available to evaluate the performance of 
SWAM and other methods in various settings. Specifically, we used the GEUVADIS LCL [47] 
genotypes and expressions as a validation dataset. We used GTEx data [14] [24] and PredictDB 
[55] to build multi-tissue imputation models. To demonstrate the ability to SWAM to 




2.5.5.1 Multi-tissue transcriptomic profiles and imputation models from the GTEx project 
To build multi-tissue imputation models using SWAM, UTMOST, naïve average, and best tissue 
methods, we used single-tissue imputation models, individual-level genotypes, and expressions 
obtained from the GTEx consortium. Single-tissue imputation models were downloaded from 
the PredictDB (http://predictdb.org/) repository for GTEx versions 6, 7 and 8 (44, 48 and 49 
tissues respectively) [3] [14] [24], which were trained using PrediXcan’s elastic net methods. 
Individual-level genotypes and expression levels were only used for the reference tissue (e.g. 
EBV-transformed lymphocytes) which is deemed to be the closest to the validation data (e.g. 
GEUVADIS LCL), using GTEx version 6.  
When evaluating multi-tissue imputation models within a single dataset, we used GTEx version 
6. When evaluating imputation models across multiple tissues and multiple datasets, we used 
various combinations of GTEx versions to evaluate the benefit of multiple imputation models 
trained from overlapping datasets. When training across different datasets, genes were 
matched by ensemble ID, ignoring version numbers. In addition to training SWAM, we also used 
the single tissue PredictDB imputation models as a basis for comparison with our method. 
2.5.5.2 Validation dataset from the GEUVADIS study 
We used individual-level genotypes and expression levels from lymphoblastoid cell lines (LCL) 
from the GEUVADIS consortium only to evaluate various methods after imputing expression 
levels with models built from other datasets. Each imputation model was evaluated by applying 
the model to GEUVADIS genotypes to impute individual expression levels, and by calculating 
the correlation between the imputed and measured expressions. We focused on 344 European 
individuals where genotypes and normalized expressions (from RNA-seq) are available, with 
comparable linkage disequilibrium (LD) structure to GTEx and DGN datasets.  
2.5.5.3 Imputation models from Depression Genes Network 
We also downloaded the imputation model trained using the 922 whole blood transcriptomes 
from the Depression Genes Network (DGN) via PredictDB. DGN was evaluated as a single-tissue 
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imputation model. It was also used in the evaluation of multi-dataset imputation models when 
DGN is combined with various versions of GTEx imputation models.  
2.5.5.4 Imputation models from UTMOST 
We compared our methods to UTMOST, another multi-tissue approach for expression 
imputation[93]. The UTMOST imputation models were jointly trained across 44 tissues from 
GTEx version 6 and were downloaded from their published online repository 
(https://github.com/Joker-Jerome/UTMOST). We applied the imputation model targeted for 
EBV-transformed lymphocytes when evaluating the imputation accuracy with the GEUVADIS 
LCL expression.  
2.5.6 Experimental Evaluation with Real Datasets 
2.5.6.1 Evaluating imputation accuracy with GEUVADIS measured expression 
We evaluated the accuracy of various imputation models by comparing imputed expressions 
from individual-level genotypes with the measured expression from GEUVADIS LCLs. Individual-
level expression were imputed across 344 European GEUVADIS samples using various single-
tissue, multi-tissue/multi-dataset methods to calculate the correlation with the normalized 
measured expression from GEUVADIS LCL. The correlation between imputed and measured 
expressions were calculated using spearman correlation and a one-sided p-value was evaluated 
by converting the correlation coefficients into t-statistics. Genes were considered “significantly 
predictable” if the Benjamini-Hochberg false discovery rate (FDR) was less than 0.05. This 
procedure was applied across all genes within each method, with the counts being tabulated. 
2.5.6.2 Comparing single-tissue and multi-tissue imputation models within a single dataset. 
With these results, we first focused on comparing the imputation accuracy of SWAM with other 
methods using GTEx v6. We compared SWAM-LCL (SWAM using GTEx EBV-transformed 
lymphocytes as reference), every single tissue imputation model from PredictDB, UTMOST-LCL 
(UTMOST using GTEx EBV-transformed lymphocytes as reference), naïve average, and best 
tissue methods. We focused on evaluation using GTEx v6 models where UTMOST models were 
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available. We also focused on genes included in the Consensus Coding Sequence Project (CCDS) 
[143] to minimize the discrepancy between imputation models.  
To keep a fair comparison with UTMOST and the single tissue methods, we restricted the set of 
genes to those that have at least one eQTL in any single tissue models from PredictDB and also 
in any UTMOST models across all reference tissues.  
2.5.6.3 Evaluating multi-tissue imputation models across multiple datasets. 
Our second comparison was conducted to examine the effect of integrating multiple 
imputation models trained from heterogeneous datasets into SWAM. Here, we used various 
combinations of GTEx and DGN resources to derive multi-tissue/multi-dataset models, such as 
combining GTEx v6 with DGN data, or combining GTEx v6, v7 and v8 altogether. For this 
analysis, the gene list was restricted to genes that were included in all three of the v6, v7 and v8 
datasets in terms of Ensemble IDs. 
2.5.7 Evaluation of SWAM in transcriptome-wide association studies (TWAS) 
To evaluate our method in the context of TWAS, we used MetaXcan [137], which infers TWAS 
results from GWAS summary statistics. We focused on the HDL and LDL traits from Global Lipids 
Genetics Consortium (GLGC) [144] and Type-2 Diabetes (T2D) from the DIAGRAM consortium 
[145]. For this analysis, we generated SWAM imputation models targeting each of the 44 
tissues from GTEx version 6. We used MetaXcan to infer the TWAS results for each of these 
tissues and applied a Bonferroni correction with false-positive rate of 0.05 based on the 
number of genes tested. We repeated this with all 44 UTMOST models as well as all 44 
PrediXcan single tissue models.  
We also compared our method with S-MultiXcan [94], a recently published extension of 
MetaXcan which uses a principal components regression to conduct trait-expression association 




















Figure 2.1 – overview of SWAM method.  
This figure demonstrates the training of the imputation model using the reference data. The inputs required for 
SWAM are a set of reference genotypes with sample matched measured expression, and the multiple prediction 
models to be included. The list of multiple prediction models must also include a model derived from the 
reference data, which can be done via prediXcan. SWAM uses these models to impute tissue-specific expression 
levels from the reference genotypes. These imputed expression sets are then compared with the measured 
expression of the reference set. The weights are calculated based on the similarity between the measured and 




Figure 2.2– simulation study comparing SWAM with naïve average, best tissue and single tissue methods.  
We ran each simulation 10,000 times, with the following default settings: 10 total tissues (1 target, 4 relevant, 5 irrelevant), 100 SNPs (2 per tissue), 10% 
genetic heritability, 50% shared heritability between relevant tissues. In addition, the sample size of the target tissue was 100 individuals, and the 
remaining tissues had 200 individuals. This was done to emphasize the importance of integrating information from other tissues when the quality of the 
target tissue model is limited. In panel (A), we varied the number of relevant tissues, from 0 to 10. Panel (B) shows the improvement when the total 
number of tissues is increased, with the number of irrelevant tissues fixed at 50% of the total. Panel (C) shows the effects of changing the shared 
heritability for the relevant tissues. We note here, that each tissue has 2 causal SNPS – for the relevant tissues, 1 of these causal SNPS is shared with the 
target tissue while the other is independent of all simulated tissues. Panel (D) shows the performance of the approaches for different levels of genetic 
heritability. This simulation demonstrates the range of heritability that we would expect to see the most improvement. Empirically, we do notice the same 
trend seen here, as SWAM performs similarly the single tissue model when the cross-validated R-squared is high. Panel (E) shows the effects of target 
tissue sample size. The x-axis pertains to the sample size of the target tissue only, and all other tissues were fixed at 200 individuals. Finally, panel (F) 




Figure 2.3 – Empirical validation of SWAM using lymphoblastoid-cell line data 
from GEUVADIS consortium.  
We used our LCL-targeted SWAM model to predict expression levels based on the 
genotypes of 344 European samples. We then calculated the concordance 
between imputed expression and measured LCL expression. We repeated this for 
all of the other methods mentioned here. (A) shows the performance of SWAM 
against the single-tissue models from 44 tissue-specific predictDB models derived 
from GTEx version 6. In (B), we derived various SWAM models using every 
combination of the following: 1) all GTEx v6 tissues, 2) all GTEx v7 tissues, 3) all 
GTEx v8 tissues, and 4) Depression Gene Network (DGN) single tissue whole blood 
model from predictDB. Here, we also included the UTMOST LCL model, naïve 


























Figure 2.4 – TWAS on LDL trait targeting liver using SWAM, UTMOST and PrediXcan models 
TWAS was performed using metaXcan on the LDL trait from the Global Lipids Genetics Consortium 
(GLGC) GWA analysis. For a consistent comparison, the SWAM and UTMOST models were derived 
from GTEx version 6 tissues, and the prediXcan model used was GTEx v6 liver. The number of 
associations were: 74, 69 and 19 for SWAM, UTMOST and prediXcan respectively. P-values were 
truncated at 10-20 in these plots. 
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2.7 Supplementary Materials 
2.7.1 Derivation of weights for SWAM 
In this section we derive the equation for the weights in SWAM. We wish to impute expression 
for a reference sample of 𝑁 individuals with genotypes 𝑋  and measured tissue-specific 
expression 𝒚𝒓. Suppose we have single tissue prediction models for 𝐾 tissues, with 𝑟 ∈
{1, … , 𝐾}. For each gene 𝑔, we obtain a set of 𝐾 predicted expression levels 𝒔𝒋
𝒈
= 𝑋 𝛽 , with 
𝑗 ∈ (1, … , 𝐾). Dropping the superscript 𝑔 for convenience, we define 𝑤 = (𝑤 , 𝑤 , … , 𝑤 )′ be 
the set of weights corresponding to each of the tissues. The SWAM estimator is thus: 
𝒎𝑺𝑾𝑨𝑴 = 𝑤 𝒔𝒋 
For further convenience, we denote 𝒎  as 𝒎. Then, for each gene separately, the values 
for 𝑤 are determined by minimizing the expression:  
𝐸 ‖ 𝒎 − 𝑦 ‖ = 𝐸 (𝑤 𝒔 ) − 𝒚𝒓 = 𝐸 𝑤 (𝒔𝒊 − 𝒚𝒓)  
Without loss of generality, we set the constraint ∑ 𝑤 = 1. The objective function to be 
minimized is 
ℒ(𝒘, 𝜆) = 𝐸 ‖𝒎 − 𝒚𝒓‖ + 𝛾 𝑤 − 1
= 𝑤 𝐸[(𝒔𝒊 − 𝒚𝒓) ] + 2 𝑤 𝑤 𝐸 (𝒔𝒊 − 𝒚𝒓)′(𝒔𝒋 − 𝒚𝒓)
+ 𝛾 𝑤 − 1  


















, 𝑖 ∈ {1, ⋯ , 𝐾} 
Solving this system of equations, we obtain the optimal weighting minimizing the expected MSE 






𝐸[(𝒔𝟏 − 𝒚𝒓) ] ⋯ 𝐸[(𝒔𝟏 − 𝒚𝒓)′(𝒔𝑲 − 𝒚𝒓)]
⋮ ⋱ ⋮
𝐸[(𝒔𝑲 − 𝒚𝒓)′(𝒔𝟏 − 𝒚𝒓)] ⋯ 𝐸[(𝒔𝑲 − 𝒚𝒓) ]
 and 𝟏 = (1,…,1)’ 
 
2.7.2 Regularization of weights 
The weights derived in the previous section provide an optimal solution to the expression 
argmin 𝐸 𝑌 − 𝑌 . In the scenario in which the tissues are highly correlated with each 
other, the matrix 𝑐𝑜𝑣 𝑌 =
〈𝑌 , 𝑌 〉 ⋯ 〈𝑌 , 𝑌 〉
⋮ ⋱ ⋮
〈𝑌 , 𝑌 〉 ⋯ 〈𝑌 , 𝑌 〉
is numerically unstable as the 
columns of 𝑐𝑜𝑣 𝑌  are no longer linearly independent. This can lead to high weights assigned 
to irrelevant tissues and lower weights for relevant tissues. Furthermore, this may result in 
weights that are over-fitted to the noise of the data.  
To correct for this, we added a diagonal matrix, 𝜆𝐼 prior to inverting the matrix 𝑐𝑜𝑣 𝑌 , giving 
us the solution 𝑤 = 𝑐𝑜𝑣 𝑌 + 𝜆𝐼 𝑐𝑜𝑟(𝑌 , 𝑌 ). To choose the correct value of 𝜆, we 
tested the prediction accuracy of 𝑌  in our validation test set for a large range of 𝜆. We found 
that prediction accuracy was low when 𝜆 = 0, likely due to overfitted and the amplification of 
noise. Larger values of 𝜆 yielded better results but ignored the correlation structure between 
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tissues. We found empirically that 𝜆 = 3 provided the best results (this value depends highly on 
the scale and normalization of the data).  
 
2.7.3 Application of SWAM to other target tissues 
Throughout our work we primarily used the LCL tissue from GTEx version 6 as our target tissue 
for application of SWAM. In addition to producing SWAM-LCL models, we also generated 
models targeting each of the 44 GTEx v6 tissues. Supplementary Figure 2.3 displays the 
heatmap of weight contribution towards each of the tissues. The rows correspond to the 
SWAM model for each tissue type, and the color intensity of the columns show the contribution 
of each tissue towards the targeted tissue (number of times the tissue contributed the highest 
weight). Overall, we observe clustering that appears to separate the tissue types quite well. For 
example, brain tissues are primarily getting high weights from other brain tissues while 
receiving low weights from all other tissue types. This heatmap provides evidence of SWAM 
being able to capture tissue-specific signals. 
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Supplementary Figure 2.1 – Using SWAM to impute expression and conduct TWAS 
The first panel shows how SWAM can be used to predict expression levels via prediXcan, while 





Supplementary Figure 2.2 – Bias-variance tradeoff for other tissues 
The principal behind SWAM is it considers the bias-variance tradeoff for each tissue, and assigns 
higher weights to tissues that reduce MSE. In this example, tissues such as Skeletal Muscle have 
a high sample size (and therefore lower variance) but may be biased as they are not the relevant 
tissue to the tissue of interest (in this case LCL). Other tissues such as Fibroblasts may have a 
lower sample size but compensate by having low bias (high relevance to tissue of interest) and 



























Supplementary Figure 2.3– The distribution of weights for SWAM for three selected genes.  
(2A) shows the ERAP 2 gene, which had a single tissue r2 = 0.801, while the SWAM model had r2 
= 0.795. (2B) depicts are scenario where SWAM is able to leverage information from other 
tissues to make up for the relatively lower quality of the target tissue – here the single tissue 
model gave r2 = 0.368 while SWAM increased the accuracy to r2 = 0.741. (2C) shows an example 
where the eQTLs are highly tissue specific. Here, SWAM improved the single tissue accuracy from 



























Supplementary Figure 2.4 – distribution of SWAM weights 
in imputation models for all 44 GTEx v6 tissues. 
Here, we used SWAM to derive multi-tissue imputation 
models for all 44 GTEx v6 tissues. Each cell in this heatmap 
depict the number of times each tissue contributed the 
highest weight to the target tissue. Here, the rows 
correspond to the target tissue and the columns correspond 
to the weight contribution of each tissue. For the sake of 
clarity, the diagonal values were not included as they were 















p-value < 0.05 
DGN Whole Blood 13213 2390 0.009018 3450 
Adipose Subcutaneous 13213 1500 0.005667 2203 
Adipose Visceral Omentum 13213 963 0.003619 1432 
Adrenal Gland 13213 735 0.002755 1151 
Artery Aorta 13213 1177 0.004426 1783 
Artery Coronary 13213 616 0.00231 926 
Artery Tibial 13213 1439 0.005399 2124 
Brain Anterior cingulate cortex BA24 13213 322 0.00117 580 
Brain Caudate basal ganglia 13213 528 0.001979 895 
Brain Cerebellar Hemisphere 13213 575 0.002172 1002 
Brain Cerebellum 13213 661 0.002498 1144 
Brain Cortex 13213 511 0.00193 878 
Brain Frontal Cortex BA9 13213 456 0.001699 770 
Brain Hippocampus 13213 336 0.001254 572 
Brain Hypothalamus 13213 339 0.001264 554 
Brain Nucleus accumbens basal ganglia 13213 454 0.001709 755 
Brain Putamen basal ganglia 13213 391 0.001461 655 
Breast Mammary Tissue 13213 933 0.003455 1430 
Cells EBV-transformed lymphocytes 13213 1552 0.005845 1943 
Cells Transformed fibroblasts 13213 1690 0.00635 2451 
Colon Sigmoid 13213 680 0.002391 1052 
Colon Transverse 13213 1013 0.003803 1536 
Esophagus Gastroesophageal Junction 13213 716 0.002689 1101 
Esophagus Mucosa 13213 1469 0.00553 2148 
Esophagus Muscularis 13213 1272 0.004808 1959 
Heart Atrial Appendage 13213 849 0.003167 1323 
Heart Left Ventricle 13213 942 0.003537 1451 
Liver 13213 427 0.001547 719 
Lung 13213 1355 0.005122 1985 
Muscle Skeletal 13213 1197 0.004454 1876 
Nerve Tibial 13213 1450 0.005483 2186 
Ovary 13213 417 0.001566 689 
Pancreas 13213 911 0.003426 1406 
Pituitary 13213 496 0.001875 808 
Prostate 13213 398 0.001421 629 
Skin Not Sun Exposed Suprapubic 13213 1063 0.003997 1619 
Skin Sun Exposed Lower leg 13213 1463 0.005489 2145 
Small Intestine Terminal Ileum 13213 450 0.001694 735 
Spleen 13213 759 0.002821 1166 
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Stomach 13213 878 0.003291 1350 
Testis 13213 956 0.003607 1563 
Thyroid 13213 1454 0.005469 2208 
Uterus 13213 297 0.001071 521 
Vagina 13213 307 0.001149 511 
Whole Blood 13213 1427 0.005343 2106 
SWAM-LCL v6 13213 3040 0.01145 4148 
NAIVE AVERAGE V6 13213 2666 0.010066 3830 
BEST TISSUE V6 13213 2493 0.009394 3663 
















Supplementary Table 2.1  – GTEx version 6 comparisons of single-tissue and multi-tissue imputation 
models using GEUVADIS LCL RNA-Seq expression as validation.  
Counts (B-H counts) are based on Benjamini-Hochberg procedure false discovery rate of 0.05. The last 













p-value < 0.05 
SWAM-LCL (GTEx v6) 13213 3040 0.01145 4148 
SWAM-LCL (GTEx v6 + DGN) 13213 3192 0.012077 4301 
SWAM-LCL (GTEx v7) 13213 3060 0.011463 4215 
SWAM-LCL (GTEx v7 + DGN) 13213 3411 0.012903 4469 
SWAM-LCL (GTEx v8) 13213 3203 0.01212 4236 
SWAM-LCL (GTEx v8 + DGN) 13213 3449 0.013046 4460 
SWAM-LCL (GTEx v6 + v7) 13213 3283 0.012383 4385 
SWAM-LCL (GTEx v6 + v7 + DGN) 13213 3361 0.012674 4480 
SWAM-LCL (GTEx v6 + v8) 13213 3134 0.01185 4274 
SWAM-LCL (GTEx v6 + v8 + DGN) 13213 3275 0.012389 4384 
SWAM-LCL (GTEx v7 + v8) 13213 3259 0.01227 4326 
SWAM-LCL (GTEx v7 + v8 + DGN) 13213 3368 0.012737 4478 
SWAM-LCL (GTEx v6 + v7 + v8) 13213 3342 0.012641 4448 
SWAM-LCL (GTEx v6 + v7 + v8 + 
DGN) 13213 3413 0.012878 4526 
UTMOST-LCL 13213 2238 0.008466 3185 
NAIVE AVERAGE 13213 2666 0.010066 3830 











Supplementary Table 2.2– Comparison of all multi-tissue methods  
We applied SWAM to all combinations of GTEx and DGN resources. For the GTEx resources, we always 
used every tissue available. In version 6, this comprised of 44 tissues. For version 7, there were 48 
tissues and version 8 contained 49 tissues. For the sake of consistency, our target tissue for each of 



















Adipose Subcutaneous 328 6689 2259 581 6847 2114 
Adipose Visceral Omentum 273 5286 1905 469 5769 1957 
Adrenal Gland 146 3784 1322 233 3816 1279 
Artery Aorta 236 5488 1850 387 6090 1844 
Artery Coronary 128 2838 1040 213 3177 1119 
Artery Tibial 329 6836 2131 584 6955 2023 
Brain Amygdala 81 1876 581 129 2081 682 
Brain Anterior cingulate cortex BA24 102 2628 838 147 2662 840 
Brain Caudate basal ganglia 126 3272 1035 194 3795 1146 
Brain Cerebellar Hemisphere 113 3810 1050 175 4482 1127 
Brain Cerebellum 137 4899 1310 209 5254 1299 
Brain Cortex 119 3422 1073 205 4169 1203 
Brain Frontal Cortex BA9 104 2812 879 175 3424 1019 
Brain Hippocampus 99 2217 708 165 2806 886 
Brain Hypothalamus 98 2219 710 170 2742 911 
Brain Nucleus accumbens basal 
ganglia 
114 2820 921 202 3629 1076 
Brain Putamen basal ganglia 98 2542 806 170 3365 1035 
Brain Spinal cord cervical c-1 76 2003 600 126 2455 744 
Brain Substantia nigra 70 1609 496 114 1892 570 
Breast Mammary Tissue 211 4280 1622 396 5076 1756 
Cells EBV-transformed lymphocytes 96 2777 1731 147 2537 1620 
Cells Transformed fibroblasts 256 6297 2336 483 7421 2428 
Colon Sigmoid 185 4257 1556 318 4847 1633 
Colon Transverse 210 4457 1771 368 4923 1781 
Esophagus Gastroesophageal 
Junction 
185 4325 1603 330 4964 1675 
Esophagus Mucosa 307 6744 2305 497 6872 2167 
Esophagus Muscularis 287 6354 2119 465 6554 2030 
Heart Atrial Appendage 231 4866 1675 372 5262 1696 
Heart Left Ventricle 233 4449 1491 386 4902 1569 
Kidney Cortex NA NA NA 73 1205 344 
Liver 134 2746 883 208 2983 976 
Lung 333 6251 2190 515 6173 2071 
Minor Salivary Gland 74 1785 652 144 2161 842 
Muscle Skeletal 421 6323 1901 706 6261 1762 
Nerve Tibial 305 7512 2179 532 7764 2051 
Ovary 99 2406 818 167 2751 909 
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Pancreas 180 4369 1504 305 4710 1532 
Pituitary 143 3691 1228 237 4262 1381 
Prostate 114 2487 926 221 3205 1125 
Skin Not Sun Exposed Suprapubic 285 6092 1997 517 6802 2011 
Skin Sun Exposed Lower leg 359 7221 2201 605 7203 2071 
Small Intestine Terminal Ileum 103 2482 991 174 2844 1145 
Spleen 119 3753 1514 227 4527 1720 
Stomach 200 3899 1518 324 4064 1542 
Testis 191 5919 1451 322 6470 1518 
Thyroid 344 7556 2249 574 7468 2130 
Uterus 82 1957 681 129 1944 699 
Vagina 91 1889 690 141 1919 725 















Supplementary Table 2.3 – comparison of GTEx v7/v8 single tissue models versus GEUVADIS LCL 
We also compared every prediXcan model derived from GTEx version 7 and version 8 tissues, and 
tested prediction accuracy against GEUVADIS LCL measured expression levels. Surprisingly, 
despite the increase in sample size, the LCL tissue from v8 performed worse than its version 7 
counterpart. The number of tissues outperforming LCL in both v7 and v8 highlight the opportunity 
























Adipose Subcutaneous 78 3.23E-06 15501 79 3.22E-06 15507 8 3.19E-06 15669 
Adipose Visceral Omentum 80 3.26E-06 15326 71 3.26E-06 15333 8 3.23E-06 15476 
Adrenal Gland 70 3.34E-06 14961 78 3.34E-06 14973 8 3.31E-06 15110 
Artery Aorta 74 3.34E-06 14990 78 3.33E-06 15000 10 3.31E-06 15125 
Artery Coronary 76 3.33E-06 15001 69 3.33E-06 15009 7 3.30E-06 15147 
Artery Tibial 84 3.33E-06 14994 81 3.33E-06 15001 11 3.30E-06 15145 
Brain Anterior cingulate cortex BA24 87 3.36E-06 14892 70 3.36E-06 14901 6 3.32E-06 15061 
Brain Caudate basal ganglia 88 3.29E-06 15216 75 3.28E-06 15221 11 3.25E-06 15372 
Brain Cerebellar Hemisphere 75 3.39E-06 14742 74 3.39E-06 14755 4 3.36E-06 14891 
Brain Cerebellum 71 3.34E-06 14991 81 3.33E-06 15006 5 3.30E-06 15150 
Brain Cortex 78 3.29E-06 15198 91 3.29E-06 15208 6 3.25E-06 15366 
Brain Frontal Cortex BA9 74 3.32E-06 15061 65 3.32E-06 15073 5 3.28E-06 15239 
Brain Hippocampus 79 3.31E-06 15098 71 3.31E-06 15106 9 3.27E-06 15269 
Brain Hypothalamus 67 3.28E-06 15265 72 3.27E-06 15274 7 3.24E-06 15419 
Brain Nucleus accumbens basal 
ganglia 73 3.30E-06 15152 83 3.30E-06 15166 7 3.27E-06 15313 
Brain Putamen basal ganglia 86 3.35E-06 14926 79 3.35E-06 14935 9 3.32E-06 15066 
Breast Mammary Tissue 77 3.19E-06 15682 79 3.19E-06 15687 11 3.16E-06 15838 
Cells EBV-transformed lymphocytes 75 3.75E-06 13344 76 3.75E-06 13347 9 3.70E-06 13504 
Cells Transformed fibroblasts 74 3.55E-06 14091 81 3.55E-06 14098 10 3.51E-06 14253 
Colon Sigmoid 73 3.31E-06 15124 79 3.30E-06 15138 11 3.27E-06 15291 
Colon Transverse 78 3.23E-06 15500 73 3.22E-06 15507 7 3.19E-06 15681 
Esophagus Gastroesophageal Junction 79 3.34E-06 14988 78 3.33E-06 14993 8 3.30E-06 15140 
Esophagus Mucosa 84 3.27E-06 15268 81 3.27E-06 15275 7 3.24E-06 15437 
Esophagus Muscularis 77 3.29E-06 15199 93 3.29E-06 15205 7 3.26E-06 15343 
Heart Atrial Appendage 88 3.36E-06 14879 90 3.36E-06 14890 12 3.33E-06 15030 
Heart Left Ventricle 73 3.43E-06 14558 82 3.43E-06 14569 8 3.40E-06 14696 
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Liver 84 3.49E-06 14325 74 3.49E-06 14337 10 3.45E-06 14497 
Lung 92 3.16E-06 15813 73 3.16E-06 15822 7 3.13E-06 15974 
Muscle Skeletal 84 3.43E-06 14560 71 3.43E-06 14564 6 3.40E-06 14696 
Nerve Tibial 88 3.22E-06 15548 87 3.21E-06 15559 9 3.18E-06 15706 
Ovary 94 3.39E-06 14754 91 3.39E-06 14760 12 3.36E-06 14898 
Pancreas 73 3.36E-06 14891 66 3.36E-06 14900 11 3.33E-06 15026 
Pituitary 82 3.22E-06 15517 87 3.22E-06 15530 7 3.19E-06 15694 
Prostate 84 3.24E-06 15420 79 3.24E-06 15429 12 3.21E-06 15588 
Skin Not Sun Exposed Suprapubic 83 3.22E-06 15545 81 3.21E-06 15555 6 3.18E-06 15735 
Skin Sun Exposed Lower leg 85 3.18E-06 15729 75 3.18E-06 15738 7 3.15E-06 15891 
Small Intestine Terminal Ileum 78 3.28E-06 15265 67 3.27E-06 15281 7 3.23E-06 15462 
Spleen 78 3.36E-06 14873 69 3.36E-06 14884 18 3.33E-06 15037 
Stomach 80 3.23E-06 15495 74 3.22E-06 15506 7 3.19E-06 15658 
Testis 80 3.03E-06 16520 83 3.03E-06 16528 9 2.98E-06 16764 
Thyroid 78 3.18E-06 15705 70 3.18E-06 15714 10 3.15E-06 15876 
Uterus 84 3.42E-06 14641 90 3.41E-06 14654 8 3.38E-06 14803 
Vagina 84 3.30E-06 15157 84 3.30E-06 15167 7 3.26E-06 15328 
Whole Blood 78 3.49E-06 14331 71 3.49E-06 14340 7 3.45E-06 14505 
Average 79.71   77.75   8.43   
Supplementary Table 2.4– TWAS association signals for SWAM 
We used SWAM to derive an tissue-specific model for every GTEx version 6 tissue, and used these models as inputs to 
metaXcan to infer TWAS results. As mentioned in the methods section, the HDL and LDL traits were from Global Lipids 

























Adipose Subcutaneous 82 4.18E-06 11964 61 4.18E-06 11969 11 3.94E-06 12688 
Adipose Visceral Omentum 69 4.26E-06 11741 68 4.26E-06 11743 10 4.01E-06 12475 
Adrenal Gland 72 4.55E-06 10998 66 4.54E-06 11004 7 4.26E-06 11737 
Artery Aorta 75 4.47E-06 11180 55 4.47E-06 11184 7 4.19E-06 11926 
Artery Coronary 61 4.39E-06 11391 58 4.39E-06 11397 7 4.13E-06 12114 
Artery Tibial 74 4.43E-06 11292 60 4.43E-06 11295 9 4.15E-06 12044 
Brain Anterior cingulate cortex BA24 53 5.00E-06 10002 62 5.00E-06 10003 8 4.64E-06 10779 
Brain Caudate basal ganglia 61 4.61E-06 10850 55 4.61E-06 10850 11 4.30E-06 11627 
Brain Cerebellar Hemisphere 65 4.94E-06 10113 64 4.94E-06 10115 11 4.60E-06 10864 
Brain Cerebellum 62 4.78E-06 10457 67 4.78E-06 10457 7 4.46E-06 11205 
Brain Cortex 61 4.69E-06 10650 57 4.70E-06 10647 8 4.37E-06 11445 
Brain Frontal Cortex BA9 66 4.67E-06 10717 57 4.66E-06 10719 11 4.34E-06 11519 
Brain Hippocampus 58 4.67E-06 10701 54 4.67E-06 10701 8 4.36E-06 11469 
Brain Hypothalamus 75 4.55E-06 10986 65 4.55E-06 10987 11 4.25E-06 11764 
Brain Nucleus accumbens basal ganglia 74 4.64E-06 10781 59 4.64E-06 10783 9 4.33E-06 11541 
Brain Putamen basal ganglia 71 4.84E-06 10323 55 4.84E-06 10327 11 4.49E-06 11129 
Breast Mammary Tissue 74 4.12E-06 12141 62 4.12E-06 12143 8 3.88E-06 12899 
Cells EBV-transformed lymphocytes 65 5.20E-06 9610 50 5.20E-06 9615 5 4.87E-06 10267 
Cells Transformed fibroblasts 61 4.80E-06 10406 60 4.80E-06 10409 10 4.51E-06 11089 
Colon Sigmoid 72 4.44E-06 11257 68 4.44E-06 11261 7 4.16E-06 12010 
Colon Transverse 74 4.25E-06 11759 61 4.25E-06 11765 10 3.99E-06 12545 
Esophagus Gastroesophageal Junction 58 4.50E-06 11117 52 4.50E-06 11119 8 4.23E-06 11823 
Esophagus Mucosa 77 4.31E-06 11595 71 4.31E-06 11603 7 4.06E-06 12316 
Esophagus Muscularis 67 4.43E-06 11285 67 4.43E-06 11289 7 4.16E-06 12029 
Heart Atrial Appendage 69 4.58E-06 10922 64 4.58E-06 10923 9 4.28E-06 11679 
Heart Left Ventricle 77 4.75E-06 10519 55 4.75E-06 10522 10 4.45E-06 11242 
Liver 63 4.97E-06 10062 69 4.97E-06 10068 7 4.63E-06 10808 
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Lung 81 4.02E-06 12428 62 4.02E-06 12433 8 3.80E-06 13152 
Muscle Skeletal 81 4.70E-06 10629 65 4.70E-06 10631 6 4.41E-06 11326 
Nerve Tibial 78 4.24E-06 11784 63 4.24E-06 11787 7 4.00E-06 12511 
Ovary 57 4.71E-06 10608 60 4.71E-06 10607 8 4.42E-06 11323 
Pancreas 60 4.71E-06 10619 63 4.71E-06 10625 7 4.38E-06 11410 
Pituitary 75 4.41E-06 11336 69 4.41E-06 11337 8 4.13E-06 12117 
Prostate 73 4.28E-06 11685 60 4.28E-06 11688 8 4.02E-06 12450 
Skin Not Sun Exposed Suprapubic 75 4.24E-06 11789 69 4.24E-06 11797 7 4.00E-06 12505 
Skin Sun Exposed Lower leg 72 4.12E-06 12144 62 4.12E-06 12149 8 3.87E-06 12904 
Small Intestine Terminal Ileum 68 4.48E-06 11150 64 4.48E-06 11151 10 4.19E-06 11938 
Spleen 70 4.66E-06 10736 55 4.66E-06 10739 13 4.36E-06 11474 
Stomach 78 4.23E-06 11833 68 4.22E-06 11838 14 3.97E-06 12580 
Testis 73 4.03E-06 12411 70 4.03E-06 12412 7 3.78E-06 13222 
Thyroid 82 4.13E-06 12106 68 4.13E-06 12113 17 3.88E-06 12873 
Uterus 60 4.93E-06 10148 61 4.93E-06 10151 8 4.62E-06 10813 
Vagina 70 4.43E-06 11285 59 4.43E-06 11288 7 4.16E-06 12018 
Whole Blood 59 4.76E-06 10511 52 4.75E-06 10518 12 4.48E-06 11168 
Average 69.27   61.64   8.84   
Supplementary Table 2.5 – TWAS association signals for UTMOST 

























TW Adipose Subcutaneous 46 7.54E-06 6634 28 7.54E-06 6628 10 6.91E-06 7234 
TW Adipose Visceral Omentum 32 1.20E-05 4174 21 1.20E-05 4173 6 1.10E-05 4542 
TW Adrenal Gland 23 1.33E-05 3760 20 1.33E-05 3758 3 1.24E-05 4048 
TW Artery Aorta 33 8.76E-06 5706 44 8.76E-06 5705 5 8.11E-06 6163 
TW Artery Coronary 13 1.65E-05 3025 21 1.65E-05 3024 3 1.54E-05 3242 
TW Artery Tibial 36 7.50E-06 6666 32 7.51E-06 6657 6 6.89E-06 7259 
TW Brain Anterior cingulate cortex BA24 6 2.03E-05 2466 14 2.03E-05 2466 2 1.88E-05 2654 
TW Brain Caudate basal ganglia 21 1.48E-05 3375 25 1.48E-05 3372 2 1.38E-05 3616 
TW Brain Cerebellar Hemisphere 12 1.26E-05 3955 18 1.26E-05 3954 3 1.18E-05 4228 
TW Brain Cerebellum 22 1.10E-05 4543 28 1.10E-05 4542 4 1.04E-05 4830 
TW Brain Cortex 19 1.49E-05 3351 33 1.49E-05 3347 3 1.40E-05 3583 
TW Brain Frontal Cortex BA9 12 1.66E-05 3013 16 1.66E-05 3013 1 1.56E-05 3211 
TW Brain Hippocampus 12 2.12E-05 2362 10 2.12E-05 2362 1 1.97E-05 2534 
TW Brain Hypothalamus 6 2.20E-05 2269 11 2.20E-05 2268 1 2.04E-05 2455 
TW Brain Nucleus accumbens basal ganglia 16 1.70E-05 2935 17 1.70E-05 2935 1 1.60E-05 3131 
TW Brain Putamen basal ganglia 14 1.91E-05 2620 17 1.91E-05 2620 5 1.78E-05 2807 
TW Breast Mammary Tissue 23 1.16E-05 4292 20 1.17E-05 4288 4 1.07E-05 4655 
TW Cells EBV-transformed lymphocytes 22 1.43E-05 3493 17 1.43E-05 3491 3 1.33E-05 3751 
TW Cells Transformed fibroblasts 52 7.02E-06 7120 35 7.03E-06 7114 7 6.50E-06 7692 
TW Colon Sigmoid 16 1.40E-05 3561 16 1.40E-05 3559 4 1.30E-05 3858 
TW Colon Transverse 24 1.11E-05 4485 24 1.12E-05 4480 4 1.03E-05 4874 
TW Esophagus Gastroesophageal Junction 14 1.45E-05 3456 17 1.45E-05 3454 3 1.34E-05 3727 
TW Esophagus Mucosa 38 7.78E-06 6425 32 7.78E-06 6423 3 7.18E-06 6961 
TW Esophagus Muscularis 31 8.37E-06 5971 33 8.38E-06 5966 4 7.70E-06 6493 
TW Heart Atrial Appendage 28 1.19E-05 4187 21 1.19E-05 4185 6 1.11E-05 4501 
TW Heart Left Ventricle 25 1.11E-05 4517 33 1.11E-05 4513 4 1.02E-05 4885 
TW Liver 16 1.86E-05 2695 19 1.86E-05 2692 4 1.72E-05 2909 
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TW Lung 42 8.32E-06 6008 16 8.33E-06 6002 5 7.56E-06 6611 
TW Muscle Skeletal 30 8.32E-06 6009 30 8.33E-06 6003 8 7.56E-06 6614 
TW Nerve Tibial 41 6.60E-06 7577 39 6.61E-06 7570 6 6.13E-06 8157 
TW Ovary 13 1.94E-05 2576 17 1.94E-05 2575 3 1.81E-05 2762 
TW Pancreas 26 1.12E-05 4449 26 1.12E-05 4447 4 1.05E-05 4771 
TW Pituitary 12 1.59E-05 3145 13 1.59E-05 3144 5 1.48E-05 3382 
TW Prostate 10 2.09E-05 2389 20 2.09E-05 2389 3 1.92E-05 2609 
TW Skin Not Sun Exposed Suprapubic 27 9.37E-06 5336 31 9.38E-06 5333 4 8.62E-06 5798 
TW Skin Sun Exposed Lower leg 42 7.10E-06 7041 35 7.11E-06 7037 6 6.55E-06 7628 
TW Small Intestine Terminal Ileum 15 1.97E-05 2538 16 1.97E-05 2536 3 1.83E-05 2729 
TW Spleen 19 1.45E-05 3456 18 1.45E-05 3456 5 1.35E-05 3698 
TW Stomach 16 1.27E-05 3945 23 1.27E-05 3943 4 1.17E-05 4271 
TW Testis 30 7.37E-06 6780 28 7.38E-06 6778 7 6.91E-06 7234 
TW Thyroid 39 6.69E-06 7478 40 6.69E-06 7469 7 6.14E-06 8140 
TW Uterus 11 2.51E-05 1991 8 2.51E-05 1991 1 2.34E-05 2139 
TW Vagina 15 2.57E-05 1946 10 2.57E-05 1944 1 2.40E-05 2082 
TW Whole Blood 42 8.23E-06 6077 30 8.23E-06 6073 3 7.42E-06 6743 
Average 23.68   23.23   4.02   
Supplementary Table 2.6 – TWAS association signals for prediXcan (single-tissue) 






Chapter 3 Revisiting Microarray Hybridization Biases in the 
Whole Genome Sequencing Era 
 
3.1 Abstract 
Traditional expression quantitative trait loci (eQTL) studies based on microarrays have 
successfully identified tremendous numbers of cis-acting associations between genetic variants 
and expression levels. However, microarray probes that contain a genetic variant can have 
weakened hybridization to RNA molecules due to base-pair mismatches, which artificially 
reduces the gene expression levels for individuals with non-reference alleles. This bias can lead 
to significant statistical associations in eQTL studies that are technical false positives. While 
existing publications have developed methods to address this issue by inferring and removing 
problematic probes (via reference panels or contrasting between groups with and without 
affected probes), it is impossible to fully correct the bias completely without knowing all genetic 
polymorphisms within the samples. In this chapter, we demonstrate that the availability of 
deep genome sequence data can be used to empower and refine existing eQTL studies by 
allowing us to correct for the reference-bias in variant-overlapping probes.  
Here, we leveraged whole genome sequence data from the Pima diabetic nephropathy cohort 
to identify variant-overlapping probes from their corresponding microarray expression levels. 
Using all variants, we found 27,767 affected probes in the Affymetrix HuGene 2.1 ST array, 
corresponding to 13,219 genes. At the probe level, >99% of strong associations (p-value < 10 -3) 
between affected probe and corresponding variant were negative in effect size. At the probeset 
(gene) level, we found a 2.0-3.5x odds ratio of having negative effect sizes compared to RNA 
sequencing expression data as a baseline. We then corrected expression levels using three 
approaches: (1) by removing affected probes identified by WGS, (2) removing affected probes 
61 
 
identified by 1000 Genomes reference panel, and (3) by adjusting affected probe levels using 
unaffected probes as a baseline. We compared these expression datasets with uncorrected 
expression in a comprehensive eQTL scan. Before correction, effect size balance was skewed in 
a negative direction for two tissues tested – (53.8% and 54.7%). This was no longer the case 
after applying correction methods, with negative ratios ranging from 45%-50% after correction. 
However, probe removal using 1000G all variants showed a large reduction in power and is 
inadvisable. We found that probe removal using Pima common variants and probe adjustment 
using Pima variants performed consistently well in terms of effect size imbalance resolution, as 
well as identifying likely false positives and false negatives. When whole genome sequence data 
are not available, removing probes using common variants from reference panels such as 
1000G can be a reasonable approach to correct for hybridization bias. 
3.2 Introduction 
Expression Quantitative Trait Loci (eQTL) studies have identified a tremendous number of cis- 
and trans- associations between genetic variants and gene expression levels and have provided 
many biological insights into the regulatory aspect of complex traits [146]. These studies have 
become increasingly viable in the past twenty years due to advances in technologies that 
facilitate high throughput measurements of gene expression. Microarrays were one of the first 
technologies that allowed researchers to assay expression levels of genes in a massively parallel 
manner, allowing for large-scale analyses of the transcriptome. Microarray platforms typically 
measure transcript abundance by using synthetic complementary DNA (cDNA) probes to bind 
with RNA molecules, which are quantified via color-coded dyes [60]. There are then various 
post-processing statistical methods which are used to generate gene-level expression estimates 
from these color intensities. Unfortunately, there are limitations with this technology that arise 
from the fact that cDNA probe sequences must be known a priori when conducting 
experiments. One well known shortcoming is that sequence variation within the probe regions 
can result in weakened hybridization between said probe and corresponding RNA molecules 
(due to base-pair mismatches) [100,101]. This can artificially reduce the estimated expression 
levels, creating statistically significant, but technically false associations between genetic 
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variant and gene expression primarily in the direction of apparent downregulation of non-
reference alleles. Even though these biases typically affect a small proportion of microarray 
probes, it has been shown that a large proportion of eQTL signals can be affected, leading to 
many potential false positives and false negatives [102].  
Because of this limitation (as well as others), microarrays have given way to next generation 
technologies such as RNA sequencing, which overcome many shortcomings by sequencing RNA 
transcripts directly. However, microarrays still have been used in recent eQTL studies [6] [7], 
and can also arise in meta-analyses or aggregate cohort studies that examine older datasets in 
which microarrays were the cutting edge technology at the time [8]. As such, there is merit to 
addressing limitations from this aging platform in the modern day. 
Recent publications have sought to address the hybridization bias by identifying problem 
probes and removing them from the analysis. Dannemann and colleagues implemented the 
algorithm ‘maskBAD’ which uses a statistical model to estimate differential binding affinity of 
probes between two experimental groups, where one group has the SNP and the other does 
not [104]. While the approach was able to identify most problem probes, some probes 
overlapping with SNPs could potentially be missed, and probes that did not overlap with SNPs 
were removed. Furthermore, the two groups (with one not affected by differential binding) 
must be identified prior to the analysis, which is not always possible in an experimental setting. 
Quigley’s equalizer algorithm detects all probes that overlap with SNPs given from a Variant Call 
Format (VCF) file, allowing for exact identification and removal of affected probes [103]. The 
author mentions that many human eQTL studies are conducted without exome or whole 
genome sequences of the individuals. To demonstrate the probe removal algorithm, common 
polymorphisms obtained from European and African sequences in the 1000 Genomes Project 
were used to identify these probes. When reviewing the overall imbalance effect of eQTLs, the 
author noted that the downstream effect of removing these probes led to a much improved but 
still incomplete resolution of the negative hybridization bias. Furthermore, if the study 
population of interest is genetically distant from both the European and African reference 
genomes, 1000 Genomes polymorphisms may not accurately identify biased probes. Knowing 
the exact genomes corresponding to the study cohort could improve expression correction 
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methods by identifying all the correct probes when compared to using reference panels such as 
1000G. With next generation sequencing, the fine-resolution genotyping of individuals has 
become more accessible to many study cohorts, which presents the opportunity to re-visit the 
issue of negative hybridization with relevant genotype information. 
In this chapter, we examine the benefits of using whole genome sequencing to identify biased 
probes more accurately. We demonstrate that this could improve estimation of expression 
levels, which in turn empower and refine existing eQTL studies. To highlight the improvement, 
we apply this approach to a population-specific cohort of Pima Native Americans, whose 
genomes differ from known reference panels for many sites. With whole genome sequence 
data, we characterize the extent of the negative hybridization bias at both the probe level and 
probeset (gene) level. We further demonstrate that using the population-specific genetic loci to 
identify and remove biased probes can result in more accurate eQTL discovery and fewer false 
positives, compared to using the 1000 Genomes reference panel. However, we also found that 
removing all affected probes might negatively affect eQTL power and accuracy of measured 
expression levels. Therefore, we also present a probe-adjustment method where, instead of 
removing all affected probes, we impute their intensity levels using information from non-
affected probes within the same probeset. We demonstrate that this approach may – in some 
situations – resolve the negative-hybridization bias without paying the price of losing power 
from removing probes. 
 
3.3 Materials and Methods 
3.3.1 Data Source 
To empirically demonstrate the different bias-correction strategies, we use data from a Pima 
Native American diabetic nephropathy cohort. In this study, deep whole genome sequencing 
was performed on 97 individuals, and renal expression data were obtained from microdissected 
biopsies of glomerular and tubular tissue compartments within the kidney, using both 
microarray and RNA sequencing techniques on the same tissue samples. The microarray 
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platform used was the Affymetrix HuGene 2.1 array, which consisted of 25-mer probe 
sequences specifically designed to target individual exons.  To convert probe intensities into 
probeset-level expression estimates, we used a custom (customCDF) probe-to-probeset 
mapping provided by the Microarray Lab from the Molecular and Behavioral Neuroscience 
Institute at the University of Michigan [148], which maps probes to genes more accurately than 
the default method [149]. Under this mapping the HuGene 2.1 platform contained 25,583 
probesets over 466,204 probes.  
We also compared the microarray data with RNA sequencing data, which was performed on the 
same tissues and overlapping samples when we need evaluations with different technologies. 
RNA-seq reads were aligned with TopHat [150] software tool and the transcript counts were 
quantified with Cufflinks [151] and normalized via log-transformation of FPKM (fragments per 
kilobase of transcript per million mapped reads).  
Deep whole genome sequencing was done for all study individuals via HiSeq X at the Macrogen 
Lab. SNPs were detected using the GotCloud SNP caller [152] and SNPs/indels were detected 
using HaplotypeCaller [153]. Affymetrix SNP arrays were used to check for genotype 
concordance with our whole genome sequence variants, and concordance was found to be very 
high (>99.9% across all samples). For 1000 Genomes variants, we used variant sites and allele 
frequencies from the phase 3 release [14]. 
3.3.2 Identification and removal of Probes overlapping with variants 
To identify probes overlapping with variants, we first downloaded a Browser Extensible Data 
(BED) file from the Affymetrix website 
(http://www.affymetrix.com/support/technical/byproduct.affx?product=HuGene-1_1-st-v1 ) 
containing information on the start and end positions of each probe. Conveniently, the genomic 
coordinates in this BED file were based on the Genome Reference Consortium human genome 
build 37 [154], which matched with the sequence alignment for the Pima cohort. We developed 
an in-house software which uses BED and VCF files as input, and outputs the full list of probes 
that contain any sequence variation. We defined a variant-overlapping probe as any probe 
whose start and stop positions contained a genetic variant. In the case of SNPs, this would 
65 
 
mean the genomic coordinates of the SNP lies between the start and stop position of the 
probe. We also included insertions and deletions (indels) in the output, using the criteria that 
the indel must be completely contained within the boundaries of the probe. 
We repeated this using different VCF files, obtaining several lists of variant-overlapping probes. 
Here, we used the Pima VCF obtained from the deep whole-genome sequencing, and a VCF file 
obtained from the 1000 Genomes project. Because of the diverse populations within the 1000 
Genomes cohort, there were many genetic variants and thus for too many probes were 
identified as problem probes. To remedy this issue, we filtered out variants with minor allele 
frequency lower than 5%. 
With the list of affected probes identified, our in-house software then directly modifies the cel 
definition file (CDF), removing the affected probes from their corresponding probesets. Using 
the new corrected CDFs, we then created an R-package compatible with Bioconductor’s oligo 
library, which is used to calculate gene expression. 
3.3.3 Probe adjustment approach 
We also implemented a probe adjustment approach where instead of removing affected 
probes, we re-calculated their values based on other probes within the probeset. Suppose a 
probeset 𝑃 has 𝑘 probes, 𝑝 , 𝑝 , … , 𝑝  ∈  𝑃, and that probe 𝑝  overlaps with a genetic 
marker(s) with genotypes denoted as 𝑥  (in the case of multiple, we pick one since they are 
almost always in high or perfect LD with each other). Let the 𝑦 , 𝑦 , … , 𝑦  be vectors to denote 
the probe intensities for all samples, corresponding to each probe. For genetic variant 𝑥 , we 
use a linear regression model to estimate a regression coefficient for each probe within the 
probeset: 
log (𝑦 ) = 𝛽 + 𝛽 𝑥 + 𝜀̂ , 𝑖 ∈ 1, … , 𝑘 












The estimated expression is as follows: 
log(𝑦 ) = 𝛽 + 𝛽 𝑥 + 𝜀̂  
 
This approach uses the non-problem probes to estimate the “true” effect the genetic marker 
has on expression levels, averaging across all unaffected probes. Here, the residuals 𝜀̂  are from 
the regression between the variant and its corresponding affected probe. These residuals 
provide an estimate of the individual-level probe intensities correcting for the technical effect 
induced by the overlapping variant.  
3.3.4 Normalization of Expression Data 
We calculated gene expression using the Bioconductor’s oligo R package [155], with sample-
level CEL files containing probe intensity information as input and using the aforementioned 
custom CDF to map the probes to probesets. We then applied Bioconductor’s Robust Multi-
Array Average (RMA) normalization algorithm to the probe level expression [67,156]. This was 
applied to each tissue and biopsy separately. Finally, we applied an inverse-normalization 
transformation across subjects for each probeset. Probesets were mapped to genes using 
Ensembl GRCh37 genes [154]. 
3.3.5 Quantification of probe- and probeset-level biases 
The overall bias quantification of identified probes was done by comparing the estimated 
enrichment of probes with both positive and negative hybridizations. To do this, we performed 
a regression analysis between every variant-in-probe (VIP: a genetic variant that overlaps with a 
probe) and the probe intensity level for its corresponding affected probe (VIP probe). We then 
repeated this for all other probes within the same probeset (probes that do not overlap with 
the variant). We used these unaffected probes to establish a baseline for comparison with the 
VIP probes.  
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In addition to our probe-level regression analysis, we performed a regression analysis to 
quantify the negative hybridization effect at the gene (probeset) level. Here, we included the 
13,219 genes that were affected by at least one VIP. We regressed every VIP against the gene 
expression level of its corresponding affected gene. To serve as a baseline for comparison, we 
used two approaches. First, we leveraged the RNA sequencing data that was also assayed from 
the same tissue sample as the microarray experiment. Since the RNA sequencing platform 
should not be susceptible to the hybridization effect, this allowed us to establish a relatively 
accurate estimate of the true gene-level enrichment of negative effect sizes. Secondly, for each 
affected gene (probeset containing an affected probe), we performed association analysis with 
all variants within the exon region of that gene. In this analysis, we excluded VIPs corresponding 
to each gene. This second approach allowed us to perform a high number of tests, while also 
allowing us to examine the effects of linkage-disequilibrium with VIPs on the hybridization bias. 
3.3.6 cis-eQTL Analysis 
Expression quantitative trait locus (eQTL) analysis was performed using mixed model 
association via the EMMAX software package [157]. A separate analysis was performed for each 
tissue and each expression correction method (uncorrected, correction using probe removal via 
Pima WGS and 1000G, and correction using probe imputation via Pima WGS). For every SNP 
and indel identified from our whole genome sequencing, we tested for association against each 
of the genes with measured expression. To account for potential confounders, we adjusted for 
age and sex as covariates. In addition, we calculated pairwise-kinship coefficients for all 
samples, using it as the fixed-effects component of the mixed model. 
We defined an eQTL as cis-acting if it was located within 1 Mb of the transcription start site of 
the associated gene. Otherwise, the eQTL signal was defined as being trans-acting. To account 
for multiple testing, p-values were adjusted by the false-discovery rate (FDR) correction 
approach, using the trans-eQTL signals to determine the false discovery rates. The unadjusted 
p-values corresponding to an FDR of 0.05 was approximately α=10-5 for all our analyses, and 
thus we used this threshold as our significance cutoff. Because of linkage disequilibrium (LD) 
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between neighboring SNPs, only the SNP with the lowest p-value was taken as the true cis-eQTL 
signal for each gene. 
3.3.7 Identification of technical false positives and technical false negatives 
Using our new corrected eQTL analyses, we revisited the uncorrected analyses and determine 
which of its signals were potentially false positives and false negatives due to the hybridization 
bias. In essence, we sought to identify signals that were lost (or gained) due to expression 
correction and determine if they were lost (or gained) because of VIPs. To do this, we 
performed pairwise comparisons between all gene signals from our uncorrected and corrected 
analyses, examining the effect sizes of peak eQTL variants, correlation between peak variants 
and VIP variants, and the association between VIP variant and gene (and probe) expression 
levels.  
For each gene, we defined it to be a false positive using the following criteria:  
 Uncorrected expression p-value < 1x10-5 and corrected expression p-value > 1x10-5 AND; 
 Peak eQTL is in high-LD with VIP (r2 > 0.1) AND; 
o Peak eQTL effect size diminishes after correction OR; 
o VIP is negatively associated with affected probe (p-value < 0.1) OR; 
o VIP is negatively associated with affected gene expression 
We defined false negatives using a similar criteria: 
 Uncorrected expression p-value > 1x10-5 and corrected expression p-value < 1x10-5 AND; 
 Peak eQTL is in high-LD with VIP (r2 > 0.1) AND; 
o Peak eQTL effect size increases after correction OR; 
o VIP is negatively associated with affected probe (p-value < 0.1) OR; 
o VIP is negatively associated with affected gene expression 
Finally, we excluded all genes in which the genotypes of the VIP had minor allele frequency less 





3.4.1 Comprehensive scan of VIPs using deep whole genome sequencing (WGS).  
We comprehensively scanned for variant-in-probes (VIPs: any SNP or indel contained within a 
probe) by comparing deep whole genome sequence (WGS) data to the genomic coordinates of 
every microarray probe. We examined 55 Pima Native American individuals (50 with glomerular 
and 54 with tubular expression data) where both deep WGS and array-based transcriptomic 
profiles (based on the Affymetrix HuGene 2.1.ST platform) were available (ClinicalTrials.gov 
number, NCT00340678). Among the 8.8 million SNPs and 1.8 million indels identified across 
these Pima genomes, we found that 29,917 (0.0028%) variants overlapped with a probe (VIPs). 
Using Pima VCFs, we observed that 6% of all probes (27,767/466,204) were affected by a VIP 
(Table 3.1A). However, despite the relatively low percentage of affected probes, because each 
probeset contains 18.2 probes on average, more than half (51.1%) of the probesets (13,219 out 
of 25,583) contained at least one affected probe, suggesting that the majority of array-based 
expression levels can potentially be affected with a bias to some degree. Per individual sample, 
we flagged an average of 10,219 affected probes (2.2% of all probes), which in turn mapped to 
6,210 affected probesets (24.3% of all probesets) on average. 
Using all 1000 Genomes variants to identify VIP probes is overly sensitive.  
We repeated this evaluation using ~80 million variants from the 1000 Genomes Project (1000G) 
[14]. As mentioned by Quigley, this approach could potentially be a viable alternative when 
individual-level WGS are not available, and it could identify affected probes with a reasonable 
accuracy when the study cohort is represented by the ancestries included in this reference 
panel. Using 1000G variants, we identified 51.1% of all probes as affected (238,207/466,204), 
which mapped to 93.1% of all the probesets (23,827/25,583). We observe that among these 
238,207 flagged probes, 212,455 were not flagged when using Pima WGS variants and are 
unlikely to have hybridization bias since they do not overlap with any Pima polymorphisms 
(Table 3.1B). We found that attempting to unnecessarily account for this high volume of probes 
led to inaccuracy in calculating expression for many genes, without providing benefit towards 
bias reduction.  
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Using common variants only achieves more reasonable sensitivity to identify VIP probes 
A much more sensible approach was to limit our scan to common variants (minor allele 
frequency > 5%), which may have a higher impact on probes compared to rare variants. For the 
sake of completeness, we applied this approach to both Pima and 1000G, creating two 
additional list of probes that were flagged based on common variants only. For Pima, the 
fraction of flagged probes and corresponding probesets were reduced to 3.5% (16,423 probes) 
and 36.0% (9,202 probesets) respectively. For 1000 Genomes common variants, we flagged 
4.6% of all probes (21,537 probes), mapping to 49.2% of all probesets (12,592 probesets). From 
We see that the 1000 Genomes common variant approach only flags 3,384 probes not 
identified by the Pima WGS (all variants) method, which is substantially fewer than the 212,455 
extra probes flagged when using all variants (Table 3.1C). Correcting for these 3,384 extra 
probes will not likely affect the expression estimates to the same magnitude, and thus this 
method appears to be a much more reliable approach. For the rest of the comparison in this 
chapter, we focused primarily on the probes identified by Pima WGS all variants, and 1000G 
common variants. 
 
3.4.2 Quantifying the effects of negative hybridization using probes identified by Pima WGS 
The availability of Pima WGS data allows us to characterize the hybridization bias at a probe 
level. To do this, we performed a linear regression between every affected probe and the 
genotypes of their corresponding VIP(s). To serve as controls, we also regressed these (VIPs) 
genotypes against the unaffected probes within the same probeset of the affected probe. 
Overall, we observe that a large proportion of probes are biased due to VIPs, and that the bias 
becomes more apparent as the regression effect size increases (Figure 3.1, Supplementary 
Table 3.1). For example, when examining all VIP probes (α = 1), 62.9% and 64.0% have negative 
effect sizes for glomerular and tubular tissues, respectively (Figure 3.1A). Given an expected 
ratio of 50% (which is observed in the unaffected probes analysis), there are roughly 3,400 
more negative probes than expected (out of a total of 26,435 total probes). Starting from α = 
10-3 and onward, we observe >99% of effect sizes being in the negative direction. In contrast, 
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our unaffected probe analysis shows 45-60% negative effect sizes across the spectrum of p-
value thresholds. This high imbalance of negative effect sizes provides evidence that strong 
associations between VIPs and their corresponding probes are almost all due to artificial 
artifacts. We also see an absence of strong positive signals, with only 1 positive signal at α = 10-5 
for glomerular and 2 positive signals for tubular. This suggests that true associations with 
positive effect sizes may also be masked by this negative hybridization bias. This could 
potentially lead to a loss of power and false positives in downstream eQTL discovery.  
We compared the effect size densities for affected and unaffected probes (Figure 3.1B). From 
here, we confirm the enrichment of negative effect sizes (from the heavy tail), as well as a mild 
shift in the median (median: -0.392 for glomerular, -0.433 for tubular) in the negative direction. 
The heavy left tail for highly significant associations (especially when t-statistic is less than -2) 
suggests that there may be a small number of probes that are greatly affected by the VIPs. The 
shift in the overall median for affected probes indicates that there are many probes that are 
mildly skewed in the negative direction – that is to say, most probes appear to have a small 
negative hybridization effect.  
Finally, we found that the position in which the variant overlaps with the probe also affects the 
severity of hybridization reduction. To test this, we calculated the distance of each VIP variant 
from the center of the affected probe sequence and tested for association with effect size. We 
found that variants closer to the center of the affected probe had stronger negative effect sizes, 
while variants near the edge of the affected probe boundaries had milder negative affinity 
(p-value < 10-15).  
3.4.3 Quantifying the effects of negative hybridization at the gene level 
Despite VIPs creating a strong negative bias for many of their corresponding probes, the impact 
of VIPs on gene expression at the probeset level is far more modest. Much like our probe-level 
analysis however, we still observe an enrichment of negative effect sizes which increases as the 
p-value threshold becomes more stringent. Upon examining all regressions (α=1) for the 
uncorrected expression, we see a slight imbalance of effect sizes across 18,109 tests (19,249 for 
tubular), with a negative ratio of 53.1% and 54.0% (confidence intervals) in glomerular and 
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tubular tissues respectively (Figure 3.2A, Supplementary Table 3.2). With more significant 
p-value thresholds, the negative ratio increases to roughly 70%. This relatively milder imbalance 
of negative signals compared to our probe regressions (70% versus >99%) can be explained with 
the knowledge that each probeset has an average of ~20 probes. Therefore, even though 
probes can be highly biased, the unaffected probes within the same probeset help mitigate the 
bias when calculating expression levels. 
Because RNA sequencing is less susceptible to expression bias arising from sequence variation, 
we repeated our experiment using RNA sequencing expression data for the same set of genes 
as a baseline for comparison. Compared to RNA-seq, there is evidence of the microarray 
hybridization bias both enriching negative signals, while also suppressing positive direction 
signals (Figure 3.3). There appears to be a clear abundance of negative effect sizes within the 
microarray associations, whereas this does not appear from the RNA-seq analysis (Figure 3.3A). 
We calculated the odds-ratio of having a negative effect size using RNA-seq as a baseline – we 
divided the microarray relative-risk by the RNA-seq relative-risk (Figure 3.3B). For the 
glomerular tissue, we observe an OR of ~2 – 3.5, while the tubular tissue shows an OR of ~2.  
We found that even non-VIP variants can be affected with hybridization bias through LD with 
VIPs. Our non-VIP regression analysis (Figure 3.2B) serves to characterize the relationship 
between affected/unaffected probesets and genetic variants within the corresponding exon 
regions of the gene. We separated this analysis into two components: 1) exon associations with 
genes containing an affected probe, and 2) exon associations with genes not containing an 
affected probe. Despite VIPs being excluded from this analysis entirely, we still observe a 
greater negative enrichment for affected genes versus non-affected genes. For example, at 
α=10-3, the glomerular tissue shows a 62.3% negative ratio for affected genes and a 54.5% 
negative ratio for unaffected genes. Similarly for the tubular tissue, there are 60.1% and 46.8% 
negative ratios for affected and unaffected genes respectively. This provides evidence that cis-
variants that are not VIPs are still negatively skewed, and could potentially be technical false 
positives. This is likely due to the linkage-disequilibrium structure, where a VIP will cause other 
variants in high LD to also be associated with the gene expression levels. 
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3.4.4 Assessment of bias correction methods  
Using our expression-correction methods, we generated ten new sets of expression data (5 sets 
for each tissue). These new datasets were derived from five correction methods: (1) Probe 
removal using Pima WGS (all variants) to identify probes, (2) Probe removal using Pima WGS 
(common variants) to identify probes, (3) Probe removal using 1000G (all variants) to identify 
probes, (4) Probe removal using 1000G (common variants) to identify probes and (5) Probe 
adjustment (see section 3.3) using Pima WGS (all variants) to identify probes. 
We repeated the VIP-regression analysis performed in 3.4.3, where we calculated association 
effect sizes between every VIP and their corresponding affected (but now corrected) gene. 
Overall, the methods all appear to improve the effect size balance, with negative ratios close to 
50% across all p-value thresholds (Figure 3.4, Supplementary Table 3.3). One exception would 
be the 1000G (all variants) probe removal method, which appears to have a higher negative 
ratio in the glomerular tissue. Based on effect size directions alone, we believe that all the 
correction methods other than 1000G (all variants) probe removal are viable. This is not 
surprising as the 1000G (common variants) method identifies many of the same probes that the 
Pima WGS method, and thus most of the expression estimates will be quite similar. 
3.4.5 Impact of hybridization bias on eQTL analysis 
Finally, we compared our expression correction approaches by performing a comprehensive 
eQTL scan across the entire genome. In contrast to our previous methods that tested only VIPs 
or non-VIP variants within exonic regions, our eQTL analysis tested every variant regardless of 
classification. Because VIPs are only a small portion of the entire genome, it is very unlikely that 
VIPs will be the peak eQTL for most genes. However, it is possible for the peak signals to be in 
linkage-disequilibrium with VIPs. As such, we broke down our results into further categories 
based on magnitude of LD between the eQTL peak and any VIPs that may affected the gene.  
We observe that peak eQTLs from both tissues are biased in the negative direction, and that all 
methods can correct this (Figure 3.5, Supplementary Table 3.4). However, there may be a slight 
overcorrection as the effect sizes in general skew slightly in the positive direction. Overall, the 
correction methods based on common variants appear to perform better than those using all 
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variants. In the Glomerular tissue, both Pima and 1000G common variants probe removal have 
better balance in effect size directions compared to their counterparts, while also identifying 
more signals. The probe adjustment approach also performs quite well, particularly in the 
tubular tissue where we observe a 50% negative ratio as well as the highest number of 
significant signals. However, the 1000G common variants approach appears to overcorrect in 
the tubular tissue, leading to a 54.5% positive effect size ratio. The 1000G all variants method 
reduces power substantially, resulting in a 21.9% and 35.7% loss of significant eQTLs in the 
glomerular and tubular tissues respectively.  
We examined the pairwise t-statistics between corrected and uncorrected genes 
(Supplementary Figure 3.1). Here, we observe a correlation of 0.88, 0.93 and 0.68 for the Pima 
probe removal, Pima probe adjustment and 1000G probe removal methods, respectively. This 
provides evidence that removing probes generates noise for gene expression estimates, which 
is particularly noticeable in the 1000G method. This in turn dilutes the effect sizes in eQTL 
analysis which reduces the number of significant signals detected. 
3.4.6 Evaluation of technical false positives and false negative eQTLs. 
We compared the list of signals lost and gained between the uncorrected and corrected 
analyses and identified false positives and false negatives using the criteria described in our 
methods section (3.3.7). For example, the RPL9 gene was classified as a technical false-positive 
by both the probe removal and probe adjustment methods (Supplementary Figure 3.2). Here, 
we observe a strong correlation between uncorrected expression and VIP genotypes (t-statistic 
= -6.899) whereas the correlation between corrected expression and VIP genotypes is near 
zero. In this scenario, the peak eQTL was the VIP, with an association p-value of 2.94x10-8. After 
expression correction, the peak eQTL was no longer the VIP and had a p-value of 5.37x10-4.  
However, not all signals gained or lost fulfilled the criteria of false positives/negatives. For 
example, the Pima probe removal method resulted in 66 and 85 signals lost for glomerular and 
tubular tissues, respectively (Supplementary Table 3.5). However, only 19 (28.8%) and 27 
(31.7%) of those lost signals were classified as false positives. This indicates that many of the 
signals that were lost may have fallen beneath the significance threshold due to noise 
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generated in expression levels due to the removal of probes, rather than being true technical 
biases. We found that overall, using common variants (in both Pima and 1000G) performed 
better – with higher ratios of false positives/negatives among the list of genes lost/gained – 
supporting the notion that removing fewer probes is advantageous. Finally, we observe that the 
probe adjustment method has the highest concordance with the uncorrected results (fewest 
signals gained/lost), but also accounts for the highest proportion of false positives/negatives 
(relative to number of signals gained/lost) in both tissues. The 1000G all variants method on the 
other hand, flags the most potential false positives (20 in glomerular, 41 in tubular) but does so 
at the expense of too many lost signals (94 for glomerular, 137 for tubular). 
 
3.5 Discussion 
In this chapter we characterized the effects of weakened hybridization in microarrays at a 
probe and probeset level, while exploring the ramifications of this technical bias on 
downstream eQTL analysis. Although methods to account for this bias have been examined in 
previous publications, none to our knowledge have leveraged whole genome sequence data to 
refine and empower these studies. In our work we first used whole genome sequencing to 
accurately identify probes with weakened hybridization. Once we identified these probes, we 
were able to characterize the extent of the bias at both the probe and probeset level by directly 
calculating regression coefficients between the variant-in-probes (VIPs) and expression levels of 
their corresponding probes/probesets. Finally, we performed downstream eQTL analysis, 
examining the effect size direction of peak eQTLs as well as their correlation with VIPs.  
Throughout our analyses, we compared correction methods that removed potentially biased 
probes from the calculation of the gene expression levels. Our hypothesis was that more 
accurate identification of probes would lead to improved analysis in terms of power, effect size 
distribution, and reduction of technical false positives and technical false negatives. We found 
in our analysis that overall, all methods – aside from probe removal via 1000G all variants – 
performed quite well. In terms of direction of effect size, these methods produced overall 
negative ratios close to 50%, which indicates that at the very least, the negative enrichment 
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from weakened hybridization has been resolved. In terms of power to discover eQTLs, we 
found that using common variants to remove probes performed better than using all variants. 
This is not surprising, as common variants are more likely to have an impact and negatively bias 
probe expression levels compared to rare variants. Furthermore, we found that removing 
probes introduced noise into the expression level estimates, which would then dilute the 
signals in an eQTL scan. Thus, limiting the list of probes removed to the most impactful ones 
would provide beneficial to the quality of the analysis. Finally, we examined the list of signals 
that were gained or lost after correcting expression levels and determined which of these were 
due to technical biases. From this, we found that methods that more accurately identified 
probes had higher success in determining false positives/negatives, while remaining relatively 
faithful to the original (uncorrected) analysis otherwise. In particular, the probe adjustment and 
probe removal with Pima common variants appeared to perform best from this angle.  
From our various viewpoints, we believe that probe adjustment via Pima all variants is the best 
approach to use, as it resolves many of the shortcomings of weakened hybridization while 
retaining high power and fidelity towards the original analysis. For methods that remove 
probes, identification of affected probes using common variants from whole genome sequence 
data appears to be the next best solution. In the scenario in which whole genome sequence 
data is not available, using common variants from a reference panel would perform adequately, 
although noise may be introduced into expression levels for genetically distant populations, 
causing both spurious signals as well as unnecessary loss of signals in eQTL analysis. 
Despite this recommendation, there are several limitations to our study and as such these 
findings should be approached with caution. First, our study population was an isolated and 
relatively homogeneous population of Pima Native Americans, and it is uncertain if the results 
from this chapter can be applied to other populations, or populations with genetic admixture. 
Next, we tested these methods using the glomerular and tubulointerstitial compartments in the 
Kidney, and findings here may not generalize to other tissues. We already noticed a slight 
difference in performance between these two tissues, with probe removal via 1000G common 
variants seemingly overcorrect – with more positive effect sizes – for the tubular tissue, as well 
as observing better performance in the tubular tissue for the probe adjustment method. In 
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addition to different tissues, our results may not extend to microarray platforms different from 
the HuGene 2.1 ST platform that was used in this study. Finally, the gene expression levels 
obtained from RNA sequence data were generated from transcript reads that may differ from 
the array-based probe sequences. Thus, the RNA-seq genes used as our baseline for 
comparison potentially interrogated different regions within the same gene compared to the 
microarray expression levels. As such, the RNA sequence gene expression levels do not provide 
exact comparisons between biased and unbiased transcript sequences, but rather serve as a 
general comparison, outlining the overall impact of negative hybridization bias at the gene 
level. 
To conclude, we revisited a well-known limitation of microarrays in assaying gene expression 
levels, using whole genome sequence data – as opposed to reference panel data – to 
characterize the list of potentially biased probes. We found that overall, WGS can more 


































Per Individual  466,204 10,219 2.2% 
Pima-all 97 466,204 27,767 6.0% 
Pima-
common 
97 466,204 16,423 3.5% 
1000G-all 2504 466,204 238,207 51.1% 
1000G-
common 
2504 466,204 21,537 4.6% 
Probeset 
Per Individual  25,583 6,210 24.3% 
Pima-all 97 25,583 13,219 51.1% 
Pima-
common 
97 25,583 9,202 36.0% 
1000G-all 2504 25,583 23,827 93.1% 
1000G-
common 
2504 25,583 12,592 49.2% 
Table 3.1A Counts of the number of probes and probesets affected by VIPs  
Information on the VIPs (SNPs and insertions/deletions) identified using the following VCFs: Pima 
WGS (all), Pima WGS (common), 1000G variants (all), 1000G variants (common). The per 
















1KG-all only 1KG-all & Pima-all Pima-all Only 
212,455 25,752 2,015 
1KG common only 1KG common & Pima-all Pima-all Only 
3,384 18,153 9,614 
1KG common only 1KG common & Pima common Pima common Only 
6,947 14,590 1,833 
1KG-all only 1KG-all & Pima-all Pima-all Only 
10,617 13,210 9 
1KG common only 1KG common & Pima-all Pima-all Only 
1,131 9,981 3,238 
1KG common only 1KG common & Pima common Pima common Only 
2,611 8,501 701 
Table 3.1B – Comparison between lists of affected probes as identified by Pima and 1000G 
variants.  
It is evident that most of the probes identified by Pima WGS are captured when using the 1000G-
all variants approach, although this method identifies far too many extra probes as being 
affected (212455). Using 1000G-common variants, this method does not capture all of the 
probes identified by Pima WGS (missing 9614 probes) but also does not flag an excessive number 
of extra probes (only 3384) 
Table 3.1C – Comparison between lists of affected probesets as identified by Pima and 1000G 
variants.  
Only 9 probesets from the Pima-all approach are not covered using the 1000G approach, 






Figure 3.1 – regression between VIP and affected/unaffected probes 
(A) shows the negative/positive ratio of effect sizes for the VIP regression against affected and 
unaffected probes identified using the Pima WGS approach. (B) shows the distribution of effect 
sizes for the same regression analysis. Medians are: -0.392/-0.433 for Glom/Tub for affected 












Figure 3.2 – regression between VIPs and probesets 
(A) in our probeset analysis, we regressed every VIP against the probeset (gene) expression levels 
corresponding to the affected probe. 2A shows the negative ratio of effect sizes for microarray and 
RNA-Sequencing expression levels of affected genes. (B) For our exon analysis, we regressed all 
variants (excluding VIPs) within the exonic region of each gene with the microarray expression levels 
of that gene. 2B shows the negative ratio of effect sizes for hybridization affected and unaffected 
genes. Here, we observe an enrichment in negative effect sizes for affected genes and whereas the 
unaffected genes are overall better balanced (Glomerular tissue shows an imbalance here, but the 
number of signals is very low). This indicates a presence of LD between exonic variants and VIPs, 
























Figure 3.3 – Comparison between Microarray and RNA-Seq effect sizes when performing regression between VIP 
and affected gene (probesets) 
(A) shows the counts of effect size directions for various p-value thresholds, with microarray counts on the left 
and RNA-Seq counts on the right. Overall, the microarray negative ratio ranged from 52% to 70%, whereas the 
RNA-Seq negative ratios ranged from 45%-55%. (B) shows the odds-ratio of having negative effect sizes for in 
Microarray genes relative to RNA-Seq genes. For the Glomerular tissue, we see a strong enrichment in negative 
effect sizes (up to 3.5 odds). In the Tubular tissue, there is milder enrichment in negative signals with an odds-
ratio of 2.2. 
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 Figure 3.4 – Comparison of uncorrected and different corrected expression approaches at the probeset level.  
Here, we regressed each VIP against their corresponding affected probeset. These plots show the negative ratio of effect sizes at 
various p-value thresholds. Overall, all correction methods appear to improve the effect size balance compared to the uncorrected 
approach, although the 1000G all variants probe removal method still displays a negative enrichment amongst signals with 





Figure 3.5 – Comparison of uncorrected and different corrected expression approaches in a 
full eQTL analysis.  
Here, performed a comprehensive eQTL scan with the uncorrected expression, and each of 
our correction strategies. We noted the effect size direction for peak eQTL variants for each 
gene. Judging from the effect size balance, it appears that probe removal using 1000G 
common variants and Pima common variants performs well in the glomerular tissue, while 
the probe adjustment method performs best in the tubular tissue. As expected, using 1000G 
all variants to remove probes likely creates heterogeneity in expression levels by introducing 








affected probes unaffected probes 




1 9,815 16,620 62.9 236,975 232,790 49.6 
0.05 430 3,711 89.6 14,534 13,308 47.8 
0.01 78 2,323 96.8 3,390 2,877 45.9 
1e-3 6 1,528 99.6 832 656 44.1 
1e-4 2 1,096 99.8 295 303 50.7 




1 9,893 17,601 64.0 241,988 246,237 50.4 
0.05 446 4,140 90.3 15,027 15,954 51.5 
0.01 76 2,623 97.2 3,615 3,612 50.0 
1e-3 13 1,718 99.2 913 878 49.0 
1e-4 6 1,259 99.5 396 418 51.4 
1e-5 2 955 99.8 233 278 54.4 
 
Supplementary Table 3.1– Direction of regression effect sizes between VIPs and probe-level 
intensities.  
For affected probes, we regressed the expression levels against the genotypes of the 
corresponding VIP. For unaffected probes, we regressed every probe within the affected 





VIP vs Microarray  
(affected probesets) 
VIP vs RNA Sequencing 
(affected genes) 
Non-VIP vs Microarray 
(affected genes) 
Non-VIP vs Microarray 
(unaffected genes) 




1 9,177 10,284 0.528 8,982 9,636 0.518 73,001 76,929 0.513 37,775 37,486 0.498 
0.1 1,062 1,520 0.589 1,290 1,226 0.487 9,440 11,247 0.544 5,010 4,853 0.492 
0.05 546 917 0.627 701 694 0.497 4,875 6,096 0.556 2,601 2,600 0.500 
0.01 138 281 0.671 221 216 0.494 1,395 1,880 0.574 609 614 0.502 
1e-3 40 90 0.692 65 70 0.519 397 656 0.623 136 163 0.545 
1e-4 20 39 0.661 29 23 0.442 126 192 0.604 61 77 0.558 




1 9,584 11,087 0.536 9,641 10,335 0.517 75,981 79,436 0.511 38,918 39,103 0.501 
0.1 1,268 1,810 0.588 1,664 1,541 0.481 10,255 12,248 0.544 5,108 5,125 0.501 
0.05 673 1,086 0.617 996 933 0.484 5,705 7,128 0.555 2,784 2,743 0.496 
0.01 201 431 0.682 417 395 0.486 1,779 2,497 0.584 709 743 0.512 
1e-3 77 181 0.702 176 182 0.508 636 959 0.601 223 196 0.468 
1e-4 40 100 0.714 99 113 0.533 363 514 0.586 114 108 0.486 







Supplementary Table 3.2– Direction of regression effect sizes between VIPs (and non-VIPs) and probeset (gene) expression.  
 
Here, we performed regression analysis between: (1) every VIP vs. microarray gene expression levels for every affected gene, (2) every VIP 
vs. RNA-seq expression levels for each affected gene, (3) variants within the exome region (excluding VIPs) vs. microarray expression levels 





Corrected (probe removal 
Pima) 
Corrected (probe removal 
1KG) 








1 9,789 9,451 0.491 9,907 9,549 0.491 9,651 9,796 0.504 9,019 9,064 0.501 
0.1 1,192 1,230 0.508 1,136 1,099 0.492 1,173 1,232 0.512 1,027 1,151 0.528 
0.05 657 687 0.511 592 605 0.505 644 707 0.523 579 647 0.528 
0.01 167 170 0.504 135 144 0.516 160 189 0.542 151 159 0.513 
1e-3 58 51 0.468 36 45 0.556 55 53 0.491 45 48 0.516 
1e-4 27 24 0.471 17 30 0.638 28 22 0.440 21 23 0.523 




1 10,386 10,304 0.498 10,362 10,321 0.499 10,204 10,477 0.507 9,481 9,774 0.508 
0.1 1,456 1,433 0.496 1,374 1,344 0.494 1,428 1,498 0.512 1,334 1,341 0.501 
0.05 797 774 0.493 730 719 0.496 774 819 0.514 714 748 0.512 
0.01 272 247 0.476 221 218 0.497 275 268 0.494 226 248 0.523 
1e-3 100 104 0.510 72 80 0.526 97 108 0.527 94 89 0.486 
1e-4 55 57 0.509 40 49 0.551 54 61 0.530 47 47 0.500 
1e-5 38 31 0.449 28 25 0.472 37 33 0.471 29 28 0.491 
 
 
Supplementary Table 3.3– Regression between VIPs and probesets after various correction methods 
 
This table shows the regression between every VIP vs. corrected microarray expression levels for each correction method. The first three 




method P-value Total 
signals 
overall High LD Low LD 





5,521 2,914 2,607 105 65 2,809 2,542 5,362 
Probe Removal: Pima all 5,450 2,696 2,754 78 89 2,618 2,665 5,351 
Probe Removal: Pima common 5,470 2,702 2,768 76 93 2,626 2,675 5,360 
Probe Removal: 1000G common 5,468 2,739 2,729 80 85 2,659 2,644 5,359 
Probe Removal: 1000G all 5,281 2,671 2,610 51 62 2,620 2,548 5,267 





940 488 452 40 30 448 422 911 
Probe Removal: Pima all 941 466 475 30 34 436 441 896 
Probe Removal: Pima common 936 456 480 32 38 424 442 894 
Probe Removal: 1000G common 912 451 461 27 33 424 428 898 
Probe Removal: 1000G all 893 455 438 22 19 433 419 836 





169 91 78 22 13 69 65 150 
Probe Removal: Pima all 162 75 87 12 14 63 73 141 
Probe Removal: Pima common 163 79 84 12 16 67 68 145 
Probe Removal: 1000G common 169 83 86 15 15 68 71 145 
Probe Removal: 1000G all 132 67 65 19 11 48 54 137 






Supplementary Table 3.4A – comparison of different correction methods in peak eQTL analysis (Glomerular tissue) 
This table shows the effect sizes at various thresholds for peak eQTLs (one per gene). The “overall” column includes all peak eQTLs, while 




method P-value Total signals 
overall High LD Low LD 
No VIP 





5,660 2,984 2,676 178 87 2,806 2,589 5,427 
Probe Removal: Pima all 5,644 2,852 2,792 101 94 2,751 2,698 5,427 
Probe Removal: Pima common 5,631 2,839 2,792 104 100 2,735 2,692 5,431 
Probe Removal: 1000G common 5,660 2,888 2,772 110 100 2,778 2,672 5,399 
Probe Removal: 1000G all 5,565 2,773 2,792 82 72 2,691 2,720 5,433 





1,161 606 555 92 46 514 509 1,029 
Probe Removal: Pima all 1,118 577 541 58 54 519 487 1,021 
Probe Removal: Pima common 1,130 544 586 57 57 487 529 1,020 
Probe Removal: 1000G common 1,101 545 556 60 56 485 500 1,018 
Probe Removal: 1000G all 1,004 499 505 45 37 454 468 943 





258 141 117 50 22 91 95 195 
Probe Removal: Pima all 234 113 121 30 29 83 92 194 
Probe Removal: Pima common 243 116 127 30 30 86 97 197 
Probe Removal: 1000G common 242 110 132 30 30 80 102 195 
Probe Removal: 1000G all 166 81 85 25 22 56 63 162 
Probe Adjust: Pima 246 123 123 38 26 85 97 198 






Supplementary Figure 3.1 – correlation between uncorrected and corrected expression 
 
Here, we calculated the pairwise concordance between uncorrected and corrected expression levels for various correction methods. While some genes 
may be heavily biased if not corrected, many genes are only mildly affected by the hybridization bias. As such, we believe that it is important to avoid 
overcorrecting or unnecessarily removing probes for these mildly affected genes. From the 1000G probe removal approach, it is evident that removing 
too many probes adds noise to the expression levels, causing concordance to be low. Because our probe adjustment approach does not remove the 
probe, but rather estimates the value using other probes within the same probeset, we observe a higher concordance with the original uncorrected 
expression levels. 
r2=0.878 r2=0.934 r2=0.681 





Supplementary Figure 3.2 – example of potential false positive gene (RPL9) 
 
Here, we see an example of a likely false positive gene – RPL9 had a significant association with 
a VIP (p-value = 2.94x10-8). After removing/adjusting the affected probe, we no longer observe a 
strong negative association, and the peak variant (which no longer was the VIP) was no longer 
























Probe Removal: Pima (all) 19 (28.8%) 66 19 (30.6%) 62 
Probe Removal: Pima 
(common) 
18 (35.3%) 51 15 (34.1%) 44 
Probe Removal: 1000G (all) 20 (21.2%) 94 10 (15.6%) 64 
Probe Removal: 1000G 
(common) 
15 (31.3%) 48 9 (17.0%) 53 
Probe Adjust: Pima 16 (40.0%) 40 9 (39.1%) 23 
Tubular 
Probe Removal: Pima 27 (31.7%) 85 10 (14.3%) 70 
Probe Removal: Pima 
(common) 
27 (40.3%) 67 11 (19.3%) 57 
Probe Removal: 1000G (all) 41 (29.9%) 137 7 (10.4%) 67 
Probe Removal: 1000G 
(common) 
27 (37.5%) 72 9 (14.3%) 63 
Probe Adjust: Pima 20 (48.8%) 41 9 (30%) 30 
Supplementary Table 3.5 – False positive/negative candidates identified by each correction approach. 
We compared the list of genes that no longer had significant eQTLs after expression correction and 
determined if they were likely false positives based on the criteria described in section 3.3.7. We repeated 
this for genes gained significant eQTLs after expression correction and determined if they were likely false 
negatives based on the criteria outlined in 3.3.7. Overall, we found that probe removal with 1000G all 
variants caused the most number of signals to change, but a relatively low proportion of these were 
actually false positives/negatives. As expected, methods that removed fewer probes changed fewer signals, 
with the probe adjustment method changing the least compared to the original analysis. However, despite 
changing the lowest amount of signals, the probe adjustment method had a high concordance with “likely” 










Systems genetics is an approach that seeks to holistically understand the biological mechanisms 
that drive complex traits and diseases [1]. These studies have the potential to unravel causal 
genes and pathways between endpoint phenotypes and DNA variation by examining 
intermediate phenotypes such as transcript, protein, or metabolite abundance. Using molecular 
phenotypes that are most relevant to the trait of interest can provide deeper insight than solely 
examining sequence variation. For example, gene expression studies such as eQTL (expression 
quantitative trait loci) mapping can be integrated with genome-wide association studies 
(GWAS) to predict causal genes and their functions. The advancement of high-throughput 
technologies and the increasing availability of large-scale molecular data have facilitated 
unprecedented studies which have furthered our understanding on various facets of systems 
genetics. For example, the UK biobank (UKBB) has collected genotypes on approximately 
500,000 UK individuals with many phenotypes, including biological measurements, lifestyle 
indicators, blood and urine biomarkers, and brain/liver imaging [125]. The database of 
published associations discovered by UKBB is freely available online for researchers to query 
[158]. The TOPMed program has collected and sequenced 53,831 genomes with diverse 
ethnicities, including European, Asian, African, Latino/Hispanic, Native American and more 
[159]. In addition to genomes, the TOPMed program has also provided phenotypic 
measurements, such as transcriptomic profiles via RNA-seq from whole blood for hundreds of 
individuals [160]. Another example is the SCALLOP consortium, which has collected many 
phenotypes, proteomic measurements and genotypes to perform large-scale cardiovascular 
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pQTL (protein quantitative trait loci) mapping, which have identified potential drug therapy 
targets [161,162]. 
Despite the increasing availability of resources, not all tissues have been studied equally, and 
disease-relevant tissues can be difficult to obtain. Some easily accessible tissues, such as blood 
or cell lines have been well-studied with large sample sizes. For example, the eQTLgen 
consortium has meta-analyzed blood eQTLs of 31,684 samples and identified ~17,000 cis-eQTL 
genes [105]. The renal tissue on the other hand, is still largely underrepresented and is still an 
emerging area of research [106]. As of this date, only a handful of studies have assayed kidney 
expression and performed eQTL analysis. While the GTEx consortium (version 8) has assayed 
RNA-seq expression levels for many tissues (49 published), the sample size for the kidney tissue 
is the lowest among all tissues (n=73) and the number of discovered cis-eQTL genes (eGenes) is 
~2.8-fold fewer than the next lowest, due to lower tissue quality and limited sample size [52]. 
Another eQTL scan was performed on 96 normal kidney samples from The Cancer Genome 
Atlas (TCGA), in which 1,886 eGenes were found [108]. One major limitation to both studies 
was that the kidney tissues were obtained from cortex in bulk, which does not represent key 
renal cell types - such as podocyte, glomerulus, tubular epithelial – that are relevant to the 
function of kidney. Furthermore, both GTEx and TCGA individuals were heavily biased towards 
European ancestry and does not represent genetic diversity of global populations.  
Recently, the Nephrotic Syndrome Study Network (NEPTUNE) performed an eQTL mapping 
(nephQTL) with micro-dissected kidney compartments (glomeruluar and tubulointerstitial) on 
187 individuals with nephrotic syndrome [106]. This resource substantially expanded our 
understandings of genetic regulation in renal tissues, even though it is focused on kidneys 
carrying rare diseases. There are increasing needs to profile the transcriptomes of each renal 
tissue compartment across diverse ancestries. The paucity of underrepresented populations in 
genomics studies is an important issue that, unless addressed properly, could contribute to 
further inequities in healthcare outcomes between different demographic groups [163,164]. 
Increasing the diversity of populations included in genomic studies could bridge this healthcare 
disparity by enriching our knowledge of genetic variation within different ancestry groups [165], 
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which will ultimately lead to improved and more accurate clinical care in a precision medicine 
setting [166]. 
Despite recent advances of eQTL studies focusing on renal tissues, systems genetics approach 
to understand the landscape of molecular and clinical profiles of renal tissues have not been 
explored yet. Molecular changes within renal tissues are more meaningful when they are also 
associated with clinical phenotypes, such as glomerular filtration rate (GFR) or albumin-creatin 
ratio (ACR). Morphometric measurements from imaging analysis of biopsy samples are also 
very important phenotypes to precisely quantify the function of individual kidneys. Multi-omics 
profiling integrated with morphometric and clinical phenotypes would make ideal resource for 
systems genetics studies to holistically understand the molecular basis of renal diseases.     
In this chapter, we present a systems genetic study focusing on microdissected renal tissue 
compartments for an underrepresented indigenous population. In particular, we study the Pima 
diabetic nephropathy cohort, which followed 97 Pima Native Americans over 15 years 
(ClinicalTrials.gov number, NCT00340678). Among the many measurements taken include deep 
whole genome sequencing, transcriptomic profiles of microdissected kidney compartments at 
two timepoints, clinical measurements related to kidney function, and morphometric features 
obtained from biopsies. With these datasets, we performed eQTL mapping, as well as 
differential expression, genome-wide association on a number of traits, and transcriptome-
wide association. Here, we discovered 805 glomerular eGenes and 1,118 tubular eGenes, with 
129 novel tissue-specific and 64 novel population-specific eGenes not identified in previous 
studies. We also identified 4,605 genes differentially regulated by renal phenotypes, enriched in 
pathways specific to cytokine-cytokine receptor interactions, focal adhesion, cancer, and ECM-
receptor interactions. We also report genome-wide significant associations with the VPC 
(volume of podocyte cell) morphometric trait for variants within the C2CD4B gene region – 
which has been identified as a potential risk variant for type 2 diabetes [167,168] – and a 
composite trait aggregated from multiple phenotypes. Our resource will help further our 
understanding of the molecular basis of diabetic renal diseases specific to cell-specific renal 




4.2.1 A Landscape of Native American Renal eQTLs with Deep Whole Genome Sequencing 
The Pima diabetic nephropathy study provides numerous longitudinal clinical and multi-omics 
resources which can be used to help further our understanding of the kidney tissue from a 
systems genetics perspective. The depth and quality of these datasets provides an excellent 
opportunity to identify novel genes associated with renal diseases [169], potentially enriching 
our knowledge of this relatively understudied tissue. Among the many measurements gathered 
in this cohort include whole genome sequence data, transcriptomic profiles, kidney-related 
clinical traits, and kidney morphometry (Figure 4.1A). Of 77 participants received a biopsy in the 
first timeframe, 40 individuals received a follow-up biopsy in the second timeframe, and 37 
dropped out of the study primarily due to poor disease progression or death. The second biopsy 
period introduced 20 new individuals to the study (Supplementary Table 4.1).  
With the availability of deep, high quality datasets, we performed several analyses including 
identifying genetic determinants of gene regulation (eQTL mapping), identifying transcripts 
associated with phenotypes, identifying genetic variants associated with phenotypes (GWAS), 
identifying genes associated with phenotypes through genetic regulation (TWAS) (Figure 4.1B). 
In our eQTL analysis, we examined the association between genotypes versus each biopsy (B1 
and B2) and tissue type - glomerulus (Glom) and tubulointerstitium (Tub) - across technologies 
(array and RNA-seq) separately, as well as jointly. Differential expression was performed using 
clinical and morphometric traits as explanatory variables under linear mixed model [170]. We 
also imputed gene expression levels using 44 tissues from Genotype-Tissue Expression (GTEx) 
Project, while applying a combined-tissue aggregate score to perform TWAS analysis on our 
morphometric and clinical traits (see Chapter 2). Finally, GWAS on morphometric, clinical, and 
composite phenotypes were performed using genotypes from whole genome sequencing 
(WGS).  
For the sake of convenience, throughout this chapter we may sometimes abbreviate each gene 
expression assay as follows: biopsy 1 glomerular array expression (B1G-Array or B1GA), biopsy 2 
glomerular array expression (B2G-Array or B2GA), biopsy 2 glomerular RNA-seq expression 
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(B2G-RNAseq or B2GR), biopsy 1 tubular array expression (B1T-Array or B1TA), biopsy 2 tubular 
array expression (B2-Array or B2TA), biopsy 2 tubular RNA-seq expression (B2T-RNAseq or 
B2TR). 
4.2.2 Discovery of Pima cis-eQTLs  
We sought to identify genetic determinants of gene regulation from the transcriptomic profiles 
of Pima Native Americans. Given the limited sample size, we focused on the cis-acting eQTLs 
identified within 1Mb of the transcription start site of each gene, from each of the 6 sets of 
transcriptomic profiles. We used linear mixed model eQTL analysis with EMMAX [157] and 
corrected for systematic variations after normalization to increase the power to detect cis-eQTL 
while correcting for false positives (see Methods). For more consistent and interpretable 
comparisons of cis-regulated genes, our results mainly focus on 19,612 protein-coding genes 
(GENCODE v27) unless indicated otherwise.  
We identified a total of 805 glomerular and 1,118 tubular significant cis-eGenes across all 
biopsies and platforms (Table 4.1). Interestingly, despite that the first biopsy was based on 
older array-based technologies, in glomerular tissue, we identified more cis-eGenes (n=435) in 
the first biopsy than the second biopsies (178 from array, 351 from RNA-seq). We suspect that 
progression of glomerular damage increased heterogeneity between samples in biopsy 2 and 
the proportion of genetic variance among the overall variance of each gene (i.e. heritability) is 
higher for biopsy 1 compared biopsy 2.  For tubulointerstitial compartment, array-based cis-
eGenes were slightly smaller for biopsy 2 (n=285) compared to biopsy 1 (n=315). However, 
RNA-seq in biopsy had much higher power to detect significant cis-eGenes (n=814). These 
results suggest that RNA-seq improves the power to detect eQTLs but heterogeneity between 
samples also substantially affect the power of eQTL studies. 
We also attempted joint eQTL analysis across three datasets using the APEX software tool 
[171], treating the overlapping sample between experiments as identical twins using linear 
mixed model. While this approach found more eQTLs compared to single array datasets, it did 
not always identify more eQTLs than our RNA-seq datasets, presumably due to large 
heterogeneity between platforms (Table 4.1, Supplementary Table 4.8). 
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4.2.2.1 Concordance of eQTLs between tissues and biopsies 
To understand the similarity and differences in transcriptomic regulation between the 
glomerular and tubular tissues, we examined the concordance cis-eQTLs between the tissue 
types, biopsies, and assays. It has been shown that eQTL overlaps can be severely 
underestimated due to limited power [172], so we considered a cis-eQTL as ‘replicated’ in one 
of other two experiments for the same tissue if the Bonferroni-adjusted p-value is nominally 
significant (i.e. adjusted p<0.05, point-wise p<0.025) at the same SNP. With these criteria, we 
observed that 28-47% of glomerular cis-eQTLs and 35-60% of tubular cis-eQTLs are replicated in 
another experiment within the same tissue (Table 4.2). When comparing within the same 
experiment but different tissues, we note that replication rates are higher overall within the 
same biopsy than between biopsies, and overlaps are higher within biopsy 1 compared to 
biopsy 2. For example, 47.1% of B1GLOM-Array eQTLs are replicated by B1TUB-Array, whereas 
only 25.2% of B2GLOM-Array eQTLs are replicated by B2TUB-Array. This trend is also observed 
in the tubular tissue, where 58.7% of B1TUB-Array eQTLs are replicated by B1GLOM-Array, but 
only 36.5% of B2TUB-Array signals are replicated by B2GLOM-Array. This lower replication rate 
in the second biopsy suggests that glomerular and tubular eGenes become more tissue specific 
as time passes on.  
4.2.2.2 Identification tissue-specific and population-specific cis-eQTLs novel to GTEx 
Next, we sought to identify potential novel cis-eQTLs discoveries from our dataset compared to 
published eQTLs from GTEx project. For each peak cis-eQTLs from our study, we classified it as 
“novel” if it was located outside of the 95% credible set of any of the finely-mapped cis-eQTLs 
for each of the 48 GTEx version 8 tissues (except for kidney) [52,173] in which the deterministic 
approach of posteriors (DAP) algorithm was used to detect eQTLs [174].  We also evaluated 
overlap with kidney cis-eQTLs from NephQTL [106], to identify kidney-specific eQTLs shared 
with European ancestry. Overall observed that ~45%-55% of Pima cis-eQTLs overlapped with at 
least one of the GTEx cis-eQTLs, with the same proportion of eQTLs overlapping with nephQTL 
signals (Table 4.3).  
99 
 
To potentially understand and identify the mechanisms behind our novel signals, we further 
classified the novel signals into three coarse categories. We hypothesized that Pima signals 
could have been novel due to the signals being (1) highly tissue-specific (expressed in kidney, 
not expressed in GTEx tissues), (2) population-specific (low non-reference allele frequency in 
non-Pima individuals) or (3) other reasons, which may include lack of power in the GTEx tissues. 
Among the genes novel to GTEx, we identified a total of 53 tissue-specific eQTL variants from 
the glomerular compartment and 83 tissue-specific eQTL variants from the tubular 
compartment, with a total of 129 tissue-specific eQTL variants between the two tissues (Figure 
4.2A, Supplementary Table 4.5). To determine tissue-specificity of each eGene, we calculated 
the median TPM for each gene across each of the 49 GTEx tissues and compared this to the 
median TPM of the RNA-seq expression levels for both tissue compartments in the Pima cohort. 
Each gene was designated as tissue-specific if the Pima median TPM was higher than the top 
5% of median TPMs among the GTEx tissues.  
Next, we found a total of 64 peak eQTLs in to be population specific, with 26 coming from the 
glomerular tissue and 45 from the tubular tissue (Figure 4.2B, Supplementary Table 4.6). To 
determine the population-specificity of novel variants, we compared the minor allele frequency 
of each peak cis-eQTL between the Pima and European populations. To do this, we examined 
specifically the European individuals from the 1000 Genomes reference panel. We defined a 
variant as being Pima-specific if the minor allele frequency difference between the two 
populations were greater than 20%, and less than 5% overall for the 1000 Genomes population.  
Finally, there were 23 genes that had both tissue-specific and population-specific eQTLs. These 
genes were involved in Acyl-CoA dehydrogenases (ACOX2, ACAD10), fatty acid metabolism 
(D2HGDH, BPHL), reactive oxygen process pathway (NDUFA6, TNXRD2), DNA binding (MSH3), 




4.2.3 Association with Phenotypes and Measured Expression  
We conducted association analysis between expression levels of each gene and phenotypes to 
identify genes differentially regulated based on phenotypes. Specifically, for each tissue 
(glomerular and tubular) and biopsy, we examined the pairwise association between each of 
the 28 phenotypes (25 morphometric and 3 clinical) and individual genes using linear model 
and identified genes significantly associated at FDR 0.05 [175]. Association between these 
measured gene expressions and phenotypes may implicate their relationships in either 
direction: genes affecting phenotypes or phenotypes affecting the genes. A total of 4,605 genes 
(2,650 in glomerular and 2,579 in tubular) were identified as significant in at least one of 
analysis, and 2,157 genes were significant in two or more analyses (Figure 4.4, Supplementary 
Table 4.12)  
Gene set enrichment analysis using KEGG pathway [176–178] with Enrichr software [179] 
identified many significantly enriched biological pathways associated with morphometric and 
clinical phenotypes. For example, cytokine-cytokine receptor interactions, which was previously 
implicated for diabetic kidneys and renal carcinoma [180–182], were significantly enriched with 
Glomerular Filtration Rate (GFR), Urinary Albumin Creatin Ratio (uACR), and multiple 
morphometric traits (VVAT_NS, VVATTT_NS, VVMM) (See Table 4.4A, 4.4B). These results 
suggest that cytokine response to activating stimulus may be an important factor involved with 
the function of diabetic kidneys. Focal adhesion pathway was significantly enriched (adjusted 
p=2.2x10-4) with numerical density of podocyte cell per glomerulus (NVPC), which is consistent 
to the previous studies capitalizing on the importance of focal adhesion in podocyte attachment 
within glomerular structure [183,184]. We also identified pathways related to cancer and ECM-
receptor interaction, which had significantly enriched associations between glomerular gene 
expression and morphometric traits measuring glomerular basement membrane width (GBM) 
and mesangial fractional volume (VVMES), suggesting potentially shared factors between 
diabetic kidneys and renal carcinoma [185,186].  
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4.2.4 GWAS with Clinical and Morphometric Traits 
We performed GWAS across 28 first biopsy and 25 second biopsy clinical and morphometric 
traits, as well as with the 13 first biopsy and 10 second biopsy composite traits (derived by 
principal components, Supplementary Materials 4.6.1). To correct for multiple traits, we used a 
conservative Bonferroni significance threshold of 2.0x10-9 (5x10-8, corrected across 25 traits). 
With this p-value threshold, we did not find any statistically significant signals. However, we 
found some marginal signals that may be suggestive of true associations. For example, for the 
biopsy 2 VPC trait (Figure 4.3A), we identified an association with variant rs11637089 (p-value = 
2.01x10-8, minor allele frequency = 38.8%), lying within the C2CD4B region, which has been 
previously identified as a risk-variant for type 2 diabetes [167,168]. Using the composite traits, 
we identified variant rs1559274 to have suggestive association with the PC3 trait from biopsy 2 
(p-value = 9.42x10-9, minor allele frequency = 30.0%), which corresponds to SV, uACR, VVPC and 
NVPC (Figure 4.3B). This top locus lies within 500KB downstream of the AGXT2 gene, which has 
been implicated in regulation of blood pressure [187]. AGXT2 was also found to have tissue-
specific and population-specific eGenes in Pima eQTLs. Given that PC3 is driven by uACR, which 
has been shown to be correlated with blood pressure [188–190] there may be some suggestive 
evidence that this genetic marker play a part in regulation of blood pressure as well. 
 Although power to detect associations in GWAS can depend on various factors including allele 
frequency and effect size or trait heterogeneity, sample size is an important factor for these 
studies [191–193]. Given that sample sizes for many GWA studies can number in the thousands 
of even tens or hundreds of thousands [194], the relatively scarcity of signals here is not 
surprising given the sample sizes (n=77, n=60 for biopsy 1 and 2 respectively). Despite the 
marginal levels of association overall, it appears that some of the top signals may provide 
meaningful insight into the biology of diabetes and kidney function. 
4.2.5 TWAS Between Predicted Expression and Clinical and Morphometric Traits 
We performed TWAS by associating predicted gene expression levels with clinical and 
morphometric traits, as well as with composite traits. Here, the predicted gene expression was 
based on a SWAM model (Chapter 2) derived from the GTEx version 8 whole blood tissue, for 
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13,907 protein coding genes (see methods). To correct for multiple testing, we used a 
Bonferroni corrected p-value threshold of 1.5x10-7 for regular traits and 3.0x10-7 for composite 
traits. While we did not discover any significant associations for the regular or composite traits, 
we found some marginal associations that may be of biological relevance. The top association 
among biopsy 2 traits was between VVPT_NS and the TFDP2 gene (p-value = 7.85x10-7), which 
contains risk variants previously identified in chronic kidney disease [195].  
 
4.3 Discussion 
In this chapter, we presented a longitudinal systems genetics resource based on the diabetic 
nephropathy cohort of Pima Native Americans, encompassing deep whole genome sequencing, 
transcriptomic profiles of two microdissected renal compartments, clinical traits, and 
morphometric phenotypes. Given that there have been few kidney transcriptomic resources 
(GTEx, nephQTL) and fewer yet with microdissected tissue compartments to differentiate 
between cell types and function, our work on this underrepresented, population-specific cohort 
can potentially provide a unique perspective of biological mechanisms underlying kidney 
disease. 
With the various analyses performed in this study, we were able to replicate numerous 
established or hypothesized pathways relevant to diabetes and kidney disease, as well as 
uncover potentially new signals. For example, our eQTL analysis replicated many signals from 
GTEx tissues, while also discovering tissue- and population-specific novel signals that we believe 
to be authentic. Indeed, among the 805 glomerular and 1,118 tubular eGenes, roughly 50% of 
the genes were also eGenes in one of the 48 GTEx version 8 tissues. On the other hand, we 
discovered 129 genes are likely novel due to tissue-specificity (genes expressed in Pima Kidney 
tissue but not GTEx tissues) and 64 genes due to population-specificity (novel signals due to 
studying a population that is distant from the GTEx samples). While the sample size of the 
cohort was sufficient to discover many eQTLs, GWAS are usually conducted using much larger 
cohorts, and often even meta-analyzed across multiple studies [196]. As such, it is not 
surprising that our GWAS provided only marginal associations for very few traits. Yet, our GWAS 
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with the VPC trait (volume of podocyte cell) identified genetic variants located within the 
C2CD4B gene region, which has been previously linked to diabetes susceptibility [167,168]. In 
addition to eQTL and GWAS, we characterized our clinical and morphometric traits in the 
context of transcriptome variation, testing for differentially expressed genes as well as 
conducting TWAS. With our measured expression association tests, we discovered 4,605 genes 
associated with morphometric traits, highlighting various relevant biological pathways such as 
cytokine-cytokine receptor interactions, focal adhesion, cancer, and ECM-receptor interactions. 
Finally, our TWAS also may have found a relevant association between VVPT_NS and TFDP2, a 
gene implicated in chronic kidney disease. All of these findings highlighted above will serve as a 
valuable resource to both validate and augment our current transcriptomic and genomic 
knowledge base for kidney structure and kidney disease progression, particular for the Native 
American population. 
The study design and quality of this dataset yields several distinct benefits that make it an 
valuable kidney transcriptome resource. Firstly, studying microdissected compartments of renal 
tissues can be extremely important in understanding the cell-type-specific regulation of renal 
transcriptomes. Even though a large number of eQTLs are shared between glomerular and 
tubular compartments, it was clear that many eQTLs are shared within the same 
compartments, even at differing time periods. Differentiating cell-types within an organ has 
been shown to more accurately identify new disease pathways by capturing the signature of 
important cell types, such as podocytes [197,198]. We expect that single-cell transcriptomic 
profiling technologies will allow us to understand cell-type-specific nature of transcriptional 
regulation in renal tissues much more precisely [199]. Secondly, the longitudinal collection of 
data gives multiple snapshots of transcriptomic profiles, allowing us to observe change in 
potential biomarkers that may be associated with renal disease state. Overall, we observed that 
eQTLs were more highly detected in biopsy 1 microarrays compared to those from biopsy 2, 
which likely could be attributed to heterogeneity due to disease progression. However, 
identifying the exact biomarkers associated with this progression remains challenging, as the 
batch effect between the two biopsies are completely confounded with the time variable. A 
future direction of research could be to deconvolute this confounder by calibrating the biopsy 2 
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microarray expression with the RNA sequencing data, which could potentially be achieved with 
more sophisticated statistical or computational methods. Finally, while GTEx provides an 
excellent reference for transcriptomic profiles of many tissues, the Pima samples have the 
benefit of being biopsied from live individuals. Because many of the high quality GTEx tissues 
are donated as transplants, the condition of the remaining tissue samples may be subpar 
compared to those from the Pima cohort. As such, we believe that our study will serve as a 
valuable resource to complement the recently growing pool of information in the field of 
kidney transcriptomics, providing both tissue-specific and population-specific insights. 
4.4 Materials and Methods 
4.4.1 Data Source 
The Pima diabetic nephropathy cohort provides a deep longitudinal catalogue of genomic, 
transcriptomic, morphometric, and clinical resource focusing on renal traits in Pima Native 
Americans. In this study, 97 individuals with minimum of 5 years of type 2 diabetes (T2D) were 
followed over a time period of 15 or more years. Many samples (n=68) had early onset of 
diabetic nephropathy. In this chapter, we focus on four different types of genomic and clinical 
measurements (Fig 4.1A) that were collected from the study. First, we deeply sequenced 97 
Pima Native Americans to comprehensively identify genetic variation within the cohort. Second, 
we assayed transcriptomic profiles between two time points with multiple technologies 
(microarray and RNA-seq) across two micro-dissected kidney compartments (glomerulus and 
tubulointerstitial). The first biopsy was taken from 2003-2007 while the second biopsy was 
taken from 2014 onward. Individuals who remained healthy enough at the second time point 
underwent the second biopsy, while those whose disease progression prevented them from 
safely undergoing an additional biopsy were excluded. Third, clinical phenotypes relevant to 
kidney functions were collected several times a year, such as Glomerular Filtration Rate (GFR), 
Urinary Albumin-Creatine Ratio (uACR), and hemoglobin A1C (HbA1c). Finally, morphometric 
measurements including volume of podocyte (VPC) and messangial cells (VVMES) within the 
glomerulus as well as cortical interstitial fractional volume (VVint) (and many more) were taken 
with each biopsy.  
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 4.4.2 Whole Genome Sequencing 
Deep whole genome sequencing was performed on 97 individuals using Illumina HiSeq X-Ten at 
the MacrogenLab. A mean depth was 32x was achieved, with 99.3% coverage of the genome 
(98.77% covered with at least 10x depth). Overall, the quality metrics looked excellent after 2 
potentially contaminated samples were identified and re-sequenced. We used the GotCloud 
[152] pipeline to produce SNP calls, using 1000G genotypes as cues. We also detected novel 
SNPs, which were included if there was strong evidence of being a true positive. We then used 
HaplotypeCaller [200] to detect both SNPs, as well as insertions and deletions (indels). We then 
generated variant call files (VCFs) using the SNPs from GotCloud and indels from 
HaplotypeCaller.  
In addition to whole genome sequencing, a genotyping array was used for 54 of the samples. 
We checked the concordance for the overlapping variant calls between these two genotyping 
technologies. Excluding 5 samples, we found the concordance overall to be very high across 
shared sites (>99.3%). Of the 5 samples with low concordance, 4 of them appear due to be a 
quality issue with the genotyping array, and the other one a sample swap.  
4.4.3 Measurements of Expression 
The expression microarray platforms used for the first biopsy were the Affymetrix HGU-133A 
(glomerular n = 21, tubular n = 22) and HGU-133 Plus 2 arrays (glomerular n = 48, tubular n = 
24). In the second biopsy, the Affymetrix HuGene 2.1 array was used (glomerular n = 50, tubular 
n = 54). All three platforms consisted of 25-mer probe sequences specifically designed to target 
individual exons. To harmonize between platform differences, we used a custom probe-to-
probeset mapping provided by the Microarray Lab from the Molecular and Behavioral 
Neuroscience Institute at the University of Michigan [148,149]. Under this mapping, the HGU-
133A platform contained 12075 probesets over 174129 probes, the HGU-133 Plus 2 platform 
contained 19703 probesets over 333134 probes, and the HuGene 2.1 platform contained 25583 
probesets over 466204 probes.  
RNA sequence data was available for both glomerular and tubular tissues in biopsy 2. Here, 
reads were aligned with TopHat [150] software tool and the transcript counts were quantified 
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with Cufflinks [151] and normalized via log-transformation of FPKM (fragments per kilobase of 
transcript per million mapped reads). SVDiff was also applied to RNA-seq data for eQTL analysis. 
4.4.4 Clinical and Morphometric Measurements 
Clinical traits were taken every six months, measuring kidney function metrics such as urinary 
albumin-to-creatinine ratio (uACR), glomerular filtration rate (GFR) and hemoglobin A1c 
(HbA1c). Morphometric traits were taken from the sampled biopsies with 25 features 
measured in the first biopsy and 22 features in the second biopsy. The full list of morphometry 
features is shown in Supplementary Figure 4.11. 
4.4.5 Normalization of Microarray Gene Expression 
To normalize expression, we applied Bioconductor’s robust-multiarray averaging (RMA) to each 
microarray platform separately. This method also takes probe-level intensities and combines 
them into probeset-level expression, which are later converted to genes. To maintain a 
consistent set of genes across the different platforms, we used a custom probe-to-probeset 
mapping provided by the Microarray Lab from the Molecular and Behavioral Neuroscience 
Institute at the University of Michigan. Under this mapping, the HGU-133A platform contained 
12075 probesets over 175,294 probes, the HGU-133 Plus 2 platform contained 19703 probests 
over 333134 probes, and the HuGene 2.1 platform contained 25583 probesets over 466204 
probes.  
Because the microarray experiment for biopsy 1 was done in two separate batches (both with 
different platforms), we used ComBat, an empirical Bayes batch correction method [68] to 
combine across platforms into a unified dataset for the first biopsy. To further deal with latent 
systematic technical effects in the array data, we used a singular-value decomposition method 
(which is outlined in the supplementary materials) similar to PEERS [201] in which we factor the 
expression matrix, identifying components of variation. We called this method SVDiff and found 
this approach worked very well in terms of removing these systematic biases, and in increasing 
the power of our eQTL analysis (see Supplementary Materials 4.6.2). 
107 
 
4.4.6 Variant-Aware Correction of Microarray Expression 
It is well-known in microarray experiments that when target probe sequences contain a genetic 
variant for an individual, there can be a hybridization bias due to differential binding affinity 
caused by said variant [100,101]. Typically, this negative hybridization will result in 
systematically lower probe intensity levels and potentially create false association signals. To 
combat this, we used our in-house software to identify probes that overlapped with Pima 
variants and removed them from the analysis (See Chapter 3). For the HGU-133A platform, we 
identified 7,542 probes (4.3% of the total probes) affecting 4,375 probesets (36.0% of the total 
probesets). For the HGU-133 Plus platform, we identified 14,840 probes (4.4% of the total 
probes) affecting 7,992 probesets (40.4% of the total probesets). Finally, for the biopsy 2 
platform, HuGene 2.1 ST, we identified 27,767 probes (6.0% of the total probes) affecting 
13,219 probesets (51.1% of the total probesets). 
4.4.7 eQTL Mapping 
Expression quantitative trait locus (eQTL) analysis was performed using mixed model 
association via the EMMAX software package [157]. A separate analysis was performed for each 
tissue. For every SNP and indel identified from our whole genome sequencing, we tested for 
association against each of the genes with measured expression. To account for potential 
confounders, we adjusted for age and sex as covariates. In addition, to account for potential 
familial-relatedness, we calculated a pairwise kinship matrix for all samples, using it as the 
fixed-effects component of the mixed model. 
We defined an eQTL as cis-acting if it was located within 1 Mb of the transcription start site of 
the associated gene. Otherwise, the eQTL signal was defined as being trans-acting. To account 
for multiple testing, p-values were adjusted by the false-discovery rate (FDR) correction 
approach, using the trans-eQTL signals to determine the false discovery rates. Even though the 
p-value thresholds at FDR < 0.05 are different between datasets (Supplementary Table 4.3), 
they were reasonably close to each other, so we used a fixed pointwise p-value threshold of 
5x10-6 for straightforward comparisons between different eQTL datasets. Because of linkage 
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disequilibrium (LD) between neighboring SNPs, only the SNP with the lowest p-value was taken 
as the true cis-eQTL signal for each gene. 
4.4.8 Combined Biopsy eQTL Mapping  
In addition to eQTL mapping with each tissue/biopsy as a separate analysis, we performed a 
joint tissue analysis where we combined across biopsies for each tissue. To do this, we used 
APEX (All-in-one Package for Efficient Xqtl analysis) [171], inputting B1GA, B2GA, and B2GR 
simultaneously, as well as B1TA, B2TA, and B2TR simultaneously. To account for duplicate 
individuals, we specified kinship coefficients of 1 (monozygotic twins) for same individuals and 
0 (unrelated) for all other pairwise relationships. The results of this analysis are shown in Table 
4.1 and Supplementary Table 4.5 alongside our main eQTL analysis. 
4.4.9 GWAS with Morphometric and Clinical Traits 
We performed a GWAS analysis between the Pima genetic variants and the morphometry and 
clinical data. Here, we tested 3 clinical traits (uACR, GFR, and HBA1c) and 25 biopsy 1 
morphometric traits, and 22 biopsy 2 morphometric traits (Supplementary Table 4.9). Like our 
eQTL analysis, adjusted for age and sex as covariates, and used the pairwise kindship matrix to 
account for familial structure. Because many of the morphometric traits are highly correlated, 
we also performed a PCA analysis on the traits, using the top 10 PCs for the analysis, in addition 
to all the original traits. 
To determine the significance threshold, we used 5x10-8 for each trait, and applied a Bonferroni 
correction based on the number of traits analyzed. For the regular traits, we used a p-value 
threshold of 2x10-9 and for the composite traits, we used a threshold of 5x10-9.  
4.4.10 Association Analysis between Measured Gene Expressions and Phenotypes 
We performed association analysis between 28 phenotypes – 25 morphometric, 3 clinical – and 
the expression levels of each gene, per tissue, biopsy, and assay. For array-based expression, 
we used quantile-normalized expressions obtained from RMA. For expression levels from RNA-
seq, we used FPKM values. The association analysis was performed using a linear model, with 
gene expression levels as the response variable and the phenotypes as predictor variables, 
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accounting for sex and age as covariates. For each dataset, we identified significantly associated 
genes using FDR < 0.05 threshold [175] and the significant genes were merged across biopsies 
and assays for each tissue and each phenotypes when summarized into Figure 4.4 and 
Supplementary Table 4.9 To perform pathway enrichment analysis, we used EnrichR [179] using 
KEGG 2019 Human database [176–178]. We reported only the significant enrichment with 
adjusted p-value < 0.001 to account for multiple comparisons. When a certain 
phenotype/tissue has many significantly enriched pathways, we only listed top 5 pathways in 
terms of p-value. 
4.4.11 Transcriptome Wide Association Analysis 
We performed transcriptome-wide association mapping by first using SWAM (chapter 2) to 
derive a whole blood model using 49 tissues from GTEx version 8 [52] and DGN whole blood 
tissue [50]. We then used PrediXcan [55] to calculate predicted expression levels based on the 
WGS genotypes of the 97 Pima individuals. From this prediction model, we successfully 
imputed 15,319 genes. We filtered these genes further using gencode v27 protein coding 
genes, resulting in 13,907 genes for the analysis. Next, we used EMMA [202] to perform mixed-
model association using clinical and morphometric traits as the outcome variable, and 
predicted expression levels as explanatory variables, adjusting for age and sex. We repeated 
this using the composite traits derived from our PC analysis (Supplementary 4.6.2). To account 
for population substructure from predicted expression levels, we calculated a covariance matrix 
between individuals across all genes and modeled it as a random effect. We accounted for 
multiple testing by setting a Bonferroni-corrected p-value threshold of 1.5x10-7 (correcting 
across 13,219 genes and 28/25 traits) for original clinical/morphometric traits, and 3.5x10-7 for 























Figure 4.1A – Overview of the Pima study 
The Pima diabetic nephropathy cohort is a longitudinal study focusing on microdissected renal tissue 
compartments – glomerular and tubulointerstitial. Among the many measurements taken from the 
study included deep whole genome sequencing, gene expression levels (microarray and RNA-seq), 
clinical phenotypes, and morphometry traits determined by biopsies performed at two time points. 
Second biopsies were only performed on individuals healthy enough to undergo the operation 8 years 
after the initial biopsy. Additional participants who were added to the study later on were classified in 





Figure 4.1B – Overview of analyses performed in this chapter 
With the multitude of datasets available, we performed various analyses to provide a multi-
faceted perspective of this unique cohort, including eQTL analysis, GWAS, TWAS, and trait-





Biopsy Platform N samples # eGenes 
B1 Glom  Microarray 69 435 
B1 Tub Microarray 46 315 
B2 Glom Microarray 50 178 
B2 Tub Microarray 54 285 
B2 Glom RNA-seq 52 351 
B2 Tub RNA-seq 55 814 
Apex-Glomerular Combined 93(171) 403 
















Table 4.1 – eGene discovery from cis-eQTL analysis  
Our main cis-eQTL analyses were performed using mixed-model regression via EMMAX [156]. 
We normalized each dataset with our SVDiff method, which is outlined in section 4.6.2. We 
also performed a combined analysis, where we aggregated across biopsies and platforms for 
each tissue type. To do this, we used the APEX software [170] to meta-analyze the multiple 





Platform # eGenes 
# Replicates 
B1GA B2GA B2GR B1TA B2TA B2TR 




















































































Table 4.2 – cis-eQTL replication across tissues and biopsies 
For every peak cis-eQTL (p-value = 5x10-6), we searched for replication for that variant with 
other tissues/platforms. We considered the eQTL to be successfully replicated in another 


















B1G (Microarray) 435 199 33 13 3 206 
B1T (Microarray) 315 151 35 19 7 160 
B2G (Microarray) 178 96 20 9 3 86 
B2T (Microarray) 285 142 25 12 1 155 
B2G (RNA-seq) 351 173 22 20 2 164 
B2T (RNA-seq) 814 358 69 37 8 438 
Table 4.3 – eQTL breakdown compared to other datasets 
We compared Pima eQTLs to other resources, namely GTEx and nephQTL. Genes were 
considered novel if they were not in the 95% credible set for any GTEx tissue, excluding kidney. 
From the list of novel genes, we further classified them as being tissue- or population-specific 
based on the criteria outlined in 4.2.2.2. For nephQTL replication, we considered a cis-eQTL 
replicated using a p-value threshold of 0.05. 
 




















Figure 4.2 – breakdown of pima cis-eQTL variants compared to GTEx version 8 
In these plots, each point is a novel gene(as defined by Table 4.3), color coded to show if they are tissue-specific, population-specific, or 
both. (A) shows the comparison of median TPM between Pima RNA-seq and GTEx tissues. Here, we approximated the TPM count in the 
Pima individuals by applying the formula: tpm = exp(log(fpkm)-log(sum(fpkm)) + log(10-6)). (B) shows the minor allele frequencies 






Figure 4.3A – GWAS results for VPC trait 
Here we observe an association signal between the biopsy 2 VPC trait and a variant within the C2CD4B region (p-value = 






Figure 4.3B – GWAS results for PC3 composite trait 
With our composite traits, we observe a significant association between biopsy 2 PC3, (which corresponds to SV, uACR,VVPC and 







Figure 4.4 –genes associated with clinical/morphometric traits (exponential scale) 
Here, we present the number of genes associated with clinical and morphometric traits. We 
performed this analysis on B1G, B2G, B2GR, B1T, B2T, and B2TR. Counts were pooled across 










Glomerular GBM glomerular basement membrane width 365 
Pathways in cancer 1.0x10-06 3.4 
ECM-recepter interaction 3.1x10-06 8.6 
Glomerular NVPC 
Numerical density of podocyte 
cell per glomerulus 245 Focal adhesion 2.2x10
-04 5.9 
Glomerular uACR urine albumin creatinine ratio 778 Cytokine-cytokine receptor interaction 1.3x10-04 3.0 
Glomerular VVAT_NS 
fraction of cortex that is atrophic 
tubules 63 
T cell receptor signaling pathway 1.0x10-03 17.8 
Chemokine signaling pathway 1.0x10-03 11.3 
Cytokine-cytokine receptor interaction 1.0x10-03 8.6 
Glomerular VVATT_NS fraction of total tubules that are atrophic tubules 57 
T cell receptor signaling pathway 4.9x10-04 19.9 
Chemokine signaling pathway 4.9x10-04 12.6 
Cytokine-cytokine receptor interaction 4.9x10-04 9.6 
Glomerular VVMES mesangial fractional volume 395 
ECM-receptor interaction 8.7x10-04 7.1 
Pathways in cancer 8.7x10-04 2.8 
Glomerular VVMM volume fraction of mesangial matrix per glomerulus 552 Complement and coagulation cascades 9.1x10
-07 8.5 
Glomerular VVPCN volume fraction of podocyte nuclei per podocyte cell 246 
Lysosome 8.8x10-07 10.0 
Protein processing in endoplasmic 
reticulum 1.9x10
-06 7.8 
Ribosome 4.1x10-06 7.8 
Prion diseases 2.1x10-04 17.0 
Spliceosome 2.8x10-04 6.7 
 










Tubular uACR urine albumin creatinine ratio 1,969 
Cytokine-cytokine receptor interaction 3.7x10-15 3.5 
Osteoclast differentiation 4.5x10-15 5.7 
Pertussis 4.2x10-09 5.7 
Hematopoietic cell lineage 2.6x10-08 4.6 
TNF signaling pathway 4.2x10-08 4.2 
Tubular GFR glomerular filtration rate 383 
Cytokine-cytokine receptor interaction 4.2x10-09 5.5 
Fc gamma R-mediated phagocytosis 1.5x10-04 7.2 
Leukocyte transendothelial migration 7.6x10-05 5.7 
Pertussis 8.0x10-04 7.0 
Chemokine signaling pathway 8.3x10-04 4.2 
Tubular VVMM volume fraction of mesangial cells per glomerulus 490 
Cytokine-cytokine receptor interaction 2.3x10-16 6.7 
Chemokine signaling pathway 5.3x10-06 4.8 
Pertussis 1.8x10-05 7.6 
Fc gamma R-mediated phagocytosis 1.8x10-05 6.7 
Pathogenic Escherichia coli infection 3.4x10-05 9.0 




4.6 Supplementary Materials 
4.6.1 PCA on Morphometric and Clinical Phenotypes 
We performed principal components analysis jointly on clinical traits and morphometric 
phenotypes. Here, we used the prcomp function in R, where we first inverse-normalized the 
data, centering around 0.  Supplementary Figure 4.2 shows the correlation structure between 
these phenotypes. The heatmap here suggests that performing GWAS on PCA composite traits 
may reduce some of the redundancy of the highly correlated traits. The PCA loadings are shown 
in Supplementary Figure 4.3. For our GWAS, we used the first 10 PCs as they accounted for 90% 
of the variation explained.  
4.6.2 SVDiff normalization of gene expression levels 
Our SVDiff procedure was designed to account for latent systematic technical effects in the 
array data. This approach was an extra normalization step applied to expression at the probeset 
level. Suppose 𝑌 is an 𝑛 × 𝑚 matrix with 𝑛 individuals and 𝑚 genes. We performed singular 
value decomposition on this matrix to factor it into the form, 
𝒀 = 𝑼𝚺𝑽∗ 
Where 𝑼 is an 𝑛 × 𝑛 unitary matrix, 𝚺 is an 𝑛 × 𝑚 rectangular diagonal matrix, and 𝑽 is a 
𝑚 × 𝑚 unitary matrix. Next, we subset each matrix, capturing the first four singular value 
components to re-estimate Y. We defined 𝑼𝑺𝑽 to be the first 4 columns of 𝑼, 𝑽𝑺𝑽
∗  to be the first 
4 rows of 𝑽∗, and 𝚺𝑺𝑽 to be a diagonal matrix with the first 4 elements of 𝚺. Using these matrix 
subsets, we defined 
𝒀𝑺𝑽 = 𝑼𝑺𝑽𝚺𝑺𝑽𝑽𝑺𝑽
∗  
Our SVDiff corrected expression was defined to be: 𝒀𝑺𝑽𝑫𝒊𝒇𝒇 = 𝒀 − 𝒀𝑺𝑽, which we used for our 





4.7 Supplementary Figures and Tables 
 
  
Biopsy 1 Biopsy 2 Combined 
Number of 
Samples 
 77 60 97 
Age at time of 
biopsy (years) 
mean 45.94 54.19 - 
sd 10.04 9.37 - 
Sex 
males 22 13 24 
females 55 47 73 
BMI (kg/m^2) 
mean 35.78 35.62 - 
sd 8.34 8.06 - 
Diabetes Duration 
by time of 
enrolment (years) 
mean - - 10 
sd - - 6.21 
min - - 2.28 
max - - 31.45 
GFR (ml/min) 
mean 145.83 128.39 - 
sd 51.23 47.4 - 
HBA1C (%) 
mean 9.36 9.71 - 
sd 2.05 2.01 - 
uACR 
normal (<30mg/g) 35 32 - 
microalbuminuria (30-
299mg/g) 
30 17 - 
macroalbuminuria 
(>300mg/g) 
12 11 - 
  





Platform Biopsy Genome Build 
Total Number of 
Probes 
Total Number of 
Probesets 
HGU133A 1 GRCh36 175,294 12,142 
HGU133Plus2 1 GRCh36 334,233 19,764 




Platform Biopsy Total Number of Genes 
RNA-seq 2 54,847 
  
Supplementary Table 4.2 – Microarray probe information for gene expression measurements 

















Supplementary Figure 4.1 – counts of genesets used for expression analysis 




Platform P-value threshold corresponding to FDR 0.05 
B1 Glomerular (microarray) 1.8x10-5 
B2 Glomerular (microarray) 1.0x10-5 
B2 Glomerular (RNA-Seq) 5.5x10-6 
B1 Tubular (microarray) 2.0x10-5 
B2 Tubular (microarray) 1.0x10-5 





Supplementary Table 4.4 – P-value thresholds corresponding to FDR of 0.05 for eQTL 
analyses 
 
For the sake of consistency and simplicity, we used p-value threshold of 5x10-6 for all of our 
eQTL analyses to declare significance. Thus, the numbers shown in the main sections for 
microarray platforms is slightly more conservative than compared to using FDR. 
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Assay Tissue-specific genes  
B1GLOM-Array AAMDC, ALG8, ARPC5, ATG12, ATP5S, BTD, C17orf75, CNN3, CPQ, CTBS, 
EFCAB2, FLT3LG, METTL22, MGST2, MIER2, NAAA, NAT8, NDUFA6, NUBP2, 
PPCDC, PRDX1, RAB8A, SKP1, SLC31A2, SLC9A3R2, SPAG7, TCF21, TEFM, 
TMEM50A, TMEM53, UBE2I, VPS51, WDR45B 
B2GLOM-Array C10orf107, DNAJC10, DNAJC15, GPRC5A, HEBP2, HPGD, LMBR1, LRP11, 
METTL5, NDUFA6, NQO2, ORMDL3, PAPOLA, PRPF40A, RABGEF1, RP1, 
ST6GALNAC3, TAPBP, VTI1A, ZNF880 
B2GLOM-
RNAseq 
BPHL, C10orf107, CCND3, CMTM8, DNAJC15, FBXO25, GNGT1, MRPL34, 
MRPL53, OR2T6, PCMTD1, RSRC1, SMIM19, TCF4, TCTN3, TMEM150C, 
TMEM230, TXNRD2, WISP3, YIPF3, ZNF250, ZSWIM7 
B1TUB-Array ABCC6, ACOX2, ALDH2, ATP6V1D, BCL2L13, BDH2, BPHL, BTD, COX11, 
CRYL1, CTSH, DECR2, DNAJC15, DYNC2LI1, DYNLT1, EFCAB2, ENTPD5, GGH, 
GUSB, HSPBP1, IL17RB, IMPA2, LACTB2, MRPL2, NDUFA6, NUBP2, PBLD, 
PCBD1, PDSS2, PIGF, RITA1, SKP1, SLC33A1, ST3GAL1, UCHL5 
B2TUB-Array ADI1, AGMAT, AGXT2, ASRGL1, CNTNAP3B, DNAJC15, DPYS, EIF4E2, FAH, 
IL17RB, KL, MMAA, MSH3, NAT8, PRELID1, PTGR2, RNF130, RNF212B, 
RNF5, SH3YL1, SLC25A26, SLC28A1, SLC6A18, TSPAN33, ZSWIM7 
B2TUB-RNAseq ACAD10, ACBD4, ACOT2, ACOX2, AGXT2, ATAD3C, ATP6V0E2, ATXN7L1, 
BPHL, BTD, C4orf19, CARHSP1, CBWD1, CDPF1, CEP104, CNTNAP3B, COA6, 
COX7A2L, D2HGDH, DHRS4, DHRS4L2, DNAJC15, DPYS, DTD1, EFCAB2, 
FAHD1, FOLR1, FUCA2, GSTA1, HIBADH, HSPBP1, IL17RB, KIAA1191, 
MCCC1, MRPL36, MRPL42, MSRA, MTFMT, MTG2, MUC20, MYL12B, NAT8, 
NDUFA6, NTPCR, OPA3, PBLD, PCTP, PHYH, PPP2R5C, PSMG4, PSPH, 
PXMP2, RAB3IP, RABGEF1, RNF212B, SLC22A18AS, SLC44A3, SLC6A18, 
SMIM19, SMIM7, ST3GAL1, TBCD, THOC3, TIMM10, TIMMDC1, TPRKB, 
TSTD1, WNT9B, ZSWIM7 
  
Supplementary Table 4.5 – Genes with novel tissue-specific eQTLs from Pima analysis 
 
Here, we see the list of tissue-specific genes that had Pima eQTLs novel to GTEx version 8. 
We checked if genes were tissue-specific by approximating their median TPM counts from 
Pima RNA-seq expression, and comparing it to GTEx median TPM counts. If the Pima median 
TPM was greater than the 95th percentile GTEx median TPM, then we defined the tissue as 
tissue-specific to the Pima population.  
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Assay Genes with population-specific peak eQTLs 
B1GLOM-Array ACOX2, BTD, DGCR8, IL17RB, LIPT1, MRPL39, NDUFA6, PGBD5, PPFIA4, 
SOWAHC, STAT6, VPS51, ZMYND10 
B2GLOM-Array ACOX2, CXCL12, DNAJC15, ESD, FXR2, GPATCH8, IL17RB, PPP6C, SLK 
B2GLOM-
RNAseq 
BPHL, CTNNB1, CXCL12, DNAJC15, GLCCI1, LAIR2, LILRA6, LIN7B, 
MIS18BP1, NT5DC4, OSTN, PPP1R3C, SFTPD, SLCO1B3, SLK, SNX15, 
TXNRD2, UBE2N, UNC5D, ZSWIM1 
B1TUB-Array ABCC6, ACOX2, BTD, CNN3, DGCR8, DNAJC15, DYNLT1, ERAP1, EXTL1, 
GLIPR1, GLP1R, GUF1, IL17RB, MRPL2, NTRK2, PALM, RAPGEF3, TNFSF12, 
TNFSF15  
B2TUB-Array DGKB, DNAJC15, FAH, GSTP1, GUF1, IL17RB, LOXHD1, MSH3, ODF3B, PBX3, 
TRIM24, TSPAN33 
B2TUB-RNAseq AC011479.1, ACAD10, AFMID, AGXT2, ATP6V0E2, ATXN7L1, BPHL, BTD, 
C17orf58, CFB, CIB2, CLIP4, CPT1A, CTNNB1, D2HGDH, DMAC1, ENPP4, 
FAHD2A, FAM212B, GNG10, IL17RB, KCNK10, MRPL42, MYL12B, NUDT12, 
PROB1, RUNX3, SEMA4D, SMN2, TBCD, TMEM163, TRIM24, UTS2, VHL, 
WDR31, ZNF587B, ZNF787 
  
Supplementary Table 4.6 – Genes with novel population-specific eQTLs from Pima analysis 
 
Here, we see the list of population-specific genes that had Pima eQTLs novel to GTEx version 8. 
These are genes corresponding to peak eQTL variants that had minor allele frequency > 20% in 






Platform # eGenes 
# Replicates 
B1GA B2GA B2GR B1TA B2TA B2TR 








































































Supplementary Table 4.7 – cis-eQTL replicates using stringent p-value thresholds for both datasets 
(p-value < 5x10-6) 




Biopsy Platform N samples # eGenes 
B1 Glom  Microarray 69 457 
B1 Tub Microarray 46 325 
B2 Glom Microarray 50 219 
B2 Tub Microarray 54 328 
B2 Glom RNA-Seq 52 583 
B2 Tub RNA-Seq 55 1275 
Apex-Glomerular Combined 93(171) 422 






Supplementary Table 4.8 – eQTL analysis with full list of genes 




Platform # eGenes 
# Replicates 
B1GA B2GA B2GR B1TA B2TA B2TR 











































































Supplementary Table 4.9 – cis-eQTL replication with full list of genes (p-value 0.025) 




Platform # eGenes 
# Replicates 
B1GA B2GA B2GR B1TA B2TA B2TR 








































































Supplementary Table 4.10 – cis-eQTL replication with full list of genes (p-value 5x10-6) 




Variable Name Definition Unit 
GBM glomerular basement membrane width nm 
VVMES mesangial fractional volume % 
VVMC volume fraction of mesangial cells per glomerulus % 
VVMM volume fraction of mesangial matrix per glomerulus % 
VVMGBM volume fraction of mesangial glomerular basement membrane per glomerulus % 
SV surface volume of peripheral glomerular basement membrane per glomerulus µm
2/µm3 
FPW_UM foot process width per biopsy from UMinn nm 
VPCN volume of podocyte nuclei µm3 
VVPCN volume fraction of podocyte nuclei per podocyte cell % 
VPC volume of podocyte cell µm3 
VVPC volume fraction of podocyte cell per glomerulus % 
NVPC numerical density of podocyte cell per glomerulus N/glom 
GLOM_CAV number of glomeruli measured for GV_CAV N 
GV_CAV glomerular volume by Cavaleri method on paraffin sections  x106 µm3 
GLOM_WG number of glomeruli measured for GV_WG N 
GV_WG glomerular volume by Weibel-Gomez method on epon section x106 µm3 
P_FPW foot process width in peripheral glomerular basement membrane nm 
INTACT percent of intact foot processes on both the peripheral and mesangial glomerular basement membrane % 
P_FEN percent of endothelial fenestration falling on the peripheral glomerular basement membrane % 
VVINT cortical interstitial fractional volume  % 
VVINT_NS fraction of cortex that is interstitium % 
VVINT_S fraction of scar cortex that is interstitium % 
VVSCAR fraction of total cortex that is scar cortex % 
VVAT fraction of total cortex that is total atrophic tubules % 
VVAT_NS fraction of cortex that is atrophic tubules % 
VVATTT_NS fraction of total tubules that is atrophic tubules % 
VVPT_NS fraction of cortex that is proximal tubules % 
VVDT_NS fraction of cortex that is distal tubules  % 
VVTT_NS fraction of cortex that is total tubules (proximal, distal, atrophic)  % 
GV derived glomerular volume variable - using GV_CAV when present and GV_WG when GV_CAV is missing x10
6 µm3 
  
Supplementary Table 4.11 – description of all kidney morphometry traits 
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Trait Glomerular signals Tubular signals 
GBM 365 21 
GFR 2 383 
GV 105 49 
HbA1c 0 1 
INTACT 16 0 
NVPC 245 1 
P_FEN 41 0 
P_FPW 1 0 
SV 66 0 
uACR 778 1969 
VPC 64 19 
VPCN 2 4 
VVAT 1147 942 
VVAT_NS 63 6 
VVATTT_NS 57 3 
VVDT_NS 8 5 
VVINT 1 0 
VVMES 395 136 
VVMGBM 38 22 
VVMM 552 490 
VVPC 3 0 
VVPCN 246 10 
VVPT_NS 0 2 
VVTT_NS 0 1 
  































Supplementary Figure 4.2A – Phenotype 
correlation structure between biopsy 1 
clinical and morphometric traits 
Supplementary Figure 4.2B – Phenotype 
correlation structure between biopsy 2 







Supplementary Figure 4.3 – PCA loadings for clinical and morphometric traits 





Chapter 5 Conclusion 
 
5.1 Summary 
The study of genetics is an integral part to understanding the biology behind our complex traits 
and can be approached in a variety of ways. Systems genetics studies across many genomes, 
transcriptomes, epigenomes, and phenomes provide us opportunities to elucidate the 
functional mechanisms of trait-associated variants in terms of gene regulation or protein 
function. In this thesis, we addressed on specific challenges related to systems genetic studies, 
including meta-imputation of expression across multiple datasets with only summary-level 
imputation models available, correcting for technical biases towards reference alleles in array-
based expression assays, and identifying tissue-specific and population-specific regulatory 
variants and trait-associated loci in the context of systems genetics with whole genome 
sequencing, transcriptomics profiles, morphometric traits, and clinical endpoints. With 
increasing number of sequenced genomes and trait-associated variants identified, it will be 
increasingly important to interpret each association signal through systems genetics approach 
that leverages molecular traits as intermediate phenotypes.  In this chapter, I will summarize 
each chapter and describe the current limitations in the methods and results described in each 
chapter and discuss future directions to expand their scope of research. 
In Chapter 2, we developed a method which leverages multiple datasets to accurately impute 
tissue-specific gene expression levels. Our method, Smartly Weighted Averaging across Multiple 
Tissues (SWAM) does not train directly from data, but rather combines extant prediction 
models by assigning weights based on their predictive performance and similarity to the tissue 
of interest. We demonstrate that when using the same set of resources (GTEx version 6 
tissues), SWAM improves prediction accuracy compared to approaches which predict gene 
137 
 
expression by training directly from raw data (PrediXcan, UTMOST). However, the major benefit 
of using the SWAM meta-imputation framework is the flexibility to combine multiple external 
resources derived from disjoint sets of individuals. Indeed, prediction accuracy is substantially 
improved when integrating whole-blood information from DGN samples into the GTEx-only 
predictions, highlighting the importance of using multiple datasets. 
In Chapter 3, we revisit a well-known hybridization bias that arises in microarray studies caused 
by genetic polymorphisms within target probe sequences. In our work, we leverage the 
availability of whole genome sequencing data to accurately identify and characterize this bias at 
both the probe and probeset (gene) level. We adjust gene expression level calculations by 
removing probes which overlap with study-specific polymorphisms and demonstrate that this 
approach resolves the negative bias more effectively compared to when using a reference 
panel to identify probes. We then propose an imputation method in which probes are not 
removed, but rather intensity levels are imputed based on values of unaffected probes within 
their probeset. This method was proposed to address the issue of unnecessarily removing 
probes ultimately reducing accuracy of expression calculation. This approach results in higher 
concordance between pre- and post- correction for many genes where probes were only mildly 
affected, while also reducing the negative bias in eQTL analysis. 
In Chapter 4, we perform a systems genetic study of Pima Native Americans enrolled in a 
diabetic nephropathy study. We integrate whole genome sequence data, gene expression and 
morphometric features derived from two microdissected renal compartments – Glomerular 
and Tubular – and clinical measurements to provide a landscape of the transcriptomic and 
genomic profiles of this cohort. Because of the high dimensionality of these datasets, we used 
various dimension reduction techniques such as PCA and TWAS to reduce the multiple testing 
burden and increase the chances of signal discovery. Studying this unique population gave us 
the ability to identify many population-specific and tissue-specific regulatory variants, as well as 





5.2 Meta-imputation of gene expression using summary-level eQTL databases 
In our second chapter, we developed a method to leverage multiple datasets to accurately 
impute gene expression levels. Previously, gene expression imputation models were derived by 
performing (penalized) regression between genetic markers and measured expression levels, 
requiring raw individual-level data. Our method, Smartly Weighted Averaging across Multiple 
Tissues (SWAM) combines these derived prediction models by assigning weights to each model 
based on their similarity to the tissue of interest. Because SWAM does not train directly from 
raw data, prediction models derived from disjoint sets of individuals can be combined. The 
ability to leverage multiple datasets effectively increases the sample size of prediction model 
building, compared to using only a single resource. We demonstrate that SWAM provides 
superior imputation accuracy when combining multiple tissues from the same cohort (GTEx) 
compared to methods that train directly from raw data. In addition, imputation accuracy can be 
improved further when integrating other external resources, such as adding whole-blood tissue 
from DGN with the GTEx tissues.  
We compared SWAM to other expression imputation methods in the context of TWAS, testing 
three traits (HDL, LDL and type-2 diabetes). In terms of power, SWAM discovered more trait-
associations than other methods that generate imputed expression levels. However, we are 
aware that there are other methods which do not impute expression, but directly conduct 
TWAS using summary-level aggregate information from multiple resources, such as MultiXcan 
and S-MultiXcan. These multi-dataset TWAS methods do outperform SWAM in terms of signal 
discovery for the traits we tested. However, expression predictions can be useful outside of the 
context of TWAS such as for mendelian randomization experiments. Overall, among methods 
that produce expression predictions, we found SWAM to have the highest accuracy when 
validating with an external resource, and to have the highest power for TWAS discovery. 
Because multiple resources can be integrated without the need for their raw data, SWAM will 
be able to take advantage of the increasing number of eQTL resources being generated. 
Because many current eQTL resources come from individuals with European ancestry, we 
validated our results with only the European samples from the GEUVADIS consortium. 
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However, there could be many population specific variants that regulate expression levels that 
may only be detected by studying the correct ethnic groups. In addition, identifying these 
variants could provide the opportunity to identify the true causal variant for other populations 
by disentangling associations caused by LD structures. When comparing to the African 
population from GEUVADIS, we found much lower concordance between measured and 
imputed expression. This trans-ethnic or multi-ethnic aspect of imputation is a challenging 
problem, particularly so given that we are not training using the full raw data. Our validation of 
SWAM therefore operates under the assumption that the population of interest matches the 
training population. One future direction could be to examine the ideal strategy to integrate 
resources for multi-population or population specific imputation.  
With the emerging availability of new gene expression resources, providing the tools for 
massive integration is very important. In the future I would like to eventually implement a web-
based version of SWAM, similar to imputation servers to facilitate this integration. This could 
simplify and streamline much of the imputation process at a large scale.  
Finally, as single-cell RNA-Seq is becoming the pre-eminent technology for gene expression 
studies, we are able to view transcriptomic profiles at a very high scale and resolution. There 
have already been many efforts to analyze this high dimensional data by distinguishing and 
calculating expression levels for different cell types [203–205]. However, technical noise and 
cell dropouts have also given rise to the need for imputation at the cellular level [206–208]. 
Since SWAM is already suited to integrate multiple datasets even with different tissue types, 
our method could be extended to scRNA-Seq, treating different cell types as separate “tissues”. 
This could potentially enrich imputations and also allow for TWAS conducted for scRNA-Seq. 
 
5.3 Revising array-based expression profiles to empower today’s systems 
genetics 
In the third chapter, we revisited the well-known negative hybridization bias in microarray 
studies while leveraging the availability of whole genome sequencing. Because microarray 
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probes are designed to target specific DNA sequences within gene regions, genetic 
polymorphisms within individuals can weaken the bond between the RNA molecules and probe. 
This in turn creates a false association between the genotypes and probe intensity, which leads 
to downstream false positives in eQTL studies, while also hiding true associations. In previous 
work, the strategy was to identify these probes by using polymorphic sites from reference 
panels (1000G), but this could incorrectly flag many probes if the population is different from 
the individuals in the panel.  In our work, we use individual-level whole genome sequence data 
to accurately identify the list of potential biased probes, removing them from the expression 
calculation. We demonstrate that this approach reduces bias more effectively compared to 
using 1000G common variants. However, our characterization of flagged probes also revealed 
that some probes are greatly affected (high technical bias) whereas others are only mildly 
affected by the SNP-in-probe effect. Because removing probes unnecessarily can potentially 
add noise to the expression estimates, we devised an imputation method where we use the 
unaffected probes within a probeset to help estimate the true unbiased intensity for the 
affected probe. We demonstrate that this imputation method provides similar levels of efficacy 
in terms of bias correction compared to removing biased probes, while also having higher 
concordance with original expression levels for genes with only mildly affected probes.  
Because of their design, microarrays will always be susceptible to hybridization biases as they 
require DNA sequences. However, with increasing knowledge of the human genome, modern 
microarrays can somewhat overcome these weakened hybridization biases by avoiding known 
polymorphic sites in their probe targets. The work done in this dissertation should be taken 
with caution as it was done using the HuGene 2.1 ST array, and may not be generalizable to the 
newer microarray platforms. Furthermore, the study population was also limited to Pima Native 
Americans, and different populations may be impacted to varying degrees depending on their 
population-specific variants. One possible future direction would be to characterize the list of 
probes as well as the extent of bias in said probes for different microarray platforms and 
different populations. Making publicly available resources such as these could aid future 




5.4 Systems genetic study on Pima diabetic nephropathy cohort  
In chapter 4, we presented a systems genetics study of the Pima diabetic nephropathy cohort, 
where we analyzed whole genome sequence data, transcriptomic profiles, clinical phenotypes, 
and kidney morphometry. Compared the currently published kidney transcriptome resources, 
this study was unique in the sense that it was one of the few with microdissected renal tissue 
compartments (as opposed to bulk kidney cortex) and focuses on an underrepresented 
population. As such, studying this cohort provided the opportunity to both replicate, and 
discover novel tissue-specific and population-specific insights into biological pathways 
underlying kidney disease. For example, our eQTL mapping discovered 805 glomerular eGenes 
and 1,118 tubular eGenes, with roughly 50% replicated in GTEx, and with a plausible 129 novel 
tissue-specific and 64 novel population-specific genes not previously identified in GTEx. In 
addition to eQTL mapping, we discovered numerous renal disease-relevant biological pathways 
for genes significantly associated with clinical and morphometric traits, including cytokine-
cytokine receptor interactions, focal adhesion, cancer, and ECM-receptor interactions [180–
186]. Our GWAS – despite the small sample size – discovered variants associated with the 
important VPC trait (volume of podocyte counts) within the C2CD4B gene region, which has 
been previously implicated in diabetes risk [167,168]. 
Despite the many resources generated from this study, there are limitations and challenges 
that arose from this deep, complex dataset that could be addressed as future directions. For 
example, although the study conducted biopsies at two time points, the assaying of expression 
levels was done in separate batches, thereby confounding the time effect with the batch effect. 
As such, because it is highly improbable to disentangle these two effects, discovering 
differentially expressed genes related to disease progression is likely infeasible. One potential 
future direction could be to use the RNA-Sequencing data (which coincides with the microarray 
expression from biopsy 2) to assist in separating out the batch and time effects. However, this 
was not within the scope of the project. Another limitation of this study was that, in order to 
obtain high quality phenotypes and transcriptomic profiles, the sample size of the cohort was 
relatively low, particularly in the context of GWAS, which can often have orders of magnitude 
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higher sample sizes [194]. Moving forward, integration of the transcriptomic facets of this study 
into larger scale GWA studies could provide further insight into the biological pathways 
underlying renal disease. Finally, with the advent of single-cell sequencing resources, we may 
able to deconvolute our gene expression into cell-type-specific resolution [209] to interpret 
eQTLs in a more precise manner. 
 
5.5 Concluding remarks  
The rapid advancement of technology, particularly in computing in the 20th and early 21st 
century has ushered in an era of revolutionary accessibility to information. With these changes 
to how quickly we receive and process data, we have been able to delve into various scientific 
topics with both unprecedented breadth and depth. The field of genetics has been rapidly 
evolving as technology improves, and with these improvements come new challenges, in both 
wetlab settings, as well as statistical and computational. The work done in this thesis has 
addressed some of the challenges in the field of genomics, such as implementing an integrative 
framework to combine multiple external resources to predict gene expression, correcting for 
technical biases in older gene expression technologies, and generating resources for emerging 
population-specific and tissue-specific systems genetics studies. It has been wonderful and 
fulfilling to contribute but a small part to our already vast expanse of knowledge in the field of 
genetics. As our understanding of genetics, biology, and science continue to grow, I look 
forward to continuing to work towards the improvement of public health by helping push the 
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